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1. Fatigue 
1.1. Dimensions of fatigue 
Recurring complaints of disturbed sleep and fatigue are very common among the general 
population and frequently co-occur. Sleep disturbances lasting at least several nights per 
month have been reported by 30% of the population [1]. One-third to 50% of the adult 
population has been found to complain of fatigue [2].  
Fatigue is a heterogeneous and multidimensional condition that is essentially subjective. No 
pathognomonic signs or diagnostic tests are available to assess this complaint. Reported 
fatigue may represent a difficult diagnostic and therapeutic problem to the medical 
practitioner, and its management should take into account different dimensions and contexts. 
The multidimensional aspects and the various types of fatigue are described below. 
 
1.1.1. Physical fatigue versus mental fatigue 
Fatigue is generally associated with physical and/or mental weakness, varying from the 
inability to exert force at the level of an individual‘s normal physical ability to the exhausted 
feeling after or during periods of cognitive activity. With respect to physical fatigue, muscular 
and central mechanisms are thought to determine physical performance [3]. Depletion of 
physical energy sources including glycogen and phosphocreatine, decrease in resting 
membrane potential and dysfunctions of the calcium pump in sarcoplasmic reticulum, and 
failure of neuromuscular transmission have been reported to be associated with muscular 
mechanisms. Central mechanisms refer to a progressive decline in the ability to activate 
muscles voluntary and is attributable to impairment at sites proximal to the neuromuscular 
junction. Supraspinal fatigue is a primary component in the central mechanism of physical 
fatigue [3].  
Mental fatigue is a much more complex phenomenon that has been associated with impaired 
cognitive and behavioural performance [4]. In this context, continued performance has been 
proposed to be associated with expected rewards and energetical costs. Adequate evaluation 
of predicted rewards and potential risks of actions is essential for successful adaptive 
behaviour. However, while both rewards and punishments can motivate to engage in 
activities, both types of motivated behaviour are associated with energetical costs. Boksem 
and Tops [4] suggested that the nucleus accumbens, orbitofrontal cortex, amygdala, insula and 
anterior cingulate cortex are involved in evaluating both the potential rewards associated with 
performing a task, as well as assessing the energetical demands involved in task performance. 
Behaviour will only proceed if this evaluation turns out favourably towards spending 
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(additional) energy. This evaluation of predicted rewards and energetical costs is proposed to 
be central to the phenomenon of mental fatigue: people will no longer be motivated to engage 
in task performance when energetical costs are perceived to outweigh predicted rewards [4]. 
 
1.1.2. Fatigue in medical disease, organ failure 
Fatigue is a common symptom in medical diseases such as cancer, HIV and other infectious 
diseases, sleep disorders and organ failure. The cause of fatigue in these conditions is 
multifactorial and may be associated with disease-related factors such as the stage of the 
disease, cachexia, pro-inflammatory cytokines, treatment, as well as sociodemographic and 
psychological factors [5, 6]. 
 
1.1.3. Fatigue in psychiatric disease 
Fatigue and psychiatric disorders are highly correlated and covary across time [7, 8]. Up to 
two thirds of subjects with chronic fatigue lasting for at least 6 months can be given a 
diagnosis of a comorbid psychiatric disorder, and the presence of a psychiatric disorder 
increases the risk of developing chronic fatigue [7]. Nevertheless, a substantial proportion of 
individuals with persistent fatigue do not suffer from psychiatric comorbidity. This condition 
has been supported by some authors as evidence for a separate diagnosis of neurasthenia [7, 
8]. The latter term is a nosological item listed in the ICD-10 classification to denote persistent 
and distressing complaints of fatigue, weakness and exhaustion in the absence of a depressive 
illness or anxiety disorder [5]. 
 
1.1.4. Neuromuscular fatigue 
In physiology, fatigue is defined as a loss in force or voluntary force-producing capacity 
during exercise [9]. Physiological fatigue may originate in both the peripheral and central 
nervous system (CNS). Peripheral fatigue results from neuromuscular dysfunction outside the 
CNS and relates to impaired neurotransmission in peripheral nerves and/or defects in 
muscular contraction. Central fatigue results from alterations or abnormalities in 
neurotransmitter pathways within the CNS. The prevalence of fatigue in neuromuscular 
disorders such as multiple sclerosis and its assessment, which involves clinical 
neurophysiological techniques and psychological measurements, has recently been reviewed 
by Zwarts et al. [10]. 
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1.1.5. Occupational aspects: time-on-duty fatigue 
The shift in the industrialized world from demanding physical effort to demanding mental 
tasks has led to increasing complaints of mental fatigue, which are common in the working 
population. Mental fatigue related to workload is dissimilar from mental fatigue in chronic 
illness, as different mechanisms are involved. It is directly linked with motivation, which in 
turn relates to obtaining rewards and avoiding harm and punishment [4]. Mentally fatigued 
subjects estimate perceived effort during exercise higher and reach a level of perceived 
maximal exertion earlier as compared with normal controls. This seems to indicate that 
mental fatigue limits exercise tolerance in humans through higher perception of effort rather 
than cardiorespiratory and musculo-energetic mechanisms [11]. In addition, sleep deprivation 
may aggravate ratings of perceived exertion during prolonged exercise [12]. To improve the 
control of fatigue-related incidents, not only hours of duty are important but also the amount 
of sleep individuals have acquired before starting service [13].  
 
1.2. Measuring fatigue 
It is not feasible to objectively assess the severity of reported fatigue, and to discriminate 
fatigue levels between and within subjects. The fatigue experience can only be measured 
using subjective self-report questionnaires. The information obtained from these instruments 
depends on the questions asked and on the interpretation by the responders. Therefore, a given 
fatigue rating scale may be limited to a specific situation and may fail to validly represent the 
fatigue experience in other conditions or samples. Taking into account the heterogeneous 
nature and various dimensions of fatigue, a rating scale should fundamentally measure 
different aspects of the fatigue experience. In recent years, a range of validated questionnaires 
has been published. Table 1 gives a comparative overview of the characteristics of the most 
frequently used fatigue questionnaires in CFS [14-16]. 
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Table 1. Comparative overview of the characteristics of the most frequently used fatigue questionnaires in CFS 
 
Scale name VAS-F FQ FSS CIS FAI MFI PFRS 
What is assessed Severity Severity Impact and func- 
tional outcomes 
related to fatigue 
Phenomenology 
and severity 
Phenomenology, 
severity, impact  
and possible  
triggers 
Phenomenology, 
severity and  
impact 
Phenomenology  
and severity 
Number of scale 
items 
18 11 9 20 29 20 54 
Scale type Visual analogue Yes/no response 
or 4-point Likert  
7-point Likert 7-point Likert 7-point Likert 7-point Likert 7-point Likert 
Target sample General medical CFS Chronic medical CFS General medical General medical CFS 
Internal consistency 0.91 - 0.96 0.88 - 0.90 0.88 0.90 0.70 - 0.91 0.84 0.96 
Test-retest reliability - - 0.84 - 0.29 - 0.69 - 0.97 
Cutoff score - - 3/4 - - - - 
Sensitivity to change Yes - Yes Yes - - - 
CIS, Checklist Individual Strength; FAI, Fatigue Assessment Instrument; FQ, Fatigue Questionnaire; FSS, Fatigue Severity Scale; MFI, Multidimensional Fatigue 
Inventory; PFRS, Profile of Fatigue-Related Symptoms; VAS-F, Visual Analogue Scale for Fatigue 
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2. Excessive daytime sleepiness 
Fatigue is a complex and heterogeneous symptom that is often confused with sleepiness by 
patients and medical practitioners due to overlap or coexistence in many psychological and 
pathological conditions [17, 18]. Moreover, it has been hypothesized that patients with CFS 
may be unable to distinguish fatigue and sleepiness due to their severe underlying fatigue 
[19]. A weak association was, however, found between both daytime complaints in sleep-
disordered patients [20, 21] as well as in CFS [18, 22].  
Fatigue and excessive daytime sleepiness (EDS) have some common characteristics such as 
tiredness and feeling the need to lay down and rest, but other features clearly differentiate 
them from each other. Their discrimination is relevant for clinical practice and research 
purposes. Fatigue is usually described as weariness, weakness, depleted energy and feelings 
of exhaustion, whereas sleepiness is related to drowsiness, an increased propensity to fall 
asleep and decreased alertness [15, 17, 20, 23, 24].  
A number of tools have been developed for the assessment of EDS. A precise history is often 
obtained by means of a sleep diary, whereas different rating scales query the patient‘s 
perception of sleepiness. The widely used Stanford sleepiness scale (SSS) [25], Karolinska 
sleepiness scale (KSS) [26] and visual analogue scales (VAS) measure short term changes in 
sleepiness, whereas other tests, such as the Epworth sleepiness scale (ESS) [27], evaluate a 
global level of sleepiness. Nevertheless, subjective measures have limitations since 
individuals are not always aware of their degree of sleepiness or their susceptibility to 
impairment. In contrast to fatigue, EDS can also be studied objectively. The multiple sleep 
latency test (MSLT) [28] has been endorsed as the gold standard objective measure for EDS 
by the American Academy of Sleep Medicine (AASM). Subjects are given multiple nap 
opportunities following nocturnal polysomnography (PSG) under standardized test conditions, 
in which the average time to fall asleep or the mean sleep latency is recorded. The results, 
however, have not consistently reflected subjective sleep outcomes [18, 19]. Other objective 
measures include the maintenance of wakefulness test (MWT) which records the ability to 
stay awake [29]. The psychomotor vigilance test (PVT) [30] and divided attention driving 
task (DADT) [31] focus more on neurocognitive function. This is especially relevant among 
commercial drivers, but these are not direct tests of physiological sleepiness.  
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3. Chronic fatigue and chronic fatigue syndrome  
Often, fatigue cannot be attributed to a diagnosis of a well defined medical condition, 
psychiatric illness or primary sleep disorder and seemingly remains unexplained. If fatigue 
persists for more than six months, the term ‗chronic fatigue‘ is used. If, in addition, a set of 
minor diagnostic criteria is fulfilled, the disorder is diagnosed as CFS.  
 
3.1. Case definitions  
Several case definitions have been developed for CFS as an illness characterized by long 
lasting unexplained chronic fatigue with a disabling impact on professional, social and daily 
functioning. The absence of another plausible explanatory disease and the presence of a 
number of associated clinical features are fundamental to this syndrome.  
The term CFS was introduced in the medical lexicon in 1988 by Holmes et al. in a publication 
of the US Centers for Disease Control and Prevention (CDC) [32]. Since then, several new 
case definitions have been introduced. In 1994, revised CDC criteria were published by 
Fukuda et al. [33]. These are standard guidelines in the United States and are most widely 
used in other countries as well. To establish the diagnosis of CFS, the Fukuda definition 
require the presence of the major criterion of chronic, incapacitating fatigue of at least six 
months duration in combination with at least four out of eight minor criteria. These minor 
criteria include short-term memory or concentration impairment, sore throat, tender cervical 
or axillary lymph nodes, muscle pain, multi-joint pain without swelling or redness, headaches 
of a new type, pattern or severity, unrefreshing sleep and postexertional malaise lasting for 
more than 24 hours. These revised CDC criteria allow inclusion of a larger number of patients 
than the previous Holmes guidelines. Additionally, all physical signs, such as palpable lymph 
nodes and documented fever, were dropped from the inclusion criteria, through which the list 
of symptoms was diminished from eleven to eight and the required number of secondary 
symptoms was decreased from eight to four.  
The key features of the different case definitions [32-36] are summarized in Table 2a and b. 
All existing guidelines are founded on expert-based consensus and are not supported by 
robust medical evidence. 
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3.2. Epidemiology  
Epidemiological data on the prevalence of CFS are quite diverse. Both the case definition 
used and the characteristics of the screened samples explain the wide ranges observed (Table 
2). 
The estimated crude point prevalence was 0 to 300 per 100.000 persons when the more 
restrictive Holmes criteria were used and 190 to 2540 per 100.000 medical patients based on 
the Fukuda criteria (Table 2). The Holmes case definition considers any psychiatric disease as 
an exclusion for the diagnosis of CFS, whereas the Fukuda criteria only retain a bipolar 
disorder and a major depressive disorder with psychotic characteristics (and hence not an 
unipolar depression) as exclusionary disorders. Furthermore, eating disorders may be either a 
life long or a five year exclusion criterion.  
The prevalence of CFS reported varies between 100 and 2100 per 100.000 patients in primary 
care and between 0 and 4800 per 100.000 individuals in community-based samples (Table 2). 
As the prevalence of CFS in the community may be quite high, epidemiological studies 
relying on referrals to outpatient clinics may lead to an underestimation of the burden of CFS 
in the general population.  
A point prevalence study of CFS in a large random sample of an ethnically diverse 
community in the US indicated a prevalence of  0.42% (95% confidence intervals 0.29-
0.56%) with highest scores in women and minority groups [46]. This finding was 
reproducible across ethnic groups and did not confirm the previously presumed predominance 
in white middle class patients, which may be due to bias attributable to accessibility and 
utilization of health care facilities [52]. 
 
3.3. Aetiology and pathogenesis 
Among other terms, CFS is also referred to as myalgic encephalomyelitis (ME), post-viral 
fatigue syndrome (PVFS), and chronic fatigue immune dysfunction syndrome (CFIDS). The 
terminology of these alternative labels might implicate the existence of a systemic 
inflammatory condition, however, no such mechanism has been irrefutably demonstrated.  
The aetiology and pathogenesis of CFS remain essentially unknown, but are generally 
believed to be multifactorial. Infections often seem to trigger CFS, although other factors 
including toxic substances, sleep disturbances and psychological trauma may be involved. 
Moreover, dysregulation of the immune or the neuroendocrine system may determine the 
pathophysiology of the illness, leading to a loss of capacity to adapt to all kind of stressors. 
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Table 2a. Key features of CFS according to different definitions 
 
Holmes et al. 1988 (CDC) Lloyd et al. 1988 Sharpe et al. 1991 (Oxford) Fukuda et al. 1994 (CDC)* 
USA [32] Australia [34] UK [35] USA [33] 
MAJOR AND MINOR CRITERIA 
Major criteria: 
- new onset of persistent or relapsing, debilitating 
fatigue,  
does not resolve with bedrest, reduction or 
impairment of daily activity, duration ≥6 months 
- exclusionary clinical conditions that may produce 
similar symptoms 
 
Minor symptom criteria: 
- mild fever 
- sore throat 
- painful lymph nodes in the anterior or posterior 
cervical or axillary distribution 
- generalized muscle weakness 
- myalgia 
- prolonged, generalized fatigue after exercise 
- generalized headaches 
- migratory arthralgia without joint swelling or 
redness 
- neuropsychologic complaints 
- sleep disturbance 
- acute onset (over a few hours  
to a few days) 
 
Minor physical criteria: 
- low-grade fever 
- nonexudative pharyngitis 
- cervical or axillary lymphadenopathy 
 
 
 
 
 
 
 
 
Major criteria: 
- generalized, chronic persisting  
or relapsing fatigue, exacerbated by minor exercise, 
significant disruption of usual daily activities, 
duration >6 months  
- neuropsychiatric dysfunction 
- and/or: abnormal cell-mediated immunity 
 
Supportive symptoms: 
- myalgia 
- arthralgia 
- headaches 
- depression 
- tinnitus 
- paraesthesiae 
- sleep disturbance 
- lymphadenopathy 
- localized muscle tenderness 
- pharyngitis 
Characteristics: 
- fatigue is the principal symptom  
- syndrome of definite onset 
- disabling fatigue that affects physical and mental 
functioning 
- duration ≥6 months 
- possible symptoms: myalgia, mood and sleep 
disturbance 
- exclusions: 
  (i) medical conditions producing chronic fatigue 
  (ii) certain psychiatric disorders (manic depressive 
illness, substance abuse, eating disorder, organic 
brain disease) 
Major criterion: 
unexplained, persistent or relapsing chronic 
fatigue,  
new or definite onset,  
not result of ongoing exertion,  
not substantially alleviated by rest, 
substantial reduction in previous 
occupational, social or personal activities 
 
Minor criteria: 
- impaired short-term memory or 
concentration 
- sore throat 
- tender cervical or axillary lymph nodes 
- muscle pain 
- multijoint pain without joint swelling or 
redness 
- headaches of a new type,  
pattern or severity 
- unrefreshing sleep 
- post-exertional malaise >24 h 
 
Exclusions: 
- active, unresolved or suspected disease 
likely to cause fatigue 
- primary sleep disorders 
- psychotic, melancholic or bipolar 
depression 
- anorexia or bulimia nervosa 
- alcohol or other substance misuse 
- severe obesity 
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DIAGNOSTIC CRITERIA 
Presence of: 2 major criteria + 
≥ 6 out of 11 minor symptom criteria + ≥ 2 out of 3 
minor physical criteria  
OR 2 major criteria + ≥ 8 out of  
11 minor symptom criteria  
Presence of: 2 or 3 major criteria + possible 
presence of supportive symptoms  
Presence of: 6 characteristics, including the 
possible presence of other symptoms (different 
from fatigue) particularly myalgia, mood and sleep 
disturbance  
Presence of: major criterion +  
≥ 4 out of 8 minor criteria  
during ≥ 6 months  
PREVALENCE 
Primary care 
300 / 100.000 [37] 
100 / 100.000 [38] 
 
 
Community-based sample 
37 / 100.000 [34] 
7 / 100.000 [39] 
75-267 / 100.000 [40] 
4-10 / 100.000 [41] 
0 / 100.000 [42] 
 
 
1000 / 100.000 [37] 
200 / 100.000 [38] 
 
 
 
4800 / 100.000 [42] 
 
 
400 / 100.000 [37] 
700 / 100.000 [38] 
 
 
 
2400 / 100.000 [42] 
 
 
500 / 100.000 [38] 
1600-2100 / 100.000 [43] 
190 / 100.000 [44] 
 
194 / 100.000 [45] 
420 / 100.000 [46]                        
1400 / 100.000 [42] 
235 / 100.000 [47] 
2540 / 100.000 [48] 
1000 / 100.000 [49] 
 
 
*The Fukuda et al. 1994 definition was used in the present thesis as diagnostic criteria for clinical and research purposes 
h, hours; ND, no data 
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Table 2b. Key features of CFS: comparison of the original and revised Canadian criteria
 
Carruthers et al. 2003 [36] Carruthers et al. 2011 [50] 
MAJOR AND MINOR CRITERIA 
Symptom clusters: 
- fatigue: new onset, unexplained, persistent or recurrent physical and mental 
fatigue, reduced activity level 
- post-exertional malaise and/or fatigue 
- sleep dysfunction 
- pain 
- neurological/cognitive manifestations 
- ≥1 symptom from 2 of the following categories: 
   (i) autonomic manifestations 
   (ii) neuroendocrine manifestations 
   (iii) immune manifestations 
- duration ≥6 months, usually acute onset, may be gradual 
Major criterion: 
- post-exertional neuroimmune exhaustion 
 
Neurological impairments: 
- neurocognitive impairments 
- pain 
- sleep disturbance 
- neurosensory, perceptual and motor disturbances 
 
Immune, gastro-intestinal and genitourinary impairments: 
- flu-like symptoms may be recurrent or chronic and typically activate or worsen with exertion 
- susceptibility to viral infections with prolonged recovery periods 
- gastro-intestinal tract 
- genitourinary 
- sensitivities to food, medications, odours or chemicals 
 
Energy production/transportation impairments 
- cardiovascular 
- respiratory 
- loss of thermostatic stability 
- intolerance of extremes of temperature 
 
DIAGNOSTIC CRITERIA 
Presence of: 7 criteria (symptom clusters) Presence of: major criterion + ≥ 1 symptom from 3 out of 4 neurological impairments + ≥ 1 symptom from 3 out of 5 
immune, gastro-intestinal and genitourinary impairments + ≥ 1 symptom from energy production/transportation 
impairments 
 
PREVALENCE 
Primary care 
110 / 100.0004 
 
Community-based sample 
ND 
Primary care 
ND 
 
Community-based sample 
ND 
Comments on the consensus criteria  of Carruthers et al. 2011 [51] :  
1) No credible substantiated recommendations given for clinical and research application of the criteria  
2) No true consensus represented of the spectrum of credible scientific views 
3) Reversion to the term ‗myalgic encephalomyelitis‘ and abolishing ‗CFS‘ 
4) Criticizing the currently accepted international diagnostic criteria (Fukuda et al. 1994) as ‗too broad‘ and search to discard published findings that have applied these criteria 
5) Cited literature biased towards positive findings 
6) Use of labels which highly suggest a notional pathophysiology  
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Some authors, however, heavily rely on one or multiple biological explanations that may co-
exist or occur in a sequential fashion [53]. Nevertheless, most hypotheses generated have not 
reached a high level of evidence, lacking prospective assessment with control groups. This is 
illustrated in table 3.  
 
3.3.1. Biologic findings in CFS 
3.3.1.1.Immunological dysfunction 
Regarding the nature of the symptoms and the finding of abnormalities in the immune system, 
it has been suggested that immunological changes play a role in CFS. Slightly increased  
parameters of inflammation and circulating pro-inflammatory cytokines such as interleukin 
(IL) 1, IL-6 and tumour necrosis factor (TNF) α have been found [71]. Ribonuclease (RNase) 
L, which plays a role in the elimination of viral mRNAs, was shown to be degraded in white 
blood cells of CFS patients [72]. The literature also suggests a skewing towards impaired 
cellular immunity including diminished natural killer cell cytotoxicity [73]. Alterations in T 
cell numbers have been described, but were not consistently found [71].  
The analysis of the immune function is a major challenge in a heterogeneous condition as 
CFS in which the cause is unknown and the variability in symptom severity fluctuates from 
day to day. Further complications exist in the analysis of immune cells which can vary in 
number depending on time and day and even mild exertion. Moreover, it is currently well 
known that the immune system is significantly influenced by stress, mood and sleep 
disturbances, which are common in CFS. In combination with the fragile nature of most 
cytokines demanding immediate blood separation and the marked variation in assay 
sensitivity and reproducibility, it is not surprising that there is little consensus on the presence, 
the nature and the degree of immune dysfunction and it is still unclear whether these defects 
are the cause or the effect of the disorder. 
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Table 3: Illustration of robustness of evidence of a number of etiologic hypotheses on CFS 
 
Etiologic 
factor 
Comparison  CFS versus controls Methods Treatment Outcome Duration of 
follow-up 
Study type Level of 
evidence 
Study 
 CFS (% positive) Controls (% positive)        
Amalgam CFS n=132;  
Relative risk estimate 
for an exposure unit of 
100 amalgam-filled 
surface-years: 
HR 0.89 (95% CI: 0.94-
1.03) 
 
No healthy controls  Disease codes 
 Dental records 
Not applicable Presence of 
conditions associated 
with dental amalgam 
Mean: 
 Initial 
cohort: 
12.5y 
 Final 
cohort: 
11.2y 
Retrospective, 
cohort study 
2 Bates  2004 [54]  
XMRV 68/101 (67%) 8/218 (3.7%) PCR Not applicable Presence of XMRV ND Retrospective, 
cohort study 
(not blinded 
PCR operator) 
 
2 Lombardi et al. 2009 
[55] 
XMRV 32/37 (86.5%) 3/44 (6.8%) RT-PCR Not applicable Presence of XMRV ND Retrospective, 
cohort study 
 
2 Lo et al. 2010 [56] 
XMRV 0/186 (0%) No healthy controls PCR Not applicable Presence of XMRV ND Prospective, 
cohort study, 
(blinded PCR 
operator) 
 
2 Erlwein et al. 2010 
[57] 
XMRV 0/142 (0%) 0/157 (0%) PCR 
Serology 
Not applicable Presence of XMRV ND Retrospective, 
multicentre, 
case-control 
 
2 Groom et al. 2010 
[58] 
XMRV 0/32 (0%)  HIV: 0/43 (0%) 
 Rheumatoid arthritis 
(RA): 0/97 (0%) 
 Hematopoietic stem-
cell or solid organ 
transplant: 0/26 (0%) 
 General cohort of 
patients presenting 
for medical care 
(matched with RA): 
0/95 (0%) 
 
PCR Not applicable Presence of XMRV ND Prospective, 
cohort study, 
monocentric 
2 Henrich et al. 2010 
[59] 
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Etiologic 
factor 
Comparison  CFS versus controls Methods Treatment Outcome Duration of 
follow-up 
Study type Level of 
evidence 
Study 
 CFS (% positive) Controls (% positive)        
XMRV 0/65 (0%) 0/65 (0%) healthy 
controls 
RT-PCR Not applicable Presence of XMRV ND Retrospective, 
case-control, 
matched, 
monocentric 
 
2 Hong et al. 2010 
[60] 
XMRV 0/50 (0%) (PCR) 
0/51 (0%) (WB) 
0/51 (0%) (ELISA) 
0/56 (0%) (PCR) 
0/53 (0%) (WB) 
0/53 (0%) (ELISA) 
0/41 (0%) blood donors  
 
PCR 
Serology 
Not applicable Presence of XMRV ND Retrospective, 
case-control, 
matched, 
monocentric 
2 Switzer et al. 2010 
[61] 
XMRV 0/32 (0%) 0/43 (0%) RT-PCR Not applicable Presence of XMRV ND Retrospective, 
Case-control, 
Matched, 
monocentric 
 Van Kuppeveld et a. 
2010 [62] 
XMRV 0/61 (0%) 
(43 patients had 
previously been 
identified as XMRV+) 
 
ND PCR 
RT-PCR 
Not applicable Presence of XMRV ND Retrospective, 
cohort study, 
monocentric 
2 Knox et al. 2011 
[63] 
XMRV 0/147 (0%) 
0/121 (0%) 
0/121 (0%) 
0/117 (0%) 
9/147 (6.1%) 
0/146 (0%) 
0/110 (0%) 
0/111 (0%) 
0/126 (0%) 
0/146(0%) 
RT-PCR 
RT-PCR 
PCR 
PCR 
Serology 
 
Not applicable Presence of XMRV ND Prospective, 
blinded, 
multicentre, 
case-control 
2 Alter et al. 2012 
[64] 
EBV 3/22 (14%) 6/22 (27%) PCR Not applicable Presence of Epstein-
Barr virus 
ND Prospective, 
(co-
twin/matched 
pair design) 
case-control 
study 
 
2 Koelle et al. 2002 
[65] OR:0.4 (95% CI: (0-2.4) 
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Etiologic 
factor 
Comparison  CFS versus controls Methods Treatment Outcome Duration of 
follow-up 
Study type Level of 
evidence 
Study 
 CFS (% positive) Controls (% positive)        
EBV Group 1: 27 CFS patients, EBV positive 
 Improvement of EI: 
Valacyclovir: +1.12 units 
Placebo: +0.42 units 
 Decreased serum IgM antibody titer to viral 
capsid antigen of EBV 
 Improved or disappearance of abnormal cardiac 
wall motion 
 Decreased resting tachycardias 
 Decrease/absence of symptoms 
 Energy Index (EI) 
point score 
 Holter monitor 
 Multigated 
(radionuclide) 
MUGA rest/stress 
ventriculographic 
examination 
 EBV serum IgM 
viral capsid 
antibodies (VCA) 
 EBV early antigen 
diffuse (EA) 
 
Group 1:  
 Valacyclovir 1.0g/6h 
(n=14) 
 Placebo (n=13) 
 Physical functional 
capacity 
 EBV serum 
antibodies 
 ECG 
 Functional activity 
appraisal 
ND Prospective, 
blinded, 
random 
placebo-
controlled 
trial 
1 Lerner et al. 
2007[66] 
 
 Group 2: 27 CFS patients, EBV positive 
 Improvement of EI: +3.2 
 Decreased serum IgM antibody titer to viral 
capsid antigen of EBV 
 Improved or disappearance of abnormal cardiac 
wall motion 
 Decreased resting tachycardias 
decrease/absence of symptoms 
 Energy Index (EI) 
point score 
 Holter monitor 
 Multigated 
(radionuclide) 
MUGA rest/stress 
ventriculographic 
examination 
 EBV serum IgM 
viral capsid 
antibodies  
 EBV early antigen 
diffuse (EA) 
 
Group 2: 
 3 months 
Valacyclovir 1.0g/6h 
 After 3 months (if EI 
had not improved): + 
oral cimetidine 
(500mg bid) or 
probenecid (500mg 
bid) 
 In case of 
valacyclovir-
associated diarrheas: 
famciclovir (14.3 
mg/kg/6h) 
 EI 
 EBV serum 
antibodies 
 ECG 
 Functional activity 
appraisal 
36 months Prospective, 
open trial 
2  
EBV Subjects: 
 5 fatigued patients, 
acute EBV infection 
 5 fatigued patients, 
with acute infection 
not due to EBV, but 
seropostive for EBV 
Subjects: 
 10 non-fatigued 
controls 
 ELISA 
 Immunoblot 
 PCR 
Not applicable Activity and host 
response to 
herpesviruses 
12 months Prospective, 
case-control, 
pilot study 
2 Cameron et al. 2010 
[67] 
Results: 
 Antibody levels: no difference between patient 
groups 
 Immunoblot confirmed ELISA results 
 EBV DNA-levels : similar to healthy controls 
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Etiologic 
factor 
Comparison  CFS versus controls Methods Treatment Outcome Duration of 
follow-up 
Study type Level of 
evidence 
Study 
 CFS (% positive) Controls (% positive)        
EBV 6 CFS patients: 
 EBV EA: 93.9% 
 Neutralizing 
antibodies against 
the EBV-encoded 
dUTPase: 44.2% 
 DNA polymerase: 
78.8% 
19 unknown persons: 
 31.6% postive for 
EBV EA 
 neutralizing 
antibodies against 
the EBV-encoded 
dUTPase: 0% 
 DNA polymerase: 
0% 
 
 ELISA 
 Neutralization 
assays 
Valacyclovir 
(14.3mg/kg) ≥ 12 
months 
 Antibody to EBV 
viral capsid 
antigen (VCA) 
IgM 
 EBV Diffuse Early 
Antigen EA(D) 
 Neutralizing 
antibodies against 
EBV-encoded 
DNA polymerase 
and EBV encoded 
dUTPase 
 
16 months Prospective, 
matched 
2 Lerner et al. 2012 
[68] 
EBV 32/61 (52% responders) 
CFS patients 
 Baseline antibody 
titers: no significant 
association with 
response 
 After treatment: 
average change in 
physical and 
cognitive functioning 
levels: +19% and 
+23% (P<0.0001) 
 Longer treatment 
was associated with 
improved response 
(P=0.0002) 
 No significant 
difference was found 
between responders 
and non-responders 
among other 
variables analyzed 
No controls  Cognitive and 
physical 
functioning levels 
 Antibody titers 
EBV VCA IgG, 
EBV NA IgG, and 
EBV EA IgG 
 
Valganciclovir 900mg/2 
x daily (3 weeks) – 
900mg/daily 
(maintenance dose) 
 Physical 
functioning 
 Cognitive 
functioning 
6 months 
after 
treatment 
Uncontrolled, 
unblinded, 
retrospective 
study 
2 Watt et al.  2012 
[69] 
HR: Hazard ratio, PCR: polymerase chain reaction, RT-PCR: real-time PCR, WB: Western blot, ELISA: Enyme-linked immune sorbent assay; EI: Energy Index, EBV: 
Epstein-Barr virus, XMRV: xenotropic murine leukaemia virus-related virus  
 
Note: Grading system for rating recommendations according to the Infectious Diseases Society of America–United States Public Health Service [70]  
1  Evidence from ≥ 1 properly randomized, controlled trial 
2  Evidence from ≥ 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from > 1 center); from multiple 
time-series; or from dramatic  results from uncontrolled experiments 
3 Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees 
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3.3.1.2.Endocrinology 
Interest in investigating the hypothalamic-pituitary-adrenal (HPA) axis in CFS arose from 
clinical similarities between CFS and states of glucocorticoid deficiencies as well as from 
early observations of reduced adrenocortical activity in chronically fatigued patients. HPA 
axis-related research in CFS is, however, hampered by the influence of various factors such as 
the presence of major depression or other comorbid conditions, early-life stress, the length of 
illness and the day time of testing. Nevertheless, about half of the basal hormone and 
challenge studies in literature indicate a mild HPA axis suppression and hypocortisolism, 
whereas no significant differences in HPA axis function between CFS patients and controls 
were apparent in other studies [74]. It is thought that physical or psychological stress is a 
predisposing and/or maintaining factor in CFS, which may be associated with HPA axis 
hypofunction.  
Corticotropin-releasing factor (CRF) is a hypothalamic neuropeptide driving adrenocortico-
tropic hormone (ACTH) release and having a key role in the regulation of metabolic, neuro-
endocrine and autonomic adaptations to stress. Additionally, there is evidence that CRF itself 
has analgesic properties and that the reduction in the availability of CRF in the CNS may 
contribute to complaints of pain and fatigue [75].  
Furthermore, the HPA axis dysfunction is possibly linked with immune disturbances in CFS. 
Inflammatory cytokines such as IL-1 can modulate release of CRF and stimulate the 
production of cortisol which in his turn exerts immunosuppressive effects. This negative 
feedback loop prevents the immune response from overshooting. However, if hypothalamic 
CRF containing neurons fail to response adequately to cytokine stimulation, the immune 
system may come in a hyper-immune state leading to excessive inflammation [74-76].  
Neuroendocrine factors such as CRF have been shown to affect sleep regulation [77]. In 
major depression, a causal relationship seems to exist between CRF hyperactivity and 
polysomnographic disturbances such as a decrease in non-rapid eye movement (NREM) sleep 
and REM disinhibition [77]. Polysomnographic findings in CFS patients show a decrease in 
slow wave sleep, an increase in sleep onset latency and a higher number of stage shifts per 
hour, however, the association with neuroendocrine changes has not yet been established [78].  
Despite a fairly consistent pattern of findings for HPA axis disturbances has found, it is still a 
matter of debate whether they have a primary role in the pathogenesis of CFS. Therefore, 
future work should focus on improving the understanding of the cause and the relevance of 
these observed changes.  
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3.3.1.3.Infections 
3.3.1.3.1. Microbial infections 
Numerous studies have investigated the role of infections in the pathogenesis of CFS and 
various viruses and virus groups have been implicated in CFS at some time, including 
Epstein-Barr virus, cytomegalovirus, parvovirus B19, human herpes virus-6, group B cox-
sackievirus, human T cell leukaemia virus II-like virus, spumavirus, hepatitis C virus, human 
lentiviruses and herpes virus-7 [78]. The detection of several viruses has, however, provided 
conflicting results and various values of seroprevalence have been published. This may, at 
least, be due to the use of different diagnostic criteria of CFS and to different viral antigens 
used throughout serological studies. In addition to viruses, several other microorganisms have 
been considered to be associated with chronic fatigue. These include several types of bacteria 
such as mycoplasma species in particular but also Borrelia [71]. 
 
3.3.1.3.2. Xenotropic murine leukemia virus-related virus (XMRV) 
Recently, a novel virus, named xenotropic murine leukaemia virus-related virus (XMRV), 
was described as possible aetiological agent of CFS, however, this hypothesis is currently 
definitely disproved.   
In 2006, researchers identified a novel retrovirus in samples from patients with prostate 
cancer who had a deficiency in RNase L function [79]. This virus got the name XMRV, 
because of its similarity with the known murine leukaemia viruses. Although there is no 
evidence to suggest an increase in prostate cancer among CFS patients, scientists at the 
Whittemore Peterson Institute and collaborators [55] looked for the virus in their CFS cohort 
since many of these patients display immunological abnormalities including RNase L 
deficiencies. In late 2009, they were able to find XMRV nucleic acid in white blood cells 
from 67% CFS patients compared to only 4% controls, although they did not find a link to 
RNase L deficiency [55]. This study generated great excitement and has a great impact in the 
CFS community, especially as the authors claimed to have cultured virus from these patient 
samples. Some patients started taking antiretroviral medications without waiting for the 
association to be confirmed [80]. This story was, however, soon mired in confusion as three 
other teams quickly published contrary reports that they could find little evidence of this virus 
in their CFS cohorts [57, 58, 62]. Additional negative reports soon followed and to date, no 
other research groups have published similar positive findings of XMRV in CFS patients. The 
discussion has been spurred by reports of other murine leukaemia virus-like viruses in CFS 
patients [81] and sample contamination [64, 82-85]. The increasing and unequivocal evidence 
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that XMRV has little to do with CFS has nowadays led to the insight that the association 
between this virus and CFS is very uncertain. 
This story shows that research results can have important consequences for public health and 
that it may raise hope for patients desperate to know the cause of their illness in hope of a 
possible therapy. Therefore, these data warrants for caution when interpreting research results. 
 
3.3.1.4.Exposure to toxic substances  
3.3.1.4.1. Toxic agents used in war 
CFS has been linked to the Gulf War Syndrome because of its similarity and overlap in 
symptoms. Gulf War veterans were exposed to a wide range of exogenous toxic agents and up 
to now, they appear to suffer more frequently from a variety of complaints, including 
depression, fatigue, headache, joint pain, muscle pain, concentration problems and memory 
loss, than non-Gulf War participants [86].  
In their study to correlate exposure to a variety of substances with health damage in Gulf War 
veterans, Haley and Kurt [87] described three syndromes using factor analysis. In subsequent 
years, several other groups have tried to replicate this work with different groups of Gulf War 
veterans, but none of them has found the same clusters of symptoms [88]. Instead, they 
hypothesized that Gulf War veterans suffered from the same symptoms as also seen in the 
general population where they have the names CFS and fibromyalgia (FM) [88].  
It remains unclear if this set of symptoms, whether they are in accordance with the criteria for 
CFS or not, are the effect of exposure to toxic agents used in the Gulf War such as nerve gas, 
pyridostigmine bromide tablets, depleted uranium, pesticides, anthrax and botulism vaccines 
or smoke from oil wells. The association between CFS and the exposure to toxins has also 
been studied in other contexts. The bioaccumulation of dioxins for instance has been known 
to be associated with a wide range of health problems. Older literature suggests higher serum 
levels of chlorinated hydrocarbons in CFS patients compared to non-CFS control subjects and 
comparable levels to that of patients with CFS symptoms with known chemical exposure [89].  
Nevertheless, some scientists believe that the health complaints of veterans may have little to 
do with anything specific in the Gulf War and everything to do with war itself, since after 
almost every major armed conflict, formerly healthy soldiers have come back sick [88]. 
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3.3.1.4.2. Amalgam 
In the field of dentistry, CFS has been linked to amalgam fillings. Mercury amalgam 
restorations have been used since 1818 and although more esthetic dental materials have 
become readily available, amalgam remains popular due to its relative low cost, durability and 
ease of use [90]. Nevertheless, dental amalgam contains about 50% mercury and sensitive 
analytical chemistry techniques showed continuous release of mercury, making its use in 
dentistry controversial [90]. Inorganic mercury primarily affects the nervous and renal 
systems, although it may also have effects on immune, respiratory, cardiovascular, 
gastrointestinal, hematologic and reproductive systems. Additionally, there is a widespread 
popular belief that CFS is associated with dental amalgams, but little epidemiological 
investigation. In a retrospective study of 20.000 New Zealand military personnel, no 
association was found between cumulative amalgam exposure and CFS. The relative risk 
estimate for an exposure unit of 100 amalgam-filled surface-years was 0.98 (95% CI: 0.94 - 
1.03) [54].  
 
3.3.2. Biopsychosocial model 
Harvey and Wessely [91] proposed a biopsychosocial model with predisposing, precipitating 
and perpetuating factors rather than a purely biologic model for all manifestations of CFS 
(Figure 1). This model is the rationale for behaviourally oriented interventions, such as 
cognitive behaviour therapy (CBT) and graded exercise therapy (GET). The authors suggest 
that a trigger instigates fatigue in predisposed individuals, which, mediated by maintaining 
factors, result in CFS [91]. In this model, the initial cause of fatigue has a limited impact on 
the eventual course of the syndrome and the perpetuating factors, which are principally 
behavioural ones, need to be addressed if recovery is to occur. The biological component of 
this model is restricted to the possible triggers and the biological responses to the initial 
fatigue. A multitude of aetiological triggers has been postulated, including infectious agents, 
stress, exposure to toxic substances, abnormalities in the CNS, immune or neuroendocrine 
systems [91]. However, no unequivocal cause-consequence relationships have been 
demonstrated for each of these supposed aetiological models. 
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Figure 1. The biopsychosocial model for chronic fatigue syndrome (CFS) of Harvey and Wessely [91]. 
 
3.3.3. CFS: a complex illness  
CFS has been marred by controversy. The situation became confused when the term ‗myalgic 
encephalomyelitis‘ was introduced and used besides ‗CFS‘. A 2002 commentary in the Lancet 
noticed that ―the fact that both names for the illness were used, symbolizes respect for 
different viewpoints whilst acknowledging the continuing lack of consensus on a universally 
acceptable name‖ [92]. Major disagreements over the aetiology and the pathophysiology of 
CFS and the wide range of treatments further compounds the confusion.  
Possibly, some medical practitioners do not acknowledge the disease as a ‗real‘ condition and 
still believe that the syndrome is ‗all in the mind‘. According to Holgate et al. [93], many 
patients feel that the medical profession attributes CFS to psychiatric or psychological 
disorders in the absence of other mechanisms. Nevertheless, these patients often resist the idea 
of having a psychiatric disorder, because psychiatric illnesses generally remain a stigma and 
are often seen as hysterical, non-existent or imaginary. This view has been strengthened by 
the only proven effective interventions being those based on symptom relief rather than on a 
specific set of underlying aetiological causes. Some CFS patients also report a moderately 
beneficial effect of graded exercise with an initial worsening of their symptoms. The 
frustration expressed by patients may reflect the scepticism of medical practitioners about the 
existence of CFS as a ‗real‘ disease.  
The five current case definitions for CFS all attempt to capture critical aspects of the illness in 
order to differentiate from similar symptom clusters that are associated with other diseases. 
The existence of such criteria is important prior to make a diagnosis as well as for research 
purposes. Nevertheless, as long as a validated biomarker for CFS is not discovered, the 
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definition remains symptom-based and the existence and use of different criteria reflect the 
complexity of the syndrome. Sometimes the criteria are modified to be more restrictive, to 
concentrate on severe disease, or less restrictive, to include the wide variety of patients with 
this syndrome. This hampers making meaningful comparisons across studies and asks for an 
improved description of enrolment characteristics of both patients and controls.  
Holgate et al. [93] emphasize a lack of research capacity in the field and the importance of 
engaging scientists to undertake research into the condition. An interdisciplinary UK 
Research Advisory Group, that includes experts from a wide range of disciplines, highlight 
that more research should be done into autonomic dysfunction, cognitive symptoms, fatigue, 
immune dysregulation, pain and sleep disorders in patients with CFS [93]. They believe that 
new research perspectives are essential in the better understanding of the illness and its 
determinants and identifying preventive and/or therapeutic targets. 
 
3.4. Subgroups within CFS 
Chronic fatigue and CFS are likely to be heterogeneous conditions in which different 
subgroups have been proposed, depending e.g. on the mode of onset, the severity of 
symptoms, the presence or absence of psychiatric comorbidity and the ways of coping. To 
seek clusters of patients who share underlying indicators, factor analysis as well as latent class 
analysis have been used [94-97]. In this way, two to five subphenotypes have been defined in 
CFS, however, no work has looked into the validity of these empirically defined clusters.  
The attempts in defining subgroups have relied on symptoms and demographic measures, 
without taking into account possibly associated biological abnormalities, such as the down-
regulated HPA axis activity. It has been suggested that such biomarkers should be added to 
reveal subphenotypes that are defined by the underlying biological processes, which are called 
endophenotypes [98, 99]. 
Vollmer-Conna et al. [98] defined discrete subject groups within patients with unexplained 
chronic fatigue using measures of symptoms, demographics, clinical measures and laboratory 
tests that have been reported to be abnormal in studies of CFS patients. The latter included 
endocrine and immune tests and PSG. Principal component analyses were performed to 
reduce the large number of variables and to look for the most explanatory ones, followed by 
latent class analyses. The resulting classes were differentiated by obesity, sleep hypopnea, 
depression, psychological stress response, objective and subjective sleep disturbance, 
interoception and menopausal status [98]. These findings were partially replicated by the 
same research group in order to validate the existence of a latent class structure of CFS [100]. 
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New insights could originate from functional CNS imaging. Different studies have shown 
evidence of reduced grey matter in CFS patients which may be suggestive for patient‘s 
common complaint of impaired memory [101-104]. It should be emphasized, however, that a 
number of biological abnormalities have not irrefutably been demonstrated in CFS, implying 
caution in including biomarkers when looking for subgroups. Nevertheless, it is now 
generally believed that CFS is a heterogeneous entity comprised of several conditions with 
different underlying pathophysiological mechanisms. 
 
3.5. Overlapping and comorbid clinical conditions 
According to the 1994 CDC criteria, the diagnosis of CFS requires the absence of medical and 
psychiatric disorders that could explain the chronic fatigue, such as OSA, narcolepsy, past or 
current diagnosis of a major depressive disorder with psychotic or melancholic features, 
bipolar affective disorders, schizophrenia, dementia, lifetime eating disorders and alcohol or 
other substance abuse within 2 years before the onset of the chronic fatigue [33]. 
Nevertheless, patients with chronic fatigue and CFS often present with additional medical and 
psychiatric diseases that are not regarded as part of the exclusion criteria and that are 
considered as comorbid disorders. These exclusionary conditions are, however, not well 
defined in the Fukuda criteria, leading to different prevalences of comorbid conditions 
described in literature. Many of these entities also show overlap in symptoms with the 
syndromal definition of CFS. Although the relationship between these overlapping conditions 
is poorly understood, it has been the focus of recent research in order to require better 
understanding and improved management. 
 
3.5.1. Fibromyalgia 
In the context of overlapping somatic syndromes, the relationship between CFS and FM has 
received the most attention in literature. The American College of Rheumatology (ACR) FM 
classification criteria were introduced more than 20 years ago [105]. For diagnosis, these 
require the presence of widespread pain for at least three months and tenderness on pressure 
in at least 11 of 18 specified sites on digital palpation, performed with an approximate force 
of 4 kg [105]. However, some problems have been recognized in the diagnosis of FM using 
these strict criteria. On the one hand, the tender point count was not always performed in 
primary care and FM diagnosis has often been a symptom-based diagnosis in practice. On the 
other hand, patients who improved or whose symptoms and tender points decreased could fail 
to satisfy the ACR 1990 classification criteria. Taken these considerations into account, a 
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broad-based severity scale that could differentiate among patients according to the level of 
FM symptoms was recently developed [106]. The most important diagnostic variables are the 
widespread pain index (WPI), a measure of the number of painful body regions, and the 
symptom severity (SS) scale, a measure of FM symptom severity. A combination of both 
parameters has given a newly proposed case definition for FM: (WPI ≥7 and SS ≥5) or (WPI 
3-6 and SS ≥9) [106]. Remarkably, the SS scale score is based on symptoms which are often 
seen in CFS patients, namely fatigue, unrefreshing sleep, cognitive problems and a number of 
somatic symptoms such as muscle pain, headache and thinking or remembering problems. 
Between 35 and 70% of CFS patients experience myalgia, headache and other local or diffuse 
pain and up to 90% of adults with FM report significant fatigue. The large overlap in 
symptomatic features is reflected in a considerable overlap between both syndromes: it has 
been estimated that in referral clinics, 35% to 70% of CFS patients meet criteria for FM and, 
conversely, 20% to 70% of those with FM have CFS [107].  
It has been hypothesised that the apparent overlap between CFS and FM results from shared 
underlying mechanisms or coexisting psychiatric disorders. Aaron and colleagues [108] 
investigated this association in a twin study by examining whether a consistently higher 
frequency of comorbid conditions among the fatigued twins would be observed when adjusted 
for the number of lifetime affective and anxiety psychiatric disorders. The odds ratio 
comparing the frequency of comorbidity between fatigued and non-fatigued twins was greater 
than 10, even after adjusting for psychiatric status, suggesting that the association was not 
solely the consequence of psychiatric illness [108]. Possible alternative explanations for the 
association between CFS and comorbid conditions are the interplay between genes and 
environmental influences. 
 
3.5.2. Insomnia and other sleep disorders 
It is assumed that sleep impairment may provoke daytime dysfunctioning. Obviously, EDS 
and fatigue may be direct consequences from primary sleep disorders, such as insomnia, 
sleep-disordered breathing and narcolepsy. Dissatisfaction with daytime functioning may 
therefore be an incentive to seek medical help for a presumed disturbance of sleep. However, 
patients without primary sleep disorders may report awakening unrefreshed from nocturnal 
sleep, commonly known as nonrestorative sleep (NRS). This is a key symptom of chronic 
unexplained fatigue and CFS. 
All CFS case definitions include a minor criterion reflecting on aspects of sleep. The terms 
used vary substantially from (aspecific) sleep disturbance, to unrefreshing and NRS, to 
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various aspects of sleep quality, sleep duration and elements of insomnia and/or hypersomnia. 
Sleep disturbance is, however, reported by the vast majority of patients who receive a final 
diagnosis of CFS, with 87-95% of CFS cases in community surveys complaining of NRS [46, 
49, 95, 109]. The construct of NRS is highly complex and suffers from conceptual 
inconsistencies. Typically, patients report awakening unrestored or unrefreshed after a 
preceding night with sufficient sleep duration. NRS was first mentioned as a symptom of 
insomnia [110]. It has been shown that insomnia patients with NRS have more frequent 
daytime sequellae than those without NRS [111, 112]. Clearly, CFS and insomnia share 
features with respect to NRS and daytime dysfunctioning and could be manifestations of one 
and the same underlying disorder. To reveal if CFS patients suffer from insomnia is 
predominantly based on their subjective complaints. A thorough study with monozygotic 
twins revealed that CFS patients mentioned more symptoms being relevant for insomnia, 
whereas polysomnographic measures of insomnia did not differ between CFS patients and 
their healthy co-twins [19]. This phenomenon is seen as ‗sleep-state misperception insomnia‘. 
Similarly, insomnia patients also report diminished activity levels and a greater number and 
severity of daytime complaints which seem not to be associated with objective measures of 
daytime performance [113]. In this manner, a phenomenon of ‗daytime performance 
misperception‘ is conceptualized as a discrepancy between a patient‘s self-perceptions of 
daytime impairment and objective measures of such impairment. It has been proposed that 
these patients may over attend or selectively attend to the potential consequences of insomnia. 
The detection of cognitive errors or physical challenges that occur during the day reinforces 
the tendency to attend to (and interpret such events as being related to) insomnia [113]. In 
contrast, good sleepers pay little attention to ‗deficits‘ and to the extent that these phenomena 
are noticed, they are not interpreted as being the result of poor sleep. Insomnia patients have 
shown to display greater ‗attentional bias‘ for sleep related stimuli than good sleepers [113].  
Primary sleep disorders, especially OSA and narcolepsy, are regarded conditions that exclude 
CFS according to the Fukuda criteria [33], however, they are frequently diagnosed in patients 
with chronic fatigue and CFS. If these conditions should be seen as diagnostic exclusion 
criteria or as comorbidities of CFS is discussed further on in this thesis [114]. 
  
3.5.3. Psychiatric comorbidity 
3.5.3.1.Prevalence 
A variety of psychiatric conditions, particularly anxiety and depressive disorders, do not 
exclude a patient from the diagnosis of unexplained fatigue and are often seen in comorbidity 
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with chronic fatigue and CFS. In research studies, this comorbidity has especially been 
investigated in patients from primary and tertiary clinical settings [115-117]. Only a handful 
of researchers examined the prevalence of psychiatric conditions in patients with chronically 
unexplained fatigue identified from the general population [118-120]. Variances in prevalence 
amongst studies may be influenced by the application of different methodologies in assessing 
psychiatric disorders and by the use of different definitions for chronic fatigue and CFS. 
Nevertheless, in studies performed in clinical as well as in community-based samples, high 
prevalence rates of psychiatric comorbidity were observed in CFS patients and slightly lower, 
but still high in chronic fatigue patients who do not fulfil the criteria for CFS. Up to 90% of 
CFS patients have been found to show at least one lifetime psychiatric condition and about 
60% have been found to fulfil the criteria for at least one current psychiatric diagnosis [117, 
118]. Up to 80% and 45% of chronic fatigue patients have been shown to suffer from a 
lifetime or current comorbid psychiatric disorder, respectively [118]. 
 
3.5.3.2.Differential diagnosis 
The comorbidity between states of chronic fatigue and psychiatric disorders does not specify a 
cause-effect relationship. Moreover, it is thought that there is merely a coincidental overlap of 
symptoms between chronic fatigue/CFS and specific psychiatric conditions. In this context, it 
needs to be considered that chronic fatigue/CFS and psychiatric disorders, such as depression 
and anxiety, share characteristic symptoms including fatigue, sleep disturbances, 
concentration problems, low mood and worry.  
The differential diagnosis between CFS and psychiatric disorders is preferably made by a 
psychiatrist. Psychiatric diagnoses in CFS patients, made by non-specialists, often differ from 
diagnoses established according to research diagnostic criteria. Deale and Wessely [121] 
showed that up to 68% of CFS patients were misdiagnosed by general practitioners and 
hospital doctors when psychopathology of psychiatric disorders was concerned. Not only the 
overlap in symptoms complicate the diagnostic process, diagnosis may also be affected by the 
views of doctors (care provider bias) and patients (e.g. social acceptability bias). Some 
doctors tends to make a psychiatric diagnosis instead of CFS when physical symptoms arise 
in the absence of any identifiable disease. In contrast, CFS patients are often fiercely resistant 
to psychiatric diagnoses and complain that they are wrongly given a psychiatric label [121]. 
These findings highlight the difficulties of evaluating psychiatric disorder in patients 
presenting with medically unexplained fatigue. Misdiagnosis or inappropriate diagnosis may 
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have serious consequences. Indeed, treatable conditions may be overlooked as well as the 
doctor-patient relationship may be irretrievably damaged.  
Assessing CFS versus psychiatric conditions lies in the subtle features that discriminate 
between disorders. The most important difference between CFS and major depression is seen 
in the core symptomatology, being anergy and anhedonia respectively [122]. Furthermore, 
low self-esteem, hopelessness and suicidal ideation are frequently seen in depression and are 
not characteristic of CFS. CFS is more often associated with anergy, frustration and stress, as 
patients do not feel up to their daily activities. Avoidance behaviour or activity reduction is 
present in CFS as well as in depression and anxiety disorders, however, in CFS it may be 
driven by lack of energy rather than fear or loss of interest [121, 122]. In a comparative study 
of patients complaining of chronic fatigue, CFS patients did not differ from those who were 
chronically fatigued but did not meet the CDC criteria for CFS with regard to the prevalence 
of psychopathology [123].  
 
3.5.4. Functional somatic syndromes: one or many?  
It has been postulated that the existence of specific somatic syndromes is largely the 
consequence of medical specialisation [124]. Specialists seem to focus on those symptoms 
pertinent to their specialty which explains the differentiation of specific functional syndromes 
rather than real differences between patients. This suggests that the primary diagnosis will 
depend on the portal of entry for assessment with a care provider bias towards CFS in general 
internal medicine, FM in physiotherapy and insomnia in sleep medicine.  
Literature demonstrates that remarkable overlap exists between individual syndromes with 
regard to case definitions, reported symptoms and non-symptom characteristics such as 
patients‘ sex, outlook and response to treatment between the individual syndromes [124]. This 
raises the question if one should rather explore a new model in which different symptoms are 
clustered which may influence each other instead of further differentiating between separated 
disorders. Clusters of symptoms have also been found within functional somatic syndromes, 
suggesting a heterogeneous nature of these disorders [125-127]. This additionally indicates a 
shortcoming in the actual division of syndromes and may encourage the development of a 
new model in order to facilitate treatment-oriented diagnosis. To develop such a model, there 
is need to further understand the commonalities across functional somatic syndromes as well 
as the factors that differentiate between and within these syndromes. Therefore, future 
research should include symptomatic, demographic and biological variables that may explain 
patients‘ complaints [99]. 
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4. Treatment 
Shorter duration of the chronic fatigue has been observed to be associated with higher rates of 
improvement and recovery [128], however, recovery rates are generally low.  
In the management of CFS, patients should first be helped to accept their illness and its 
functional limitations since a short-term treatment is hitherto not available. Indeed, a lack of 
knowledge about factors that could account for and predict successful treatment in CFS 
complicates the therapeutic process. To date, therapeutic strategies for CFS include 
psychological, physical and pharmacological interventions. Randomised controlled trials have 
been carried out to assess the effectiveness of treatments including self-help treatment [129], 
antidepressants [130-132] and dietary supplementation with fatty acids [133] and folic acid 
[134]. However, no definitive proof of favourable effects for any of these therapies has been 
given until now. There is more evidence for positive effects of cognitive-behavioural 
approaches [135] and exercise therapy [136].   
 
4.1. Cognitive-behavioural therapy (CBT) and graded exercise therapy (GET) 
CBT is a psychological therapy model, delivered mainly by clinical psychologists, that 
facilitates the identiﬁcation of unhelpful, anxiety-provoking thoughts. The aim of the 
treatment is to change the cognitive and behavioural factors assumed to be responsible for 
perpetuation of the patient‘s symptoms and disability. Negative thoughts, including fears 
about symptoms or activity, are addressed using behavioural tasks and skills training. These 
consist of establishing a baseline of activity and rest and a regular sleep pattern, followed by 
collaboratively planned gradual increases in both mental and physical activity. Furthermore, 
CBT helps participants to address social and emotional obstacles through problem-solving 
[136].   
GET in CFS is delivered  mainly by physiotherapists and based on the assumption that the 
syndrome is perpetuated by reversible physiological changes of deconditioning and avoidance 
of activity. The aim of the treatment is to help the patient gradually return to appropriate 
physical activities, reverse the deconditioning and thereby reduce fatigue and disability. In 
practice, a baseline of achievable exercise or physical activity is established, followed by a 
negotiated, incremental increase in the duration of time spent physically active. Walking is the 
most commonly chosen exercise [136].  
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4.1.1. Response to CBT and GET 
There is substantial evidence that CBT and GET are efficacious in the treatment of CFS. 
Patients were more likely to have reduced fatigue symptoms at the end of the CBT treatment 
compared with usual care and other physiological therapies, including relaxation techniques, 
counselling and support [135, 137, 138]. GET seems to produce similar effects as CBT in 
CFS with regard to overall outcome as well as fatigue, functional impairment, depression and 
anxiety [138]. However, point estimates, as used for a small number of studies with relatively 
small sample sizes, suggested that CBT might be a more effective treatment for CFS patients 
with comorbid depression or anxiety [138]. This finding may reflect the greater emphasis on 
the role of emotional factors in the perpetuating of fatigue.  
Promising outcomes at short to medium term follow-up have been resulted from randomized 
controlled trials, however, there are only limited data on the long-term response of CBT for 
CFS [139] in contrast to the proven positive long-term effects of CBT in insomnia [140]. 
More studies are needed to get more insight in the characteristics of patients who show 
relapses and who could potentially benefit from more sessions or additional intervention 
strategies.  
There is a remarkable variation in the response to CBT and GET among CFS patients [135, 
137, 138, 141]. Some of them fully recover, others only show a modest reduction in 
symptoms and a considerable number of patients do not profit from the therapy. It is supposed 
that some patients believe that a gradual increase in mental and physical activity may lead to 
an increase in symptoms. Many patients also feel that CBT implies that their symptoms are 
‗psychological‘ although the biopsychosocial model of CFS underlying CBT does not state 
that there is an absence of a somatic cause for CFS symptoms but only assumes that cognitive 
and behavioural factors contribute to its maintenance [139]. Such thoughts might hamper 
efficient treatment. The variation in effect sizes could also be linked to the heterogeneity of 
CFS. Several subgroups of patients have been identified, however, these subgroups could 
hitherto not unequivocally be linked to the response to CBT and GET [139, 142]. It should be 
interesting to get more knowledge about patient‘s characteristics in order to improve the 
outcome of behavioural interventions by selecting those patients who have a reasonable 
chance of improving from CBT and/or GET or by developing additional treatment strategies. 
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4.2. Pharmacotherapy 
CFS patients usually use a wide range of conventional and alternative medicines, since they 
are often desperate to try anything and hope to find some relief for their disabling symptoms. 
An Australian study with 94 CFS patients found that the most commonly used conventional 
medicines where those acting on the CNS [143]. Antidepressants were taken most frequently 
by 41% of the patients, followed by simple analgesia such as paracetamol, aspirin and 
NSAIDs (37%), sedative and hypnotics (27%) and opioids (13%). Alternative medicines and 
supplements were often used by the same study subjects: 47% reported to take B vitamins, 
24% used magnesium and 7% were taking a co-enzyme Q10 supplement [143]. The literature 
shows that application of different medicinal therapies and the frequent concomitant use of 
multiple drugs in CFS patients. Nevertheless, none of these medicines has been proven to be 
uniformly effective [143-145]. E.g., CFS patients may be thought to benefit from 
antidepressants, since CFS and depression show similarities in symptomatology and possible 
etiology and pathogenesis. Moreover, there is significant overlap between CFS and FM for 
which antidepressants have shown consistent efficacy [145]. Nevertheless, the number of 
randomised controlled trials, evaluating the efficacy of pharmacological treatments in CFS 
patients, is scarce in contrast with the widely studied nonpharmacological interventions. 
Methodological shortcomings, such as the lack of control groups and not randomised or 
blinded studies, also lead to a high risk of bias. Additionally, the severity of symptoms 
fluctuates in CFS and temporary improvements may mistakenly be attributed to the treatments 
used. It is clear that more evidence from randomised and blinded clinical trial is needed to get 
insight in the long-term effects of antidepressants in particular and pharmacotherapy in 
general on CFS to get better guidance for the management of this condition. To date, 
pharmacotherapy can not be considered first-line treatment in CFS and should rather be used 
in the context of self-management and rehabilitation.  
 
4.3. From perpetuating factors to individualized-oriented therapy 
There is a remarkable variation in the response to CBT and GET among CFS patients, which 
may be influenced by factors concerning the treatment protocol, the treating therapist and the 
patient himself. Higher effect sizes seems to be observed for individual therapeutic 
assessments than for group programs [146, 147]. This may, at least partly, reflect the 
individual differences between CFS patients and the heterogeneity of perpetuating factors. 
Together with the fact that therapeutic effects are not always maintained in the long-term and 
that drop-out rates are fairly high, may insist a more individualized therapy approach [148]. 
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Nevertheless, factors that could account for and predict successful treatment in CFS are not 
well known and should be studied via process-outcome studies that focus on putative 
mechanisms of change. Such studies are scarce, although in CFS, some perpetuating factors 
such as membership of a self-help group, receipt of sickness-benefits low sense of control, 
strong focus on symptoms, emotional problems and passivity have been found to predict 
negative treatment-outcome of CBT [149], whereas a decrease in symptom-focussing 
predicted a positive outcome for CBT [150].  
Van Houdenhove and colleague [148] propose that individualized treatment should consist of 
three components. First, comorbid illnesses including depression, anxiety and sleep disorders 
should be treated adequately in order to minimize patients‘ emotional and physical distress. It 
is not yet clear, however, if treatment of these comorbid disorders may diminish fatigue 
complaints.  
Second, the patient should be offered a plausible illness theory that can be the starting point 
for translating the therapeutic rationale into concrete practice. The attitude of the therapist 
towards the treatment goals has shown to affect the expectations and perceptions of the 
patient. If the therapist says that recovery is possible, the patients expectations raise, which 
may lead to a change in the perception of symptoms as well as disability.  
Third, the perpetuating factors that will be concretely targeted during the therapy should be 
discussed with the patient. Patients should be encouraged to correct unhelpful thoughts and 
attitudes and to gradually increase activities in accordance with their personal objectives. 
They should learn how to pace their activities instead of periodically exceeding their limits 
and provoking repeated setbacks manifesting as post-exertional malaise.   
 
5. Care path for unexplained chronic fatigue 
In view of these observations, the significant overlap of the different entities and functional 
somatic syndromes as well as the significant prevalences of comorbidity both in the field of 
sleep disorders as psychiatric disease, it is postulated that patients that are labeled with one of 
these syndromes should be systematically and thoroughly assessed (and often reassessed). 
Hence patients referred to our multidisciplinary tertiary care referral center (Department of 
General Internal Medicine, Infectious Diseases and Psychosomatic Medicine, University 
Hospital Ghent) for assessment of longstanding chronic fatigue, are invited to systematically 
enter an integrated path of care (Figure 2). This includes an internal medicine assessment, a 
psychodiagnostic screening, a physiotherapeutic assessment and a PSG in combination with a 
MSLT. The internal medicine assessment consists of a physical examination and integrates 
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the results of previous investigations. The psychodiagnostic screening includes an evaluation 
by a psychologist and psychological testing using validated questionnaires. The 
physiotherapeutic evaluation focuses on a screening for musculoskeletal comorbidity such as 
FM, according to the ACR criteria, and other impairments that are suitable for physical 
rehabilitation. If psychopathology is suspected, further psychiatric diagnosis is started. The 
multidisciplinary discussion yields either a final diagnosis or a tentative diagnosis in selected 
patients, in whom response to treatment is considered an additional diagnostic criterion.  
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Figure 2. Path of care for unexplained fatigue. Full lines indicate systematic, interrupted lines additional steps. 
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6. Research aims 
Because of the relative lack of objective and subjective data on sleep in CFS, we aimed to 
build a large patient sample fitting the prevailing Fukuda et al. definition of CFS. In order to 
assess further research questions, important gaps in objective data needed to be filled in 
through descriptive research.  
In view of the complexity and lack of robustness of both the syndromal definitions and the 
different aetiological hypotheses, approached in the introduction, we hypothesize that the 
syndromal constellation of CFS actually erroneously groups together a larger spectrum of 
underlying pathology, that needs to be differentiated. Furthermore, we wish to explore the 
causal relationship between sleep and daytime dysfunction (fatigue) in this patient population, 
in which we challenge the commonly held unidirectional paradigm of adequate sleep as a 
prerequisite for daytime functioning.  
 
To encounter the first hypothesis, we aim: 
 To explore the diagnostic categories of patients with unexplained chronic fatigue 
through systematic clinical analysis 
 
- To explore the prevalence of final diagnostic categories of patients with 
presumed CFS  
- To assess primary sleep disorders in CFS through systematic 
polysomnography and multiple sleep latency test 
 
For the second hypothesis, we aim: 
 To assess the existing literature on sleep in CFS 
 
 To explore subjective sleep parameters and sleep quality in CFS patients 
 
- To assess subjective sleep quality and daytime sleepiness in a large sample of 
CFS patients  
- To validate a previously reported three-factor scoring model of the Pittsburgh 
Sleep Quality Index in a large sample of CFS patients 
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 To assess objective sleep measures and subjective sleep parameters in a large sample 
of patients with unexplained chronic fatigue and their mutual correlation  
 
 To explore the interrelationship of self-report questionnaires on different dimensions 
in the construct of chronic fatigue and CFS 
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Abstract 
Objective 
To assess undiagnosed and comorbid disorders in patients referred to a tertiary care center 
with a presumed diagnosis of chronic fatigue syndrome (CFS). 
Methods 
Patients referred for chronic unexplained fatigue entered in an integrated path of care, 
including internal medicine assessment, psychodiagnostic screening, physiotherapeutic 
assessment and polysomnography + multiple sleep latency test. Final diagnosis resulted from 
a multidisciplinary team discussion. Fukuda criteria were used for the diagnosis of CFS, 
DSM-IV-TR criteria for psychiatric disorders, ICSD criteria for sleep disorders. 
Results 
Out of 377 patients referred, 279 (74.0%) were included in the study [84.9% female; mean 
age 38.8 years (SD 10.3)]. 
23.3% had a diagnosis of unequivocal CFS. In 21.1%, CFS was associated with a sleep 
disorder and/or psychiatric disorder, not invalidating the diagnosis of CFS. 9.7% had a 
predominant sleep disorder, 19.0% a psychiatric disorder and 20.8% a combination of both. 
Only 2.2% was diagnosed with a classical internal disease. 
In the total sample, a sleep disorder was found in 49.8%, especially obstructive sleep apnea 
syndrome, followed by psychophysiologic insomnia and periodic limb movement disorder. A 
psychiatric disorder was diagnosed in 45.2%; mood and anxiety disorder were most 
frequently observed. 
Conclusions 
A multidisciplinary approach to presumed CFS yields unequivocal CFS in only a minority of 
patients, and reveals a broad spectrum of exclusionary or comorbid conditions within the 
domains of sleep medicine and psychiatry. These findings favor a systematic diagnostic 
approach to CFS, suitable to identify a wide range of diagnostic categories that may be 
subject to dedicated care. 
 
Key words 
Chronic fatigue syndrome, comorbidity, prevalence, psychiatric disorders, sleep disorders
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Abbreviations 
AASM American Academy of Sleep Medicine 
AHI   apnea-hypopnea index 
BMI   body mass index 
CFS   chronic fatigue syndrome 
DSM-IV-TR Diagnostic and Statistical Manual of mental disorders, 4
th
 edition – text 
revision 
ICSD-2  International Classification of Sleep Disorders, 2
nd
 edition 
MSLT  multiple sleep latency test  
OSA   obstructive sleep apnea 
PLMD  periodic limb movement disorder 
PLM   periodic limb movements 
PSG   polysomnography 
REM   rapid eye movements 
SD   standard deviation 
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Introduction 
Chronic fatigue syndrome (CFS) is characterized by long lasting, unexplained fatigue with a 
disabling impact on professional, social and daily functioning. The absence of any obvious 
underlying disease, and the presence of a number of associated clinical features are 
fundamental to this disorder. Several case definitions have been introduced, including the 
revised CDC (Centers for Disease Control and Prevention) criteria published by Fukuda et al. 
in 1994 (1). These are now the standard guidelines in the US and are widely used in other 
countries as well. To establish the diagnosis of CFS, the Fukuda definition require a major 
criterion of unexplained, incapacitating fatigue of at least six months duration, in combination 
with at least four out of eight minor criteria. These minor criteria include postexertional 
malaise lasting for at least 24 hours, sore throat, tender cervical or axillary lymph nodes, 
muscle pain, multi-joint pain without swelling or redness, headache of a new type, pattern or 
severity, memory and concentration impairment and unrefreshing sleep. 
Fatigue, the main feature of CFS, is a complex, heterogeneous and multidimensional 
phenomenon. It is a common denominator referring to various aspects of impaired physical, 
mental, emotional and neurocognitive functioning (2-4). Fatigue is a frequent manifestation of 
a variety of medical, neurological and psychiatric conditions but it may also appear as a side 
effect of pharmacological treatment.  
With regard to fatigue and associated symptoms, the syndromal definition of CFS overlaps 
with other entities such as insomnia (5;6), obstructive sleep apnea (OSA) (7), fibromyalgia (8) 
and mood disorders (9). The Fukuda criteria stipulate limited exclusion criteria within the 
primary psychiatric disorders, such as past or present diagnosis of a major depression with 
psychotic features, bipolar affective disorders, schizophrenia of any subtype, delusional 
disorders of any subtype, dementia of any subtype, anorexia nervosa or bulimia nervosa (1). 
As a result, the Fukuda criteria allow a diagnosis of CFS, even in the presence of a mood 
disorder, without specification to which extent this disorder needs to be treated. Within the 
primary sleep disorders, sleep apnea, without indication of severity, and narcolepsy are 
conditions that exclude a diagnosis of CFS (1). Primary and secondary insomnia (DSM-IV-
TR) (10) do not feature within the Fukuda exclusions, although insomnia can explain the 
somatic symptoms in a number of presumed CFS patients (5;11). 
 
Chronic unexplained fatigue is best approached from a biopsychosocial perspective (12) 
within a multidisciplinary setting. A monodisciplinary approach may lead to a spurious 
diagnosis of CFS as treatable psychiatric or sleep disorders may go unnoticed.  
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Patients with unexplained chronic fatigue are referred to our tertiary care center to confirm or 
exclude a presumed diagnosis of CFS. Appropriate medical and psychodiagnostic 
investigation may reveal some specific nosological entities that are either exclusionary or 
comorbid to CFS. The aim of the current study was to assess the prevalence of these disorders 
in the group of patients referred to our center.  
  
Methods 
Patient recruitment took place between June 2010 and February 2011. Typically, patients 
were referred for confirmation of a presumed diagnosis of CFS. Criteria to be enrolled in the 
present study were unexplained fatigue persisting for at least six months, and a minimum age 
of 18 years. Participants gave written informed consent. The study was approved by the 
institutional Ethical Review Board of the University Hospital Ghent, Belgium. 
 
Multidisciplinary assessment 
Assessment of chronic fatigue at our center follows a holistic approach that is based on the 
biopsychosocial model by Wessely et al. (12). The initial diagnostic part of the integrated path 
of care (Figure 1) involves internal medicine assessment, psychodiagnostic screening, 
rehabilitation assessment, and polysomnography (PSG) combined with a multiple sleep 
latency test (MSLT). The internal medicine assessment consists of comprehensive history 
taking, also considering any previous medical diagnoses or investigations, and a physical 
examination. If indicated, routine lab tests, chest radiography and echography of the abdomen 
are carried out. A rehabilitation physician evaluates whether any musculoskeletal comorbidity 
is present that is potentially suitable for physiotherapeutic management. Psychodiagnostic 
screening, performed by a medical psychologist, includes history taking, the administration of 
validated questionnaires (Table 1) and psychological tests. Psychiatric consultation is 
scheduled when the history is remarkable for a past or present psychiatric disorder, and 
whenever hints for the presence of a psychiatric disorder emerge from the psychodiagnostic 
evaluation or from the multidisciplinary discussion (Figure 1). Psychiatric diagnosis complies 
with DSM-IV-TR criteria (10).  
 
Sleep assessment 
Sleep history is based on an interview that integrates the results of relevant sleep 
questionnaires (Table 1). Sleep diagnosis is in keeping with the ICSD-2 nosology (13). 
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PSG and MSLT are recorded and scored according to the American Academy of Sleep 
Medicine (AASM) manual (14). Sleep parameters derived from PSG include time in bed, total 
sleep time, sleep efficiency, sleep latency, REM sleep latency, time spent in the different 
sleep stages, wakefulness after sleep onset, arousal index, apnea-hypopnea index (AHI) and 
presence of periodic limb movements (PLM). MSLT includes assessment of mean sleep 
latency and presence of sleep onset REM-sleep.  
OSA is defined by an AHI ≥5/h in combination with associated symptoms (e.g. excessive 
daytime sleepiness, fatigue, or impaired cognition). Severity of OSA is classified as mild (5≤ 
AHI <15), moderate (15≤ AHI <30) or severe (AHI ≥30). 
Patients were asked to withdraw from hypnotics (benzodiazepines and z-drugs) at least three 
weeks before PSG was performed. 
 
Diagnostic decision making and categories 
The outcome of the multidisciplinary discussion is a diagnostic decision regarding 
unequivocal CFS, CFS with comorbidity, or a condition that excludes CFS.  
In unequivocal CFS, no symptoms or signs of coexisting sleep or psychiatric disorders are 
observed. CFS with comorbidity is defined as a combination of chronic unexplained fatigue 
meeting the major and minor Fukuda criteria, with a comorbid condition that may contribute 
to, but does not sufficiently explain the degree of reported impairment. Typically, coexisting 
mood disorder or sleep disorders (e.g. OSA, insomnia, or periodic limb movement disorder 
(PLMD)) are being considered ‗comorbid‘ in a number of patients. Predominant sleep and/or 
psychiatric disorders are judged exclusionary to CFS, as they tentatively explain the full 
clinical picture, including fatigue. In this case, the diagnosis of CFS is not assumed in the first 
instance, but may be reconsidered in a subsequent stage, pending insufficient symptomatic 
relief following adequate treatment of the primary disorder.  
Diagnostic categories include: 1) CFS without comorbidity (unequivocal CFS), 2) CFS with 
comorbidity, 3) a predominant sleep disorder, 4) a predominant psychiatric disorder, 5) a 
combination of a sleep and psychiatric disorder, 6) a classical internal medicine disease (with 
or without associated psychiatric or sleep disorders), 7) no final diagnosis (complaints of 
chronic fatigue remaining unresolved). 
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Statistical analysis 
Descriptive statistics were performed with SPSS Statistics version 19. 
 
Results 
Inclusion and demographics 
Three hundred seventy-seven patients were referred for evaluation of chronic fatigue (Figure 
2). Seven patients (1.9%) were excluded because of the age requirement. Fifty-eight patients 
(15.4%) did not give informed consent and in 17 patients (4.5%) data were incomplete, 
mostly due to cancellation of appointments. In sixteen patients (4.2%) complaints of fatigue 
had been present for less than six months. Two hundred seventy-nine patients (74.0%) who 
met the inclusion criteria were enrolled in the study. 
The majority of the patients was female (n = 237; 84.9%). The mean age was 38.8 years (SD 
10.44); mean body mass index (BMI) was 25.0 kg/m² (SD 5.19). A minority (n = 104; 37.2%) 
had a certificate of higher education. 
 
Final diagnoses 
An overview of the final diagnoses is presented in Figure 2 and Figure 3a.  
Of the 279 included patients, 224 (80.3%) met at least four of the minor Fukuda criteria. Of 
these, 65 subjects (23.3%) had a final diagnosis of unequivocal CFS. In 59 patients (21.1%), 
CFS was associated with psychiatric disorders (n = 7; 2.5%), sleep disorders (n = 45; 16.1%) 
or both (n = 7; 2.5%) that were judged comorbid and did not exclude the diagnosis of CFS. 
One hundred patients (35.8%), in spite of fulfilling the major and minor criteria of CFS, were 
diagnosed with another predominant condition, i.e. a psychiatric disorder (n = 35; 12.5%), a 
sleep disorder (n = 18; 6.5%), a combination of both (n = 41; 14.7%), an internal disease with 
or without sleep or psychiatric comorbidity (n = 4; 1.4%),  and other conditions (n = 2; 0.7%). 
Fifty-five patients (19.7%) did not meet the minor Fukuda criteria. Eighteen (6.5%) of these 
patients had a diagnosis of a predominant psychiatric disorder, 9 (3.2%) a predominant sleep 
disorder, 17 (6.1%) a combination of both, and 11 (4.0%) other conditions. 
Only 6 patients (2.2%) of the total sample had a final diagnosis pertaining to the domain of 
classical internal medicine. Internal disorders consisted of post viral asthenia (4 patients) and 
diabetes mellitus (2 patients). In one patient the diabetes was associated with severe obesity, 
liver steatosis and hemochromatosis. Moreover, a psychiatric comorbidity was present in 1 
and a sleep disorder in 2 patients of this subgroup.   
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Sleep disorders 
In 242 out of 279 patients (86.7%) the minor criterion of ‗unrefreshing sleep‘ was positive. 
Objective sleep assessment revealed (predominant or comorbid) sleep disorders in 139 
patients (49.8%) of the total sample. Ninety patients (32.0%) had  a single sleep disorder, 
whereas a combination of two and three sleep disorders was present in 46 (16.4%) and 3 
patients (1.1%), respectively.  
A wide range of sleep disorders was observed (Figure 3b) , OSA being the most prevalent 
(n=80; 28.7%). Mild, moderate and severe OSA were diagnosed in 61 (21.9%), 14 (5.0%) and 
5 patients (1.8%), respectively. Other prevalent diagnoses were psychophysiologic insomnia 
(n=43; 15.4%), PLMD (n=34; 12.2%) and hypnotic dependent sleep disorder (n=14; 5.0%).  
 
Psychiatric disorders 
In the total sample, a (predominant or comorbid) psychiatric disorder was diagnosed in 126 
patients (45.2%). The majority of these patients (n = 86; 30.8%) had an axis I diagnosis, 14 
(5.0%) an axis II diagnosis and 26 (9.3%) a combination of both.  
Mood disorder was most prevalent (n = 74; 26.5%), followed by anxiety disorder in 39 
patients (14.0%) (Figure 3c). Sixteen patients (5.7%) had a diagnosis of undifferentiated 
somatoform disorder. 
 
Discussion  
The present study is remarkable for the finding that multidisciplinary assessment of presumed 
CFS confirms unequivocal CFS in only a minority of patients, and reveals a broad spectrum 
of exclusionary or comorbid conditions within the domains of sleep medicine and psychiatry. 
In the total group of patients referred to our tertiary care center, different diagnostic categories 
were identified including unequivocal CFS (23.3%), CFS with significant comorbidity that 
does not invalidate the diagnosis of CFS (21.1%), predominant sleep disorders (9.7%) and 
predominant psychiatric disorders (19.0%).  
OSA, being the most prevalent sleep disorder in the recruted patient sample, was observed in 
28.7%. In other CFS referral centers, prevalence rates of ±45% have been reported (15;16). 
Obviously, OSA is a salient comorbid, or even an exclusionary disorder that is to be 
considered in the differential diagnosis of CFS. The prevalence of OSA is estimated 4% in 
men and 2% in women in the general population (17). Patients with chronic unexplained 
fatigue are often sedentary and even bedridden (18), which might predispose them to obesity 
and sleep-disordered breathing (19). However, the weight status of the present patient sample 
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approximates normalcy (mean BMI 25.0 kg/m²) and is similar to that of the overall Belgian 
adult population (mean BMI 25.3 kg/m²) (20). This finding is in accordance with limited 
published data which suggest that patients with chronic unexplained fatigue and CFS are not 
excessively overweight or obese (21). Interestingly, the high prevalence of OSA in our patient 
group is in parallel with the rates of unrelated clinical samples, such as arterial hypertension 
(30-85%), congestive heart failure (20-50%), and metabolic syndrome (82%) (22). The use of 
PSG to identify OSA has been advocated in clinical populations at risk for OSA (23), and 
seems from the present data also recommendable in CFS patients. 
Insomnia was observed in a relatively small number of enrolled patients (15.4%)  which is in 
contrast with data from the general population that demonstrate a higher prevalence (27.2%) 
(24). This may be due to selection bias, because patients with a clear history of insomnia are 
directly being referred for dedicated insomnia-treatment in our hospital. Similarly, hypnotic-
dependent sleep disorders (5.0%) may also be underrepresented because patients were asked 
to withdraw from sleeping pills before PSG was carried out. 
Hitherto, a strong connection between CFS and psychiatric disorders has been reported. In a 
community-based study, Nater et al. found that 57% of individuals with CFS had at least one 
current and 89% one lifetime psychiatric diagnosis (25). In clinical CFS patients, significant 
coexistence with psychiatric disease was found (26-29). However, in our patient sample, we 
mostly observed predominant diagnoses of mood disorder and anxiety disorder, that actually 
exclude CFS (40.2%), whereas psychiatric disturbances that do not invalidate the diagnosis of 
CFS were less frequent (5.0%). The predominance of exclusionary over comorbid psychiatric 
disorders probably resulted from the formal psychodiagnostic evaluation, psychiatric 
diagnostic work-up and multidisciplinary discussion. As a consequence, we contend that 
insufficiently recognized psychiatric morbidity should be addressed prior to labelling chronic 
fatigue as CFS.   
Data on prevalence rates of personality disorder in CFS patients are inconsistent. Previously 
reported figures ranging between 28 and 39% (26-28;30) were not confirmed by Courjaret et 
al. (31) and by Kempke et al. (32) who found that, respectively, in only 12% and 16% of 
female CFS patients a personality disorder could be identified. In the present sample, the 
prevalence of personality disorder (especially cluster B and C) amounted to 14.3%, which 
approximates the latter figures. Differences in methodology, including sample size, selection 
bias and the use of different self-report questionnaires, may explain the variety in prevalences 
among different studies.  
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Diagnoses pertaining to classical internal medicine are scarce in our sample, probably because 
they already had been detected at the level of primary or secondary care. This finding would 
imply that, at the tertiary care level, there is no need for repeating extensive medical tests to 
detect underlying internal diseases. With respect to health policies pertaining to CFS, it is 
recommended to limit laboratory and imaging tests in terms of number and reiteration.  
Obviously, the present reclassification of presumed CFS into categories of unequivocal CFS, 
comorbid CFS and exclusionary conditions is the result of a systematic and integrated 
multidisciplinary approach, including internal medicine, medical psychology, psychiatry and 
rehabilitation medicine. As such, this approach differs from monodisciplinary case 
management, that tends to label medically unexplained symptoms (MUS) into organ- or 
specialty driven syndromal definitions, e.g. irritable bowel syndrome, fibromyalgia, and 
myalgic encephalomyelitis. Unraveling the intricacies of MUS is not a focus of interest for 
many general practitioners and organ specialists. Often, the characteristics of precipitating and 
perpetuating factors that are operational in MUS are insufficiently documented. Moreover, 
salient comorbidity in the domains of psychopathology and sleep medicine may go unnoticed.  
From our data, it is clear that a tendency to prematurely establish a diagnosis of CFS, carries a 
risk of underdiagnosis of other treatable disorders. Dedicated methods for differentiated  
assessment of chronic fatigue, such as ours, may provide means to reorient patients towards 
integrated care programs based on multimodal therapy, taking into account previously 
undetected psychiatric and/or sleep disorders. At the same time, this approach may serve as a 
corrective tool against overlabelling with non-validated syndromal definitions. The wide 
range of treatable disorders that is found in the present sample may serve as a justification for 
the need to systematically assess clinical CFS patients in a multidisciplinary setting. 
 
A limitation of this study is the lack of follow-up of patients after treatment. Assessment in 
our center is part of a regional network of care. Our intervention focuses primarily on the 
diagnostic pathway, and a number of patients is subsequently referred back to the treating 
physician. Therefore, systematic follow-up data on the effect of recommended treatment 
regimens are not available. The report hence focuses on the initial diagnostic classification, 
which could be subject to adjustment following reassessment after the therapeutic phase. 
 
In conclusion, a multidisciplinary approach to patients with presumed CFS referred to a 
tertiary care center seems necessary in order to identify a wide range of diagnostic categories 
relevant to appropriate care. A high prevalence of predominant sleep and psychiatric disorders 
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is found. These findings favor thorough screening including psychodiagnostic testing, formal 
psychiatric diagnosis and objective assessment of sleep parameters in patients with presumed 
CFS.  
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Table 1. Overview of psychodiagnostic and other questionnaires 
Questionnaire Dimension explored 
Symptom Checklist-90-Revised (33) Psychological distress 
Chalder Fatigue Scale (34) Severity of fatigue 
Medical Outcomes Study 36-item Short Form Health Survey (35) Global mental and physical health 
Epworth Sleepiness Scale (36) Excessive daytime sleepiness 
Pittsburgh Sleep Quality Index (37) Global sleep quality 
NEO-Five Factor Inventory (38) Personality assessment 
Checklist Individual Strength (39) Phenomenology and severity of fatigue 
Millon Clinical Multiaxial Inventory (40) Psychopathology 
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Figure 1. Path of care for unexplained fatigue. Full lines indicate systematic, interrupted lines optional steps. 
Internal medicine 
assessment 
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Patients referred for evaluation of CF 
n = 377 
Patients with presumed CFS 
n = 279 
≥ 4 minor Fukuda criteria 
n = 224 
Unequivocal CFS 
n = 65 
Exclusion: 
 < 18 years: n = 7 
 no informed consent: n = 58 
 insufficient data available: n = 17 
 fatigue < 6 months: n = 16 
< 4 minor Fukuda criteria 
n = 55 
CFS with comorbidity 
n = 59 
CFS excluded 
n = 100 
 CFS + psychiatric disorder: n =  7 
 CFS + sleep disorder: n = 45 
 CFS + both: n = 7 
 Psychiatric disorder: n = 35 
 Sleep disorder: n = 18 
 Psychiatric + sleep disorder: n = 41 
 Internal disease: n = 4  
      (1 psychiatric and 2 sleep disorders) 
 Other condition: n = 2 
Psychiatric 
disorder 
n = 18 
Sleep 
disorder 
n = 9 
Psychiatric +  sleep 
disorder 
n = 17 
Other 
condition 
n = 11 
 Internal disease: n = 2 
 Other condition: n = 2 
 No final diagnosis: n = 7 
 Figure 2. Flow chart of patients referred for evaluation of unexplained chronic fatigue, and final diagnoses in patients with presumed CFS 
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Figure 3. Relative prevalence of (a) final diagnosis; (b) sleep disorders, (c) psychiatric 
disorders in patients with presumed CFS 
Idiop. hypersom.: Idiopathic hypersomnia 
 79 
c. 
14,0
26,5
4,3
0,4
1,1 1,4
5,7
1,8
5,7
6,8
0,0
5,0
10,0
15,0
20,0
25,0
30,0
A
nx
ie
ty
 d
is
or
de
r
M
oo
d 
di
so
rd
er
S
ub
st
an
ce
 re
la
te
d 
di
so
rd
er
P
sy
ch
ot
ic
 d
is
or
de
r
P
er
va
si
ve
 d
ev
el
op
m
en
ta
l d
is
or
de
rs
E
at
in
g 
di
so
rd
er
s
U
nd
iff
er
en
tia
te
d 
so
m
at
or
fo
rm
 d
is
or
de
r
C
lu
st
er
 A
C
lu
st
er
 B
C
lu
st
er
 C
%
 o
f 
p
a
ti
e
n
ts
 
Figure 3. Relative prevalence of (a) final diagnosis; (b) sleep disorders, (c) psychiatric 
disorders in patients with presumed CFS 
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Abbreviations 
CAP   cyclic alternating pattern 
CDC   Centers for Disease Control and Prevention (USA) 
CFS  chronic fatigue syndrome 
CPAP   continuous positive airway pressure 
DIS  difficulty with initiating sleep 
DMS   difficulty with maintaining sleep 
EDS   excessive daytime sleepiness 
EEG   electro-encephalography 
FFT   fast Fourrier transformation 
FMS   fibromyalgia syndrome  
MOS SF-36  medical outcomes study short form 36-item 
NREM  non-rapid eye movement 
NRS   nonrestorative sleep 
OSA   obstructive sleep apnea 
PSD   primary sleep disorder 
PSG   polysomnography 
REM   rapid eye movement 
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Summary 
Chronic fatigue syndrome (CFS) is a disabling condition characterized by severe fatigue 
lasting for more than six months and the presence of at least four out of eight minor criteria. 
Sleep disturbance presenting as unrefreshing or nonrestorative sleep is one of these criteria 
and is very common in CFS patients. 
Biologically disturbed sleep is a known cause of fatigue and could play a role in the 
pathogenesis of CFS. 
However, the nature of presumed sleep impairment in CFS remains unclear. Whilst 
complaints of NRS persist over time, there is no demonstrable neurophysiological correlate to 
substantiate a basic deficit in sleep function in CFS. Polysomnographic findings have not 
shown to be significantly different between subjects with CFS and normal controls. 
Discrepancies between subjectively poor and objectively normal sleep suggest a role for 
psychosocial factors negatively affecting perception of sleep quality. Primary sleep disorders 
are often detected in patients who otherwise qualify for a CFS diagnosis. These disorders 
could contribute to the presence of daytime dysfunctioning. There is currently insufficient 
evidence to indicate that treatment of primary sleep disorders sufficiently improves the fatigue 
associated with CFS. Therefore, primary sleep disorders may be a comorbid rather than an 
exclusionary condition with respect to CFS. 
 
  86 
Introduction 
Recurring complaints of disturbed sleep and fatigue are very common among the general 
population. Patients who present with a combination of these symptoms may perceive 
malfunction of sleep as the prime cause of tiredness and other impairments in daily life. 
Because of this attribution, dissatisfaction with daytime functioning may be an incentive to 
seek medical help for a presumed disturbance of sleep. 
Fatigue is a common denominator referring to various aspects of impaired physical, mental, 
emotional and neurocognitive functioning. Lack of energy, weakness, attention deficits, 
memory problems and irritability are typically associated with the construct of fatigue. It is a 
frequent manifestation of a variety of medical, neurological and psychiatric diseases. It may 
also appear as a side effect of pharmacological treatment. 
Presently, there is ample evidence to confirm that sleep curtailment, whether experimentally 
induced or self-imposed, is causally associated with fatigue. Likewise, primary sleep 
disorders (PSD) are a known cause of fatigue and excessive daytime sleepiness (EDS). 
Clinical improvement of these symptoms can be expected from adequate treatment of the 
underlying sleep disorder. 
Finally, fatigue often remains unexplained, leading to the construct of chronic fatigue 
syndrome (CFS), in which unrefreshing sleep is a prominent (but ill-defined) feature. 
The aim of the present review is to: 
1. give an overview of definitions, health impact and epidemiology of CFS; 
2. explore current insights into restorative and nonrestorative aspects of sleep; 
3. assess the relations between sleep and CFS 
 
Definitions, health impact and epidemiology of CFS 
CFS is characterized by long lasting pathologic fatigue with a disabling impact on 
professional, social and daily functioning. The absence of any obvious underlying disease, 
and the presence of a number of associated clinical features are fundamental to this disorder. 
The term CFS was coined in 1988 by Holmes et al. in a publication of the US Centers for 
Disease Control and Prevention (CDC) [1]. Since then, several new case definitions have 
been introduced. In 1994, revised CDC criteria were published by Fukuda et al. [2]. These are 
standard guidelines in the US and are widely used in other countries as well. 
To establish the diagnosis of CFS, the Fukuda et al. guidelines require a major criterion of 
pathological, incapacitating fatigue of at least six months duration, in combination with at 
least four out of eight minor criteria. These minor criteria include postexertional fatigue 
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lasting for at least 24 h, sore throat, tender cervical or axillary lymph nodes, muscle pain, 
multi-joint pain without swelling or redness, headache of a new type, pattern or severity, 
memory and concentration impairment and unrefreshing sleep. The key features of the 
different case definitions (Holmes et al., 1988 [1]; Lloyd et al., 1990 [3]; Sharpe et al., 1991 
[4]; Fukuda et al., 1994 [2]; Carruthers et al., 2003 [5]) were recently reviewed by Christley et 
al.[6]. All existing guidelines are founded on expert based consensus and lack robust medical 
evidence. 
Depending on the case definitions and the characteristics of the population screened, a wide 
prevalence range is reported: between 100 and 2100 per 100,000 patients in primary care 
[7,8], and between 0 and 4800 per 100,000 individuals in community-based samples [3,9]. As 
the prevalence of CFS in the community may be quite high, epidemiologic studies relying on 
referrals to outpatient clinics may lead to an underestimation of the burden of CFS in the 
general population. 
Chronic fatigue and CFS negatively affect socio-economic status and health-related quality of 
life. The substantial economic impact of these disorders was shown in earlier investigations. 
In the UK, the estimated three-month costs per patient with chronic fatigue or CFS were 
£1906 [10], whereas in the US, the annual cost per CFS patient amounted to $20,000 [11]. 
CFS has a significant adverse impact on quality of life. When validated instruments such as 
the medical outcomes study short form 36 item (MOS SF-36) are used [12], physical and 
mental health scores seem equally or even more affected in CFS as compared with serious 
chronic illness such as multiple sclerosis, end stage renal disease and cardiac failure [13-15]. 
While the pathogenesis of CFS remains essentially unknown, it is best conceptualized as a 
biopsychosocial model. From a biological perspective, it has been contended that 
abnormalities of the central and autonomic nervous systems may be present and that 
infectious agents may be involved [16,17]. However, there is currently no compelling 
evidence to accept that these conditions would play a significant role in patients with 
established CFS. 
There is theoretical standing and empirical evidence for the cognitive behavioral model of 
medically unexplained symptoms in general and for CFS in particular [18]. In this construct, 
predisposing, precipitating and perpetuating factors play a role in the ontogenesis of the 
disorder. Whilst a biological agent may be related to the onset, the chronicity of CFS may 
rather be determined by psychosocial factors such as maladaptive behavior, negative 
conditioning and obtaining a socially accepted label of ‗medical illness‘ [18]. 
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The persistent absence of any clear pathophysiological substrate, biological marker or 
diagnostic test challenges the construct of CFS. Accordingly, the clinical methods for case 
finding and the acceptance of CFS as a disease entity remain problematic in both society and 
amongst the medical community. An overview of the actual controversies in CFS was 
recently presented by Holgate et al. [19]. 
CFS may overlap with other chronic functional syndromes such as fibromyalgia syndrome 
(FMS), temporomandibular joint pain and irritable bowel disorder [20,21]. Diffuse muscular 
pain, fatigue and sleep disturbances are part of the syndromal definitions of both CFS and 
FMS, which is a condition characterized by local tender points and chronic diffuse body pain 
[22]. Taking into account the respective case definitions, 20-70% of patients with FMS meet 
the criteria for CFS [23-25], and conversely, 35-70% of those with CFS have coexistent FMS 
[24,26]. Obviously, this similarity in clinical picture may be confusing and incite semantic 
discussions on fundamental themes such as pathogenesis and nosological classification. As 
these conditions may constitute different spectra of the same biomedical and psychosocial 
processes, a unifying concept should be developed to integrate the various functional somatic 
syndromes characterized by different degrees of pain, fatigue and disturbed sleep [27]. 
 
The restorative function of sleep 
Because unrefreshing or nonrestorative sleep (NRS) is a hallmark of CFS, insights into the 
restorative function of sleep are mandatory. The present section gives an overview of our 
current understanding of this feature, while the next section expands on the construct of 
nonrestorative sleep. 
Sleep is a universal phenomenon in living creatures. While sleep is conceived essential for 
normal life, its functions are as yet incompletely understood. Regarding non-rapid eye 
movement (NREM) sleep, most theories suggest a role in energy conservation and nervous 
system recuperation, whereas rapid eye movement (REM) sleep is thought to be implicated in 
localized recuperative processes and emotional regulation [28]. Yet, how sleep could serve 
the need for regaining bodily energy remains largely unexplained. 
That sleep is for rest and restoration of body and mind is above all an intuitive notion. The 
feeling of recuperation after a good night of sleep is so fundamental that a restorative function 
is attributed to sleep from mere subjective experience. Presumably, it is a time of quiescence 
when the body seems to be able to generally reverse the wear and tear accumulated during 
wakefulness [29]. Conversely, when night-time sleep is curtailed or interrupted, people may 
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experience a lack of replenishment that expectedly would have occurred if their sleep had 
been normal. 
It is surprising that scientific evidence for a psychophysiological recovery process during 
sleep is still lacking. Shortage of sleep, however, unveils a lack of restoration. All kinds of 
sleep deprivation, whether acute complete sleep loss, chronic partial sleep restriction, or sleep 
fragmentation, result in increased daytime sleepiness, various aspects of mental fatigue and in 
demonstrable neurocognitive impairment [30]. Therefore, the emergence of 
psychophysiological ‗nonrestoration‘ after loss of sleep could be accepted as a proof by 
contradiction that sleep has a role to replenish the body and mind for daily functioning. In 
addition, sleep curtailment increases sleep propensity [31] and subsequent sleep is 
characterized by a rebound of slow wave activity [32], which could tentatively signify an 
intensified recovery process in the brain [33]. 
 
Nonrestorative sleep 
While adverse effects of sleep loss on daytime performance were already substantiated more 
than a century ago [34], medical attention for insomnia-like daytime symptoms in the 
presence of normal sleep duration is of a more recent date. The clinical phenomenon of 
interest is a subjective experience of unrefreshing sleep. Typically, patients report awakening 
unrestored or unrefreshed after a preceding night with sufficient sleep duration. From the 
1970s on, unrefreshing sleep was observed as a frequent complaint in unexplained chronic 
pain and fatigue. Borrowing from the theory that sleep serves a restorative purpose, the 
construct of NRS was introduced as a possible lead to the etiologies of CFS and fibromyalgia 
syndrome (FMS) [35]. NRS was first mentioned as a symptom of insomnia in the Diagnostic 
and statistical manual - third edition- revised (DSM-III-R) of the American Psychiatric 
Association in 1987 [36], and subsequently embraced by other coding systems, including the 
International classification of sleep disorders - second edition (ICSD-2) [37] and research 
diagnostic criteria (RDC) [38]. 
In a recent review, it was pointed out that the construct of NRS is highly complex, and suffers 
from conceptual inconsistencies [39]. NRS currently lacks a uniform working definition, 
known causal agents, and empirically validated assessment and treatment strategies. While 
different descriptions of NRS have been used in the past, the following definition is currently 
proposed: ‗a feeling of being unrefreshed upon awakening that occurs at least three times a 
week for at least one month‘ [39]. To conceptualize NRS as a distinct condition, that is not a 
symptom of another disorder, two additional criteria are appended, i.e., normal sleep duration, 
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and the absence of an organic sleep disorder [39]. This construct remains a theoretical model 
and requires further empirical validation [40]. Finally, current evaluation of NRS is based on 
a dichotomous approach (i.e., present or not), whereas its severity may vary among patients. 
No self-report questionnaires are currently available to assess different degrees of NRS. 
As a consequence of variant definitions, methods and target populations, disparate figures on 
the prevalence of NRS have been reported in the general population, varying from 1.4% to 
35% [39]. Interestingly, NRS is not invariably associated with subjective daytime 
dysfunction. In the general population, only one fifth of individuals with NRS reported 
fatigue or irritable mood [41]. 
As waking up unrefreshed is a frequent manifestation of insomnia or organic sleep disorders 
[37], it has long been debated whether NRS may exist in the absence of known sleep or health 
problems. To clarify this matter, Roth and colleagues investigated a cohort of subjects 
selected on a self-report of awakening unrestored or unrefreshed at least three times weekly 
over a period of three months [42]. Impaired daytime functioning was an obligatory inclusion 
criterion. Individuals with evidence of any medical, neurological, or psychiatric condition 
were excluded. Polysomnography (PSG) was used to rule out organic sleep disorders. Out of 
226 patients, 115 (50.9%) had NRS with normal sleep duration, and had no difficulties with 
initiating sleep (DIS) or maintaining sleep (DMS). In these NRS-only patients, PSG showed 
no relevant differences regarding sleep architecture or indices of sleep disturbance in 
comparison with healthy controls. Whilst this is the first study to show that NRS may exist 
outside the context of classical insomnia, organic sleep disorders, and comorbid diseases, no 
inferences could be drawn on any underlying pathophysiological mechanism. PSG did not 
provide a ‗diagnostic marker‘ for NRS and the pathophysiological construct of ‗nonrefreshing 
sleep‘ could not be validated. Furthermore, as the trial was limited to subjects with significant 
daytime dysfunction, the correlation between NRS and impaired daytime function could not 
be addressed. 
The absence of any objective indicators that corroborate the subjective report of ‗feeling 
unrefreshed upon awakening‘ is a salient weakness of the NRS construct. 
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Sleep complaints and assessment of sleep in chronic fatigue and CFS 
In all available case definition guidelines of CFS, sleep problems are described as a minor 
criterion (Table 1). The terms used vary substantially from (aspecific) sleep disturbance, to 
unrefreshing or nonrestorative sleep, to various aspects of sleep quality, sleep duration and 
elements of insomnia and/or hypersomnia. Evidently, the lack of uniformity in working 
definition mirrors the gap in our understanding of the pathophysiological role of sleep in CFS. 
Sleep disturbance is reported by the vast majority of individuals who receive a final diagnosis 
of CFS (Table 1) [43-47]. This complaint persists over a time course of several years after 
diagnosis [48]. 
A complaint of NRS is present in 87-95% of CFS cases identified in community surveys [48-
51] (Table 1). Subjects with CFS have a very high co-occurrence of NRS and daytime 
dysfunction. In a study by Unger et al., the adjusted odds ratio for NRS in CFS in comparison 
with non-fatigued controls was estimated to be 28.1 (95% confidence interval = 7.4-107.0) 
[47]. Insomnia patients with NRS have more frequent daytime sequelae than those without 
NRS [41,52]. Sarsour et al. found that NRS vs. no NRS insomnia groups had a different 
prevalence of decreased daytime physical function (73% vs. 33%), cognitive function (51% 
vs. 20%) and emotional function (53% vs. 22%) [52]. In the study by Ohayon, all measures of 
impaired daytime functioning were at least twice as frequent in NRS subjects compared to 
those without NRS [41]. These studies indicate a potential relationship between NRS and the 
various aspects of daytime fatigue, but the fundamentals of this connection remain to be 
further explored. Clearly, CFS and insomnia share features with respect to NRS and daytime 
dysfunctioning, and could actually be manifestations of one and the same underlying disorder. 
For semantic reasons, different diagnostic labels are being used in current clinical practice. 
PSG is the standard clinical tool to objectively assess sleep complaints and to establish their 
neurophysiological correlates. Sleep recording has been performed in subjects with CFS with 
two purposes: 1) to elucidate as yet undisclosed mechanisms that would explain the impaired 
restorative function of sleep, and 2) to identify PSD that would exclude the diagnosis of CFS. 
Obviously, treatable PSD must be excluded if investigation is aimed at finding the very nature 
of unrefreshing sleep. On the other hand, if PSD are believed to account for the CFS 
symptoms, their treatment should remediate the complaint of fatigue. If not, PSD are not 
exclusionary, but unrelated or - at the most - comorbid conditions. In the subsequent  
paragraphs, these two aspects will be expounded separately. 
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Structural and dynamic aspects of sleep in chronic fatigue and CFS 
PSG has been performed in CFS patients using different outcomes, including classical sleep 
architecture, spectral analysis, sleep stage dynamics and the study of cyclic alternating 
patterns (CAP) in the sleep electro-encephalography (EEG). 
Regarding sleep architecture, i.e., the structural and temporal features of sleep with respect to 
wakefulness and the different sleep stages, data are available from a twin study and from a 
survey in the general population. 
Investigators from the University of Washington have conducted a monozygotic co-twin 
control study of 22 pairs discordant for the phenotype of CFS. In this sample, they explored 
subjective and objective measures of insomnia [53], as well as objective measures of sleep 
[54]. Compared with their healthy co-twins, the subjects with CFS had more subjective 
complaints of insomnia and poor sleep. However, no relevant differences were found between 
CFS and healthy co-twins in the objective polysomnographic measures. Only percent NREM 
stage 3 and percent stage REM sleep were slightly increased in the individuals with CFS, as 
compared with their healthy controls (NREM stage 3: 10.7% vs 8.6%; REM: 27.7% vs. 
24.4%, P ≤ 0.05). There was no convincing evidence to support a major role for abnormalities 
in sleep architecture in CFS. Although the subtle differences in the PSG outcomes did not 
sufficiently account for the prominence of sleep complaints in the CFS group, there was an 
indication that individuals with CFS may suffer from an element of sleep-state misperception. 
PSG has been performed in a subset of cases and non-fatigued controls from a population 
based survey, i.e., the Wichita CFS surveillance study [55,56]. Approximately 18% of persons 
with CFS and 7% of asymptomatic controls were diagnosed with severe PSD and were 
excluded from further analysis. The final assessment of PSG data comprised 35 individuals 
with CFS and 40 controls. Despite the fact that sleep problems were significantly more often 
reported by people with CFS as compared with healthy subjects, common characteristics of 
sleep architecture did essentially not differ between these groups. 
Thus, the hypnogram does not seem to discriminate individuals with CFS from healthy 
controls. Whilst methodological issues including limited montage and only single night  
recordings(57) may have an influence on these results, the methods used are identical for 
individuals with CFS and healthy controls. Therefore, the lack of difference between the two 
groups may not be due to technical limitations in the first place, but rather to limitations  
inherent to the very method of assessing sleep architecture. Defining sleep stages by 
conventional scoring methods is a crude and arbitrary approach to the physiological process 
of sleep, and subtle anomalies may go unnoticed. 
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Early reports have drawn attention to the appearance of prominent alpha activity in NREM  
sleep, also known as ‗alpha-delta sleep‘. This EEG abnormality has been conceptualized as an 
intrusion of wakefulness into sleep, that could be a neurophysiological correlate of NRS [58]. 
Alpha-delta sleep has been observed in heterogeneous groups of patients presenting with 
chronic daytime dysfunctioning, especially in FMS [59-62]. Meanwhile, it has become 
evident that alpha-delta sleep is not an essential feature of NRS [39], nor a consistent marker 
of FMS or CFS [63]. Moreover, alpha-delta sleep may be observed in subjects with other 
disorders or who do not complain about fatigue [64]. 
Measurement techniques that analyze sleep EEG on a continuous basis may be more suitable 
to detect delicate neurophysiological intricacies of sleep. Power spectrum analysis of the EEG 
has been utilized in different groups of subjects with CFS and has failed to corroborate 
intrusion of alpha activity in NREM sleep as a clinically relevant issue. Armitage et al. 
reassessed 13 pairs of female twins out of the original 22 pairs from the Washington CFS twin 
registry [65]. PSG was repeated and power spectral analysis using fast Fourier transformation 
(FFT) was applied on the EEG recordings. No significant differences in spectral power in any 
frequency band were found between co-twins with or without CFS. Phasic alpha activity,  
coupled with delta was noted in five subjects with CFS but was also present in four out of five 
healthy co-twins, indicating that this finding rather reflects genetic influences on the sleep 
EEG. PSG recordings from the individuals that were included in the Wichita CFS surveillance 
study were reassessed using FFT [66]. The spectral power of each frequency domain for each 
sleep state was compared between persons with CFS and matched controls. Surprisingly, 
alpha power was reduced during NREM stages 2 and 3, and REM sleep in the CFS group. In 
a clinical population, Guilleminault et al. compared 14 consecutive patients with chronic 
fatigue to 14 controls. Using FFT, they also found decrements in the power of the alpha bands 
in the patient group [67]. In conclusion, power spectrum analysis of the EEG does not seem to 
provide strong evidence for abnormal alpha intrusion in NREM sleep in subjects with chronic 
fatigue. Analysis of other spectral bands (theta, delta, beta) shows inconsistent results. For 
instance, delta power has been reported increased [67,68], decreased [66], or to be similar 
[65] in CFS groups as compared with normal controls. 
Increased CAP rates in NREM are presumed to be an index of sleep instability [69]. 
Guilleminault et al. also looked at CAP rates in their sample of clinical CFS patients versus 
controls [67], to find significantly higher values in subjects with chronic fatigue as compared 
with controls (50.9± 32.0 vs. 27.0 ± 26.2, P= 0.04). They speculated that this mechanism may 
be associated with a complaint of unrefreshing sleep. An investigation of sleep stage 
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dynamics [70] showed different profiles regarding probabilities of transitions from waking to 
sleep and between different sleep stages, when comparing CFS and FMS patients with 
controls. In addition, the rates of these transitions were also significantly increased in subjects 
with CFS and FMS. Evidently, these results are preliminary, as the new paradigms on which 
they are based must be reassessed by independent research groups. If these findings can be 
replicated, their relevance in respect of hypothetical models of sleep dysfunction should be 
determined. 
In conclusion, an undisclosed disturbance of the neurobiological sleep process may still be a 
plausible explanation for NRS and daytime dysfunction in CFS. However, no robust 
pathophysiological correlate has been identified as yet to demonstrate that a deficit in sleep 
function is accountable for these symptoms. The concept of nonrestorative sleep is 
contentious as it carries the attribution that the problem lies intrinsically within sleep. By the 
same token, sleep may be normal. It is conceivable that chronic fatigue may persist 
throughout the entire 24-h period, and is already noticed by the individual after the period of 
nocturnal sleep. The timing of the first experience of fatigue, i.e., upon awakening in the 
morning, may falsely raise the individual‘s perception that something is wrong with sleep. 
Until a specific neurophysiological impairment is demonstrated, the claim that NRS is part of 
the domain of CFS - or insomnia - will remain speculative. 
 
Primary sleep disorders in chronic fatigue and CFS 
PSD, including primary insomnia, obstructive sleep apnea (OSA), periodic limb movement 
disorder and narcolepsy, are not infrequently diagnosed in patients who otherwise meet the 
Fukuda et al. criteria for chronic fatigue or CFS [43,44,55,71-74]. Taking an appropriate sleep 
history and performing PSG are key to detecting these disorders. Due to different criteria, 
diagnostic methods, as well as different target populations, the prevalence rates of PSD vary 
substantially among studies (Table 1). The Wichita CFS surveillance study revealed the 
presence of severe PSD in 18% of subjects with CFS in the general population [55]. In 
clinical settings, the prevalences of PSD vary between 46 and 81% [43,44,71,73]. 
Two issues stand out in the clinical differentiation between PSD and CFS. First, the constructs 
of primary insomnia and CFS overlap considerably. Psychophysiological insomnia, more than 
any other sleep disorder, is associated with high scores on daytime fatigue [75]. As discussed 
earlier, NRS is a hallmark in the contemporary nosological definitions of both insomnia and 
CFS. Patients with CFS tend to increase the duration of staying in bed, leading to decreased 
sleep efficiency [46,76]. They also may suffer from DIS, DMS or both [71,77]. All these 
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findings are also characteristic of insomnia [78]. Therefore, the concepts of insomnia and CFS 
should be further clarified with respect to mutual differences and similarities. Second, organic 
sleep disorders, especially sleep apnea and narcolepsy, are regarded conditions that exclude 
CFS [2]. This concept has recently been challenged. In a comparative study, Libman et al. 
found no significant differences between CFS patients with and without associated OSA 
regarding subjective sleep variables, CFS symptoms, indexes of anxiety and depression, and 
MOS SF-36 quality of life parameters [79]. Neither was there a difference in fatigue scores 
between subgroups who were and who were not compliant for treatment with nasal 
continuous positive airway pressure (CPAP) [79]. From these findings, the authors concluded 
that OSA should not be an exclusion criterion for CFS. On the other hand, there is preliminary 
evidence to indicate that treatment of PSD may reduce scores of daytime fatigue. In moderate 
to severe OSA, a recent placebo controlled trial with nasal CPAP demonstrated a significant 
reduction in fatigue and increase in vigor (P values <0.05) in a group of 29 subjects treated 
with active CPAP, but not in a group of 30 subjects receiving placebo treatment [80]. The 
beneficial effect of CPAP treatment was most pronounced in patients with high levels of 
fatigue at onset. In contrast, EDS was reduced only in a subset of patients who were 
excessively sleepy at onset. Clearly, more studies are needed to brace these results, especially 
in patients whose presenting complaint is severe chronic fatigue. It is not yet clear whether 
primary severe fatigue is sufficiently responsive to adequate treatment of comorbid sleep 
disorders. 
 
Practice points 
1) The concept of NRS implies that fatigue is the consequence of dysfunctional sleep, whilst 
evidence for such cause-effect relationship has not yet been provided. Preferably, this 
complaint should be referred to as ‗waking up unrefreshed‘. Moreover, a uniform working 
definition should be validated, based on an empirical approach involving experts, clinicians 
and patients. 
2) Patients who report NRS are not necessarily functionally impaired during the daytime. The 
combined presence of unrefreshing sleep and daytime impairment is found in patients with 
more severe symptom scores. 
3) Patients in whom CFS is suspected should be routinely screened for the presence of PSD. 
Assessment is based on appropriate questionnaires and semi-structured history. PSG should 
be carried out in individuals with high pre-test probability for PSD. CFS can be excluded, not 
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by the mere presence of PSD, but by satisfactory symptomatic relief obtained by causal 
treatment. 
4) CFS overlaps with FMS and other functional disorders. Because of the lack of a solid 
pathophysiological basis, they do not fit well into currently used nosological catalogs, or may 
receive different names in different classification systems. To avoid using stereotypical 
syndromal names, a descriptive approach may be employed. Such procedure would consist of 
scoring the various aspects and the degree of severity of the constituent symptoms fatigue, 
sleep disturbance and pain. Thus, a multidimensional functional disorder may be configured. 
This construct would fit a biopsychosocial impairment model rather than a labeled disease. 
This approach may hold promise to avoid excessive somatisation and to tailor symptomatic 
treatment to the individual patient‘s needs. 
 
Research agenda 
1) Gaining insight into the nature of psychophysiological recovery during sleep, and the 
subjective experience of unrefreshing sleep, will require clarification of relevant 
neurobiological processes that are as yet elusive. 
2) To study sleep as a functional process, future studies should replicate analyses of EEG 
power spectrum and dynamic sleep stage shifts. Non-EEG techniques such as functional brain 
imaging may also prove relevant in the exploration of sleep in CFS patients. 
3) Further investigations should focus on the relation between alleged NRS and daytime 
dysfunction. The null-hypothesis would postulate that sleep is basically intact in NRS. 
According to this concept, fatigue is a 24-h occurrence and is already perceived upon 
awakening in the morning, leaving sleep as an ‗innocent bystander‘. 
4) Since the role of PSD in CFS is unclear, interventions are needed to assess the 
symptomatic effects of causal therapy on fatigue as a primary outcome. Randomized 
controlled trials may clarify whether PSD are to be considered an exclusion criterion vs. a 
comorbidity to CFS. 
5) The diagnostic criteria of primary insomnia and CFS overlap considerably, NRS being a 
prominent common denominator. The disease characteristics of both conditions should be 
assessed simultaneously in patient cohorts, to investigate a potential common 
pathophysiological background. 
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Table 1: Sleep complaints as a criterion for case finding in CFS 
Holmes et al. 1988 (CDC) Lloyd et al. 1988 Sharpe et al. 1991 (Oxford) Fukuda et al. 1994 (CDC) Carruthers et al. 2003 
USA Australia UK USA Canada 
SLEEP PARAMETERS 
Minor symptom criterion:  
sleep disturbance (hypersomnia  
or insomnia) 
Possible symptom: sleep 
disturbance, persistent > 6  
months with no other cause  
Possible symptom: sleep 
disturbance: 
(i) subjective report of a change  
in duration or quality of sleep 
(ii) distinguished from feelings  
of daytime fatigue or tiredness 
(iii) should: 
     (a) be complained of 
     (b) not be a response to  
     external disturbance 
     (c) be a change from the  
     previous state 
     (d) be persistant 
(iv) should be described as 
     (a) type: hypersomnia or  
     increased sleep;insomnia  
     or reduced sleep (either  
     difficulty getting off to sleep,  
     early waking or subjectively  
     disturbed or unrefreshing  
     sleep) 
     (b) severity:amount of  
     change in duration of sleep 
(hours) 
Minor criterion: unrefreshing 
sleep 
 
Exclusions: primary sleep 
disorders such as sleep apnea and 
narcolepsy 
Cluster 'Sleep dysfunction': 
unrefreshing sleep, poor sleep 
quality or rhythm disturbances (such 
as early, middle or late insomnia, 
with reversed or irregularly irregular 
insomnia, hypersomnia, abnormal 
diurnal variation of energy levels, 
including reversed or chaotic diurnal 
rest and sleep rhythms) 
 
Remark: Small number of patients 
do not have sleep dysfunction, but 
no other diagnosis fits. A diagnosis 
of ME/CFS can be maintained if 
infectious illness type onset. 
 
Exclusions: treatable sleep disorders 
(such as UARS, OSA/CSA, RLS)  
PREVALENCE OF NON-RESTORATIVE SLEEP / UNREFRESHING SLEEP 
Community-based sample 
ND 
 
 
 
 
Clinical setting 
 
 
 
 
ND 
 
ND 
 
87.5%(49) 
95.4%(48) 
93.0%(50) 
92.2%(51) 
 
95.0%(46) 
 
 
ND 
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PREVALENCE OF PRIMARY SLEEP DISORDERS 
Community-based sample 
ND 
 
Clinical setting 
62.5%(43) 
81.0%(44) 
 
ND 
 
 
ND 
 
ND 
 
 
58.3%(71) 
46.0%(73) 
 
 
18.6%(55) 
 
 
ND 
 
 
ND 
 
 
ND 
ND, no data 
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1. Subjective sleep quality and daytime sleepiness in a large sample of patients with 
chronic fatigue syndrome (CFS) 
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Abstract 
Chronic fatigue syndrome (CFS) is characterised by incapacitating fatigue in combination 
with a number of minor criteria, including unrefreshing sleep without further specifications, in 
the absence of psychiatric and internal disease. As little data exist on subjective sleep quality 
and daytime sleepiness, these parameters were assessed in a large sample of CFS patients. 
Consecutive patients with a diagnosis of CFS in a tertiary referral centre filled out the Fatigue 
Questionnaire (FQ), Medical Outcomes Study 36-Item Short Form Health Survey (MOS SF-
36), Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI). Inclusion 
comprised 415 individuals (mean age 40.5 yr, SD 7.9, range 18-64; 86% female). Mean FQ 
(26.90; SD 4.04), mean Global Physical Health from the MOS SF-36 (29.30; SD 12.25) and 
Global Mental Health from the MOS SF-36 (49.62; SD 18.31) scores corresponded with 
literature data for similar CFS samples. High mean ESS (10.51; SD 5.52) and global PSQI 
(10.17; SD 4.02) were observed. No significant relationship was found between ESS and 
global PSQI. In contrast, regression analysis demonstrated a significant cubic relation 
between ESS and ‗PSQI without daytime dysfunction‘. A subgroup (n = 69) with an 
insomnia-like phenotype low ESS (< 5), high PSQI (mean 11.51; SD 3.86) was observed. The 
assessment of subjective sleep quality and daytime sleepiness in a large sample of CFS 
patients indicated high mean PSQI and ESS values. ESS and ‗PSQI without daytime 
dysfunction‘ were inversely related at the spectral ends of ESS. A distinct subgroup with 
clinical features of insomnia was identified. 
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Introduction 
Chronic fatigue syndrome (CFS) is a disabling condition characterized by mental and physical 
exhaustion that is not relieved by rest and that lasts for more than 6 months in the absence of 
nosologically defined internal or psychiatric diseases (1). As the pathogenesis of CFS is 
unknown, no pathognomonic signs or specific tests are available to establish a formal 
diagnosis. Therefore, the case definition of CFS is based on a syndromal concept, combining 
chronic unexplained fatigue with at least four out of eight accompanying symptoms: unusual 
post-exertional malaise, impaired memory or concentration, unrefreshing sleep, headaches, 
muscle pain, joint pain, sore throat and tender cervical nodes (2). These criteria, published by 
Fukuda et al. in 1994, prevail as a standard in current clinical practice and scientific research. 
Complaints of disturbed or unrefreshing sleep are very common in CFS patients. While this 
symptom is listed as one of the concurrent criteria in the case definition (2), the guideline 
provides no instruction as how to assess the nature of the CFS-related sleep disturbances, and 
offers no clarification on its pathological relevance. This is problematic because fatigue and 
unrefreshing sleep are also a hallmark of nosologically defined sleep disorders, e.g. insomnia, 
narcolepsy and the sleep apnoea syndromes (SAS) (3, 4). Without proper clinical assessment 
of sleep complaints, a primary sleep disorder may go unnoticed in patients complaining of 
chronic fatigue (5, 6). The role of sleep disturbances in the pathogenesis and severity of CFS 
remains speculative. Conceptually, poor sleep quality may contribute to daytime fatigue and 
impaired performance. Inversely, too much rest and napping during the daytime may 
compromise nocturnal sleep quality. Assessments in the general population (7) and in 
chronically ill (8) have revealed positive associations between sleep complaints and daytime 
functional impairment. On the other hand, complaints of poor sleep do not necessarily result 
in objectively measurable daytime dysfunction (9, 10). Therefore, disturbed sleep may be a 
mere co-symptom, rather than a causal factor in the clinical manifestations of CFS. Literature 
on sleep symptomatology in CFS patients is scarce. Questionnaires on subjective daytime 
sleepiness, i.e. the Epworth Sleepiness Scale (ESS) (11) and on subjective sleep quality, i.e. 
the Pittsburgh Sleep Quality Index (PSQI) (12) have been developed and validated for the use 
in diverse clinical and general populations. Yet, only few studies have included data on ESS 
(13, 14) or PSQI (15, 16) in CFS patients. The lack of descriptive data on sleep-related 
complaints impairs our understanding of cause-effect relationships between disturbed sleep 
and daytime symptoms of CFS. The objectives of the present study were to assess ESS and 
PSQI in a large sample of CFS patients diagnosed according to the Fukuda criteria, as well as 
their mutual relationship. 
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Methods 
Subjects and procedures  
Consecutive patients with a final diagnosis of CFS according to the Fukuda criteria (2) in a  
multidisciplinary tertiary care reference centre were included in this study, which was 
approved by the institutional Ethical Review Board. All patients filled out the ESS (11), the 
PSQI (12), the Medical Outcomes Study 36-Item Short Form Health Survey (MOS SF-36) 
(17) and the Fatigue Questionnaire (FQ) (18). Daytime sleepiness was assessed by the ESS on 
a scale ranging from 0 to 24 with a cut-off score of > 10 indicating excessive daytime 
sleepiness. Sleep quality was evaluated by the PSQI. The PSQI generates 7 component scores 
ranging from 0 to 3 each, defining different aspects of sleep quality and daytime functioning. 
A global PSQI score > 5 has been validated as an indication of subjectively perceived severe 
sleep difficulty in at least 2 component scores, or moderate difficulty in more than 3 
component scores (12). The correlation between PSQI and ESS was explored in our patient 
sample. The seventh component score of the PSQI probes daytime dysfunction, which 
consists in part of daytime sleepiness. This component overlaps with the ESS, confounding 
the relation between the two scales (19). Consequently, we used the global PSQI without the 
seventh component score, which was labelled ―night-time PSQI‖, to assess the relation 
between sleep quality and daytime sleepiness. Global mental and physical health was assessed 
with the MOS SF-36, generating 8 health dimensions each scored on a scale from 0-100. 
Normative data are available for healthy reference populations (20, 21) and many illnesses, 
including CFS (22-24). Severity of fatigue was measured by the 11-item FQ (18), using the 
Likert method, resulting in a score ranging from 0-33.  
 
Statistical analysis 
The data were analysed with SPSS (PASW 17.0). First, we report a number of descriptive 
statistics, Spearman correlations between age, gender, ESS, the PSQI scales, MOS SF-36 
scales and the FQ, and Welch t-tests between the group of men and the group of women for 
all these variables. The MOS SF-36 component values were compared with published data of 
a reference sample (22) and samples of CFS patients (23, 24) using Welch-Satterthwaite t-
tests. Significance testing was two-tailed; the cut-off level was set at 0.05. Second, we 
examined the relationship between ESS and ―night-time PSQI‖. The residuals of the linear 
regression between these variables demonstrated strong curvature, so polynomial (third order) 
regression was performed between ―night-time PSQI‖ as a dependent variable in function of 
centered ESS and its square and cubic as independent variables. Centering was done to reduce 
  113 
collinearity. The plot of the resulting cubic equation revealed the possibility of distinct 
subgroups, at the spectral ends of ESS. We divided the patients in 5 groups according to their 
ESS values, with a nearly equal number of patients in each group, and did a one-way 
ANOVA variance analysis with Tukey‘s tests to analyse the ―night-time PSQI‖ differences 
between the groups. 
 
Results 
The study sample consisted of 415 patients with a confirmed diagnosis of CFS. The mean age 
was 40.53 (SD = 7.91), range 18-64 years, and 86% was female. The mean score of the FQ 
was 26.90 (SD = 4.04; Cronbach‘s alpha = 0.78). The MOS SF-36 scores indicated poor 
health-related quality of life in comparison with published data of a reference population, and 
comparable results with respect to other studies in CFS patients (Table 1). The mean score on 
the ESS was 10.51 (SD = 5.52; Cronbach‘s alpha = 0.86). Excessive sleepiness was observed 
in 53% (Fig 1A). The mean global PSQI score was 10.17 (SD = 4.02; Cronbach‘s alpha = 
0.64). Poor sleep quality was found in 86% (Fig 1B). The mean values and the Spearman 
correlations between all variables of the study are shown in Table 2. For the discrete variable 
gender, Welch t-tests between the group of men and the group of women revealed no 
statistical significance for all variables, except for age: mean 42.36 (SD = 7.41) for men, 
mean 40.23 (SD = 7.96) for women (p = 0.048). No significant relationship was found 
between ESS and global PSQI. In contrast, a significant negative correlation was observed 
between ESS and ―night-time PSQI‖. Further regression analysis demonstrated a significant 
cubic relation between ESS and ―night-time PSQI‖ (Table 3), yielding an S-shaped curve (Fig 
2). This shape suggests three subgroups based on ESS values: a low ESS / high ―night-time‖ 
PSQI group, a middle group with intermediate values of both scores, and a high ESS / low 
―night-time‖ PSQI group. Division of the patients in 5 groups according to their ESS values, 
with a nearly equal number of patients in each group, revealed that the subgroup with the 
lowest ESS values (ESS < 5) had significantly higher levels of ―night-time PSQI‖ than each 
of the other groups (p < 0.001, by one-way ANOVA, p < 0.05 by Tukey‘s test). The ―night-
time PSQI‖ values of the other groups did not differ significantly from each other. 
Specifically, this means that statistical significance could be demonstrated in the low ESS 
subgroup (ESS < 5), but not in the high ESS subgroup (ESS > 15). 
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Discussion 
This study describes the hitherto largest sample of CFS patients in respect of subjective sleep 
and sleepiness characteristics. High scores were found on the subjective measures of both 
poor sleep quality and daytime sleepiness. The demographic characteristics of the present 
sample of CFS patients are in keeping with previous reports (25). The low MOS SF-36 
dimension scores in our patient group indicated significant impact on both global mental and 
physical health. These scores are similar to previously reported figures in CFS outpatients 
treated in specialised referral settings (23, 24), and indicate comparable severity of illness. 
The mean FQ score approximates the recently reported mean FQ score of 24.4 (SD = 5.8) in a 
clinical cohort of CFS patients (26), and is clearly larger than values reported at baseline in a 
large drug intervention trial in CFS patients (15). Hence, the present sample can be considered 
as representative and congruent with previously reported CFS cohorts. Published data on 
measures of somnolence are scarce in CFS patients. A small study compared a standard 
objective measure of sleepiness (i.e. a 4-nap multiple sleep latency test, MSLT) and two 
subjective measures (i.e. the ESS and the Stanford Sleepiness Scale) of sleepiness in twenty 
monozygotic twin pairs discordant for CFS (13). CFS twins reported significantly more 
subjective sleepiness than their healthy co-twins despite similar non-pathological mean sleep 
latencies on MSLT. It was suggested that patients with CFS may mistake their chronic 
disabling fatigue for sleepiness. Another limited study evaluated the relationship between 
fatigue and sleepiness in CFS patients not co-morbid for primary sleep or psychiatric 
disorders (14). Sixteen untreated CFS patients were compared with 13 untreated SAS patients 
and 12 healthy controls. Whilst higher than the control group on all measures, compared to 
SAS, the CFS group had higher subjective fatigue and lower subjective and objective 
sleepiness. These findings seemed to support the clinical distinction between fatigue and 
sleepiness, despite possible overlap in symptoms of both daytime conditions. Both studies are 
restricted by small sample size. The present investigation demonstrates a broad range of ESS 
values in a large CFS cohort, corresponding to a normal-like distribution between the 
delimiting values of 0 and 24. More than half of the patients reported an ESS score above 10, 
indicative of perceived excessive daytime sleepiness. As MSLT was not performed in the 
present study, no statement on subjective vs. objective sleepiness can be made. PSQI as a 
measure of disturbed sleep has been investigated in a few trials dealing with CFS patients. 
Neu et al. assessed different subjective measures (PSQI, Fatigue Severity Scale scores and 
intensity of affective symptoms by the Hamilton Depression and Anxiety scales) and 
objective findings using polysomnography (PSG) in 28 ―pure‖ CFS patients after exclusion of 
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primary sleep and psychiatric disorders (16). Compared to age- and gender-matched healthy 
controls, CFS patients had significantly higher PSQI scores (9.54±4.0 vs. 2.42±1.2 in 
controls), without any evidence of PSG abnormalities, suggesting sleep quality misperception. 
Subjective sleep quality showed a correlation trend with severity of fatigue. Baseline 
measurements in a large multicenter randomized controlled drug intervention trial showed 
high PSQI scores, ranging between 8.87 and 9.42 (15). In the present investigation, a mean 
PSQI score of 10.17 was found, whilst 86% of the subjects had a PSQI > 5 as an indication of 
poor sleep quality. PSG, however, was not carried out in our sample, leaving the question of 
potential inappropriate perception of sleep quality unanswered. High PSQI values in the vast 
majority of our patients, however, confirm that poor subjective sleep quality is indeed an issue 
in CFS. This observation corroborates the relevance of disturbed sleep as a diagnostic 
criterion for CFS. The ‗daytime dysfunction‘ subscale has the weakest correlation with the 
global PSQI (Table 2). Hence, PSQI omitting ‗daytime dysfunction‘ (i.e. ―night-time PSQI‖) 
seems a better probe for subjective sleep quality than the global scale and avoids overlap with 
the ESS. No correlation was found between ESS and global PSQI, in contrast with a 
significant negative correlation between ESS and ―night-time PSQI‖. This is explained by the 
PSQI item ‗daytime sleepiness‘ that is part of the seventh component score ‗daytime 
dysfunction‘. A positive correlation between ESS and the ‗daytime dysfunction‘ component 
counterbalances the negative correlation with the other PSQI components. Whilst no 
significant relation between ESS and global PSQI emerged, regression analysis demonstrated 
a significant cubic relation between ESS and ―night-time PSQI‖ (Fig 2). From the 
corresponding curve, the existence of three subgroups was postulated: a low ESS / high 
―night-time PSQI‖ group, a middle group with intermediate values of both scores, and a high 
ESS / low ―night-time PSQI‖ group. Only in the middle group with intermediate ESS and 
PSQI values no significant correlation between ESS and ―night-time PSQI‖ was observed. 
Such orthogonal relationship between ESS and PSQI after subtraction of the ‗daytime 
dysfunction‘ component has recently been reported by Buysse et al. in a survey of a 
community sample (19). In the current sample of CFS patients, however, an inverse relation 
between ESS and ―night-time PSQI‖ becomes evident at the spectral ends of ESS. Significant 
differences in ―night-time PSQI‖ were observed in the ESS < 5 vs. ESS ≥ 5 but not in the ESS 
< 16 vs. ESS ≥ 16 subgroups (the latter probably due to insufficient statistical power). This 
suggests that very low sleepiness and high levels of sleep disturbance cluster together, as well 
as high sleepiness and low sleep disturbance. These associations at both ends of the ESS 
spectrum may correspond to a clinical profile of insomnia and hypersomnia, respectively. In 
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primary insomnia, complaints of substantial sleep disturbance are often associated with 
increased alertness (9, 27), whereas in idiopathic hypersomnia excessive daytime sleepiness 
persists despite normal nocturnal sleep (28). The hypothesis that clinical profiles of insomnia 
and hypersomnia may be discerned among CFS patients creates new perspectives for the 
nosological approach. As a consequence of the inadequate definition of sleep disturbances in 
the minor CFS criteria, patients with primary sleep disorders may still qualify for the 
diagnosis of CFS. While narcolepsy and SAS are explicitly mentioned as exclusionary 
conditions in the Fukuda criteria, primary insomnia and idiopathic hypersomnia – that would 
be diagnosed as such by sleep medicine physicians – may still go unnoticed in the clinical 
assessment at CFS referral centres. As a potential pitfall in medical diagnosis, the minor 
criterion of nonrestorative sleep or sleep disturbance needs to be detailed in future revisions of 
the CFS definition. Meanwhile, it is recommended to carefully assess the sleep disturbances 
in individual patients who present with a primary complaint of chronic unexplained fatigue. 
Finally, some limitations of the present investigation need to be acknowledged. Only 
subjective sleep quality and sleepiness measures were evaluated. No PSG or MSLT 
assessments were performed, leaving the potential influence of subjective perception on the 
outcome variables unexplored. Furthermore, the study has a cross-sectional design and, 
therefore, conclusions are beyond the scope of probing cause-effect relationships, but are 
limited to association of factors. A major strength of the study is the large sample of Fukuda 
criteria confirmed CFS patients.  
In conclusion, the subjective assessment of daytime sleepiness and sleep quality in a large 
sample of CFS patients revealed high mean ESS and PSQI values. ESS and ―night-time 
PSQI‖ were inversely related at the spectral ends of ESS. Evidence was shown for a distinct 
subgroup with an insomnialike phenotype, and possibly for an additional subgroup with a 
hypersomnia-like phenotype. This observation invokes the necessity to transcend prevailing 
semantics and syndromal definitions in the approach of this as yet insufficiently understood 
disorder. 
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Table 1. Mean, standard deviation, Cronbach's alpha of the MOS SF-36 scales, and Welch-Satterthwaite t-test values (our sample compared with 
other samples). The Welch-Satterthwaite t-test is used to adjust for the inequality of the variances. 
  
Physical 
Functioning 
Role 
Physical 
Role 
Emotional Vitality 
Mental 
health 
Social 
Functioning 
Bodily 
Pain 
General 
Health 
CFS sample of this study         
Mean 42.67 10.23 65.76 27.45 60.02 44.93 34.52 29.80 
Stand. deviation 19.66 21.20 42.93 13.68 18.05 21.90 19.71 14.13 
N 413 409 403 413 412 412 413 413 
Cronbach's alpha 0.86 0.68 0.89 0.63 0.83 0.79 0.87 0.64 
         
Reference sample of Picavet et al. (22)         
Mean 82.50 77.70 80.20 69.40 65.90 84.20 87.20 77.30 
Stand. deviation 24.80 37.80 23.60 19.60 20.00 23.10 30.60 17.10 
N 3664 3664 3664 3664 3664 3664 3664 3664 
Cronbach's alpha 0.92 0.90 0.86 0.81 0.77 0.64 0.87 0.80 
Significance of difference with our sample <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
         
CFS sample of Myers and Wilks (23)         
Mean 52.40 21.20 60.00 27.20 61.80 49.30 50.90 39.80 
Stand. deviation 31.00 34.40 43.90 22.30 21.80 28.10 29.50 21.90 
N 85 85 85 85 85 85 85 85 
Significance of difference with our sample < 0.01 < 0.01 ns ns ns ns < 0.0001 < 0.0001 
         
CFS sample of Rakib et al. (24)         
Mean 41.10 8.20 52.50 22.40 60.10 42.60 38.10 30.20 
Stand. deviation 21.30 20.40 45.10 16.60 20.00 24.70 20.30 16.00 
N 73 73 73 73 73 73 73 73 
Significance of difference with our sample ns ns ns < 0.05 ns ns ns ns 
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Table 2. Mean, standard deviation and Spearman correlations of the variables used in this study. 
 Mean (SD) 2 3 4 5 6 7 8 9 10 11 12 13 14 
1.Age  40.53 
(7.91) 
-.03 -.01 -.14** .09 .07 -.01 .08 .03 .03 .03 -.00 -.05 -.04 
2.ESS  10.51 
(5.52) 
 -.07 -.19** -.08 -.10* .15** -.16** .45** -.06 -.15** -.20** -.15** .23** 
3.PSQI subj. sleep quality    1.63 
(0.84) 
  .49** .47** .40** .36** .17** .15** .72** .72** -.24** -.23** .17** 
4.PSQI sleep latency    1.69 
(1.10) 
   .34** .36** .22** .16* .01 .64** .66** -.09 -.10* .15** 
5.PSQI sleep duration     0.64 
(0.88) 
    .71** .24** .05 .16* .69** .70** -.12* -.14** .01 
6.PSQI sleep efficiency     1.25 
(1.27) 
     .22** .07 .07 .72** .74** -.07 -.10* .04 
7.PSQI sleep disturbances    1.60 
(0.61) 
      .06 .22** .47** .45** -.28** -.29** .20** 
8.PSQI use of sleep 
medication 
   1.37 
(1.40) 
       .02 .46** .48** -.06 -.09 .02 
9.PSQI daytime dysfunction    1.99 
(0.75) 
        .30** .13** -.37** -.34** .32** 
10.Global PSQI  10.17  
(4.02) 
         .98** -.25** -.28** .18** 
11.Nighttime PSQI    8.18  
(3.85) 
          -.20** -.23** .13* 
12.SF36 global physical health 29.30  
(12.25) 
           .41** -.40** 
13.SF36 global mental health 49.62  
(18.31) 
            -.38** 
14.FQ fatigue 26.90  
(4.04) 
             
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Figure 1. Frequency distribution of ESS (A) and PSQI scores (B) 
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Figure 2. Plot of the Cubic Regression Equation of Night-time PSQI in function of ESS.  
Equation: Estimated Night-time PSQI = 8.161 – 0.0017976 * (ESS – 10.5060)**3 
0,00 5,00 10,00 15,00 20,00
Epworth Sleepiness Scale
4,00
6,00
8,00
10,00
N
ig
h
tt
im
e
 P
S
Q
I
  120 
References 
 
1. Jones JF, Lin JM, Maloney EM, Boneva RS, Nater UM, Unger ER, et al. An evaluation of 
exclusionary medical/psychiatric conditions in the definition of chronic fatigue syndrome. 
BMC Med. 2009;7:57. 
2. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A, et al. The chronic 
fatigue syndrome - a comprehensive approach to its defintions and study. Annals of Internal 
Medicine 1994;121:953-9. 
3. Medicine AAoS. The international classification of sleep disorders - 2nd edition. 
Westchester, IL2005. 
4. Lichstein KL, Means MK, Noe SL, Aguillard RN. Fatigue and sleep disorders. Behaviour 
research and therapy 1997;35:733-40. 
5. Fossey M, Libman E, Bailes S, Baltzan M, Schondorf R, Amsel R, et al. Sleep quality and 
psychological adjustment in chronic fatigue syndrome. Journal of behavioral medicine 
2004;27:581-605. 
6. Reeves WC, Heim C, Maloney EM, Youngblood LS, Unger ER, Decker MJ, et al. Sleep 
characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results 
from a population-based study. BMC Neurology 2006;6. 
7. Ohayon MM. Prevalence and correlates of nonrestorative sleep complaints. Arch Intern 
Med 2005;165:35-41. 
8. Manocchia M, Keller S, Ware JE. Sleep problems, health-related quality of life, work 
functioning and health care utilization among the chronically ill. Quality of life research 
2001;10:331-45. 
9. Chambers MJ, Keller B. Alert insomniacs - are they really sleep-deprived. Clinical 
Psychology Review 1993;13:649-66. 
10. Riedel BW, Lichstein KL. Insomnia and daytime functioning. Sleep Med Rev 2000;4:277-
98. 
11. Johns MW. A new method for measuring daytime sleepiness - the Epworth sleepiness 
scale. Sleep 1991;14:540-5. 
12. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality 
index - a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-
213. 
13. Watson NF, Jacobsen C, Goldberg J, Kapur V, Buchwald D. Subjective and objective 
sleepiness in monozygotic twins discordant for chronic fatigue syndrome. Sleep 2004;27:973-
7. 
  121 
14. Neu D, Hoffmann G, Moutrier R, Verbanck P, Linkowski P, Le Bon O. Are patients with 
chronic fatigue syndrome just 'tired' or also 'sleepy'? J Sleep Res 2008;17:427-31. 
15. Blacker CV, Greenwood DT, Wesnes KA, Wilson R, Woodward C, Howe I, et al. Effect 
of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. 
JAMA 2004;292:1195-204. 
16. Neu D, Mairesse O, Hoffmann G, Dris A, Lambrecht LJ, Linkowski P, et al. Sleep quality 
perception in the chronic fatigue syndrome: Correlations with sleep efficiency, affective 
symptoms and intensity of fatigue. Neuropsychobiology 2007;56:40-6. 
17. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 1. 
Conceptual framework and item selection. Med Care 1992;30:473-83. 
18. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. 
Development of a fatigue scale. J Psychosom Res 1993;37:147-53. 
19. Buysse DJ, Hall ML, Strollo PJ, Kamarck TW, Owens J, Lee L, et al. Relationships 
between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and 
clinical/polysomnographic measures in a community sample. J Clin Sleep Med 2008;4:563-
71. 
20. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey 
questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 
1993;306:1440-4. 
21. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: 
normative data for adults of working age. BMJ 1993;306:1437-40. 
22. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal 
diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004;63:723-9. 
23. Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic 
fatigue syndrome. Qual Life Res 1999;8:9-16. 
24. Rakib A, White PD, Pinching AJ, Hedge B, Newbery N, Fakhoury WK, et al. Subjective 
quality of life in patients with chronic fatigue syndrome. Qual Life Res 2005;14:11-9. 
25. Centers for Disease Control and Prevention. Chronic fatigue syndrome. http:// 
www.cdc.gov/cfs/cfscausesHCP.htm . 10-03-2006. 
26. Cella M, Chalder T. Measuring fatigue in clinical and community settings. J Psychosom 
Res 2010;69:17-22. 
27. Hauri P, Fisher J. Persistent psychophysiologic (learned) insomnia. Sleep 1986;9:38-53. 
  122 
28. Billiard M. Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the 
International classification of sleep disorders, 2nd edition. Sleep Med Rev 2007;11:377-88. 
 
  123 
2. Validation of the three-factor model of the PSQI in a large sample of chronic 
fatigue syndrome (CFS) patients 
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Abstract 
Objective:  
To evaluate whether a 3-factor model of the Pittsburgh Sleep Quality Index (PSQI) scale 
would fit the constellation of sleep disturbances in patients with a diagnosis of chronic fatigue 
syndrome (CFS). 
Methods:  
Consecutive CFS patients filled out the PSQI. Scores from this self-report questionnaire were 
examined with exploratory and confirmatory factor analysis (CFA). 
Results:  
Four hundred thirteen CFS patients were included for analysis in this study. CFA showed that 
the 7 PSQI component scores clustered into the 3 factors reported by Cole et al. (2006), i.e. 
Sleep Efficiency, Perceived Sleep Quality and Daily Disturbances. In contrast with the single-
factor and all 2-factor models, all factor loadings were significant, and all goodness-of-fit 
values were acceptable. 
Conclusion:  
In CFS, the PSQI operates as a 3-factor scoring model as initially seen in healthy and 
depressed older adults. The separation into 3 discrete factors suggests the limited usefulness 
of the global PSQI as a single factor for the assessment of subjective sleep quality, as also 
evidenced by a low Cronbach's alpha (0.64) in this patient sample. 
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Introduction 
Chronic fatigue syndrome (CFS) is a disabling condition characterized by chronic fatigue of a 
new or definite onset that lasts for at least 6 months and that is not explained by medical or 
psychiatric causes[1]. Next to this major criterion, the 1994 case definition requires the co-
occurrence of at least four out of eight minor criteria: unusual postexertional malaise, 
impaired memory or concentration, unrefreshing sleep, headaches, muscle pain, joint pain, 
sore throat and tender cervical nodes [1]. These 1994 CDC diagnostic criteria prevail as a 
standard in current clinical practice and scientific research. Complaints of unrefreshing sleep 
and poor sleep quality are common in CFS patients. The Pittsburgh Sleep Quality Index 
(PSQI) is one of the most used and validated questionnaires to measure sleep quality and 
disturbances during the past month [2]. The self-report questions are divided into 7 clinically 
derived components of sleep difficulties: subjective sleep quality, sleep latency, sleep 
duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications and 
daytime dysfunction. Individual component scores are summed to yield one global score or a 
single factor, with higher scores indicating poorer sleep quality. Psychometric properties of 
the PSQI have been examined and found to be appropriate in relation to internal consistency 
[2,3], concurrent validity [3,4] and discriminative validity [3,4] in a range of clinical and 
healthy populations. 
Using a cross-validation approach in healthy and depressed elderly US adults, Cole et al.[5] 
found that a single summed global score did not best capture the multidimensional nature of 
sleep disturbances. An exploratory factor analysis (EFA) followed by a confirmatory factor 
analysis (CFA) on the 7 quality components revealed that a 3-factor scoring model 
significantly better fitted than either the original single-factor or a 2-factor model. This model 
documents sleep disturbances in the separated factors Sleep Efficiency, Perceived Sleep 
Quality and Daily Disturbances. 
Three other studies provided evidence that a multiple factor scoring method of the PSQI could 
be more appropriate to assess sleep problems compared to the originally proposed single- 
factor method. In a sample of Nigerian university students, a 3-factor model of the PSQI was 
identified performing EFA, however, the factors differed from Cole's findings [6]. EFA and 
subsequent CFA on the PSQI results deriving from a sample of Australian adults determined a 
2- and 3-factor scoring model with slight differences in the optimal factor structures compared 
to the model of Cole et al. [7]. Conducting CFA, the original 3-factor model [5] was also 
found to better fit than a single-factor model in renal transplant recipients [8]. Although the fit 
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indices noticed were not as good as those found by Cole et al. [5], an additional pathway 
significantly improved its fit [8]. 
Differences in sample characteristics may account for the different factor structures identified 
in various studies since sleep patterns, sleep quality and perception of sleep are influenced by 
a range of factors related to age, health and culture [9–11]. As a consequence, there is a need 
for further studies examining the factor structure of the PSQI. 
The aim of this study was to evaluate whether the 3-factor model of the PSQI reported by 
Cole et al. [5] would fit the constellation of sleep disturbances in a large sample of patients 
with CFS. 
 
Methods 
Patient recruitment 
Consecutive patients with a final diagnosis of CFS according to the Fukuda criteria in a 
multidisciplinary tertiary care referral center were included in this study [12]. The sample was 
approved by the Ethical Review Board of the Ghent University Hospital. 
 
Questionnaire 
All patients filled out the PSQI and scores were calculated according to the scoring guidelines 
provided by Buysse et al. [2]. 
 
Statistical analysis 
To investigate the validity of the 3-factor model of the PSQI proposed by Cole et al. [5], CFA 
was performed using SPSS (PASW 17.0) and the AMOS module (5.0). An EFA was 
performed to investigate the validity of the single-factor and all 2-factor models. The fit of 
the models was estimated with the Maximum Likelihood Algorithm. 
In line with published recommendations, several indices were used to assess the model fit 
[13,14]. These include χ² and its related degrees of freedom (d.f.) and probability (p), 
goodness-of-fit index (GFI), adjusted goodness-of-fit index (AGFI), comparative fit index 
(CFI), root mean square error of approximation (RMSEA) and the consistent Akaike 
information criterion (CAIC). Chi-square assesses whether a significant amount of observed 
covariance between items remains unexplained by the model. A significant χ² (pb0.05) 
indicates a bad model fit. The RMSEA is a fit measure based on population error of 
approximation [15]. It is unreasonable to assume that the model will hold exactly in the 
  127 
population. Therefore the RMSEA takes into account the error of approximation in the 
population. A RMSEA value b0.05 indicates a close fit and values up to 0.08 represent 
reasonable errors of approximation in the population. The GFI and the AGFI assess the extent 
to which the model provides a better fit compared to no model at all [16]. These indices have 
a range between 0 and 1, with higher values indicating a better fit. A GFI >0.90 and an AGFI 
>0.85 indicate a good fit of the model. The CFI is an incremental fit index [17]. It represents 
the proportionate improvement in model fit by comparing the target model with a baseline 
model (usually a null model in which all the observed variables are uncorrelated). The CFI 
ranges between 0 and 1, with values >0.90 indicating an adequate fit. The CAIC is a 
goodness-of-fit measure which adjusts the model's chi-square to penalize for model 
complexity and sample size [18]. This measure can be used to compare non-hierarchical as 
well as hierarchical (nested) models. Lower values on the CAIC measure indicate better fit 
[18]. 
 
Results 
The study sample included 415 CFS patients (mean age 40.53 years, SD 7.91; 86% female) 
[12] from which 413 completely filled out all PSQI items, allowing analysis with the AMOS 
module. 
Table 1 provides the descriptive statistics for the global PSQI, the 7 PSQI components and the 
Spearman's intercorrelations. Generally, high PSQI scores were found with a mean global 
score of 10.17 (SD 4.02, Cronbach's alpha 0.64). Poor sleep quality was observed in 86% of 
the patients using the recommended cut-off point of 5 [12]. 
Several inter-component correlations were not significant; the highest correlation was found 
between ‗sleep duration‘ and ‗habitual sleep efficiency‘ (r=0.71). 
Fig. 1 shows the results of the CFA performed on the 3-factor model proposed by Cole et al. 
[5]. All factor loadings were significant and all goodness-of-fit values were acceptable 
(χ2=14.70, d.f.=11, p=0.20; GFI=0.99; AGFI=0.97; CFI=0. 99; RMSEA=0.03; 
CAIC=134.10). In contrast, the single-factor model proposed by Buysse et al. [2] indicated a 
poor fit with the data (χ2=109.90, d.f.=14, pb0.001; GFI=0.92; AGFI=0.85; CFI=0.84; 
RMSEA=0.13; CAIC=208.23) as was also the case for all 2-factor models (significant χ2 
values; results not shown). 
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Discussion 
This is the first time that the PSQI factor structure was examined in a large sample of CFS 
patients. CFA demonstrated that the PSQI 
operated as a multiple factor scoring model in CFS, which is consistent with previous findings 
in different subject groups [5–8]. Moreover, the 3-factor model proposed by Cole et al. [5] 
showed good fit criteria and the 7 PSQI component scores clustered into the factors Sleep 
Efficiency, Sleep Quality and Daily Disturbances. Therefore, the 3-factor model could 
improve the sensitivity of the PSQI in assessing sleep problems in CFS compared to the 
global PSQI as a single factor. 
This limitation of the single-factor global PSQI is further evidenced by the low Cronbach's 
alpha in our sample (0.64) as an indicator of internal consistency, in contrast with the 
Cronbach's alpha (0.83) of the original PSQI description [2]. 
In conclusion, CFA confirmed that the PSQI operates as a 3-factor scoring model in CFS. The 
separation of the PSQI into 3 discrete factors suggests the limited usefulness of the global 
PSQI as a single factor for the assessment of subjective sleep quality in CFS patients. 
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Table 1 Pittsburgh Sleep Quality Index (PSQI) component correlations and descriptive 
statistics 
 Mean (SD)  1   2   3   4   5   6   7   8 
1. Subjective sleep quality 1.63 (0.84) ― .49** .47** .40** .36** .17** .15** .72** 
2. Sleep latency 1.69 (1.10)    ― .34** .36** .22** .16* .01 .64** 
3. Sleep duration 0.64 (0.88)     ― .71** .24** .05 .16* .69** 
4. Habitual sleep efficiency  1.25 (1.27)      ― .22** .07 .07 .72** 
5. Sleep disturbances 1.60 (0.61)       ― .06 .22** .47** 
6. Use of sleep medication 1.37 (1.40)        ― .02 .46** 
7. Daytime dysfunction 1.99 (0.75)         ― .30** 
8. Global PSQI 10.17 (4.02)          ― 
*Correlation is significant at the 0.05 level (2-tailed), **Correlation is significant at the 0.01 level (2-tailed) 
 
 
 
 
 
Figure 1 Confirmatory factor analysis (CFA) of the 3-factor model for the PSQI in CFS. Standardized 
β-coefficients (factor loadings, all significant) and R² values are shown (R² values shown above each 
variable).  
GFI, Goodness-of-fit index; AGFI, Adjusted goodness-of-fit index; CFI, Comparative fit index; RMSEA, Root mean square 
error of approximation; CAIC, Consistent Akaike information criterion.    
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Abstract 
Objectives 
This study aimed to assess objective parameters of sleep and sleepiness in a large sample of 
patients with unexplained chronic fatigue and to compare the results with data from a 
reference population. Furthermore, the relation was assessed between these objective results 
and subjective scores derived from questionnaires probing mental and physical health, sleep 
quality, daytime sleepiness and fatigue.  
 
Methods 
Objective sleep parameters derived from polysomnography (PSG) and multiple sleep latency 
testing (MSLT). Subjective assessment comprised history taking, psychological tests and the 
administration of validated questionnaires.  
 
Results 
Out of 377 eligible patients, 245 subjects were included (mean age 38.6 years, SD 10.69, 
86.1% female). Significant differences in several objective sleep parameters were observed 
between the unexplained chronic fatigue and reference groups (i.e. decreased total sleep time, 
sleep efficiency and %REM; increased sleep latency, %NREM1, wake after sleep onset and 
arousal index). This sleep profile suggests an insomnia phenotype in patients with 
unexplained chronic fatigue. Neither PSG nor MSLT data were correlated with fatigue, and 
were only weakly correlated with mental health and subjective sleepiness. The latter was not 
substantiated by objective data from the MSLT.  
 
Conclusions 
The overall lack of correlation between subjective scores and objective indices derived from 
PSG and MSLT may suggest that these tests are inappropriate to explain symptoms of 
daytime sleepiness and fatigue in patients with unexplained chronic fatigue. However, their 
application remains justified for the demonstration of comorbid primary sleep disorders in this 
patient group.  
 
Key words 
Chronic fatigue syndrome; polysomnography; MSLT; SF36; ESS; PSQI; FQ 
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Introduction 
Fatigue is a common complaint among the general population. It is a subjective experience 
with aspects of lack of energy, weakness, attention deficits, memory problems and emotional 
instability. Whilst fatigue may often be attributed to a well-defined medical condition, 
psychiatric illness or primary sleep disorder, a definite cause cannot be determined in many 
patients, even after comprehensive clinical investigations. If unexplained fatigue persists for 
more than six months, the term ‗chronic fatigue‘ is used. If, in addition, at least four out of 
eight minor diagnostic criteria are present, a diagnosis of ‗chronic fatigue syndrome‘ (CFS) 
may be established according to the Fukuda criteria [1].  
Fatigue is conceptually different from excessive daytime sleepiness (EDS), as the latter 
phenomenon refers to an inability to stay awake in normal conditions [2]. EDS is also quite 
prevalent in patients with CFS, and high scores on self-report questionnaires have been 
observed [3]. In these patients, however, little information is available on EDS assessed by 
objective means, such as the multiple sleep latency test (MSLT). A study in co-twins 
discordant for CFS revealed a discrepancy between scores on self-reported sleepiness that 
were higher in the CFS group and the results of the MSLT that were normal and quite similar 
in the CFS and control groups [4]. Evaluation of objective sleepiness has not been carried out 
in sufficiently large clinical samples of patients with chronic fatigue.  
A complaint of disturbed or nonrestorative sleep (NRS) is one of the minor criteria in the 
prevailing guidelines for case definition [1]. Sleep disturbances are indeed reported by the 
vast majority of patients with CFS, and may include complaints of insufficient or too little 
sleep. Literature data on the nature of sleep complaints and impaired sleep quality assessed by 
PSG are limited and controversial [5].  
Because figures from large clinical samples are lacking, the present study was designed to 
assess objective parameters of sleep and sleepiness in a large sample of patients referred with 
unexplained chronic fatigue (UCF), in which previous clinical investigations had not revealed 
any medical or psychiatric disease as an obvious cause of this presenting symptom. These 
data were compared with published data from a reference population. In addition, it was 
explored whether self-reported scores of fatigue, daytime sleepiness, sleep quality and quality 
of life are correlated with or predicted by objective variables derived from polysomnography 
(PSG) and MSLT.  
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Methods 
Patient recruitment took place between June 2010 and February 2011.  
Patients were admitted to our tertiary care referral centre for further clinical investigation of 
UCF. Prior to referral they had been examined by conventional methods in primary and/or 
secondary care settings. These previous assessments did not reveal any underlying medical or 
psychiatric diseases that would obviously explain the severity and duration of the reported 
chronic fatigue.  
Criteria for enrolment were UCF persisting for at least six months, and a minimum age of 18 
years. Participants gave written consent. The study was approved by the institutional Ethical 
Review Board of the University Hospital Ghent, Belgium. 
 
Objective sleep assessment 
PSG and MSLT were recorded and scored according to the manual of the American Academy 
of Sleep Medicine [6]. Sleep parameters derived from PSG included time in bed, total sleep 
time (TST), sleep efficiency (SE), sleep latency (SL), REM sleep latency (REM SL), 
percentage of TST spent in the different sleep stages (NREM1, NREM2, NREM3, REM), 
wakefulness after sleep onset (WASO), arousal index and apnea-hypopnea index (AHI).  
MSLT consisted of taking four naps and assessing mean sleep latency and presence of REM 
sleep at sleep onset. 
A mean sleep latency equal to or less than 8 minutes was considered indicative of clinically 
relevant hypersomnia, as this is the diagnostic cut-off in narcolepsy patients [7]. 
MSLT could not be performed in a subgroup of patients because of technical issues 
(environmental noise due to reconstruction works). 
Patients were asked to withdraw from hypnotics (benzodiazepines and z-drugs) at least three 
weeks before PSG was performed. 
 
Subjective assessment 
Subjective assessment comprised history taking, psychological tests and the administration of 
validated questionnaires, i.e. Medical Outcomes Study 36-Item Short Form Health Survey 
(SF36) [8], Epworth Sleepiness Scale (ESS) [9], Pittsburgh Sleep Quality Index (PSQI) [10], 
and Fatigue Questionnaire (FQ) [11] (Table 1). Out of these questionnaires, the parameters 
global mental and global physical health, daytime sleepiness, global sleep quality, and fatigue 
were considered for further analysis. Clinically relevant daytime sleepiness is considered with 
an ESS score > 10, whereas poor sleep quality is defined as a PSQI score > 5.  
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Statistical analysis 
The data were analysed with SPSS (PASW 17.0).  
Descriptive statistics of the relevant objective (predictor) and subjective (outcome) variables 
were computed.  
Because female patients represented 86.1% of the sample, some comparative analyses were 
limited to this gender category.  
Simple regressions were performed to investigate the relation between predictor variables and 
age in female patients.  
Welch T tests were carried out to assess differences between female patients and matched age 
subgroups from the general population [12]. 
Correlations between all study variables were calculated using the method of Spearman. In 
addition, multiple regression analysis was performed . 
 
Results 
Three hundred seventy-seven patients were referred for evaluation of UCF. Seven patients 
(1.9%) were excluded because of the age criterion. Fifty-eight patients (15.4%) did not give 
informed consent and in 51 patients (13.5%) data were incomplete, mostly due to cancellation 
of appointments. In sixteen patients (4.2%), complaints of fatigue had been present for less 
than six months. Two hundred forty-five patients (65.0%), who met the inclusion criteria, 
were enrolled in the study. Of these, 169 patients (69.0%) underwent MSLT.  
 
The majority of the patients was female (n=211; 86.1%). The mean age was 38.6 years 
(median = 38.0; SD = 10.69; range 18-63); mean body mass index was 25.1 kg/m² (median = 
24; SD = 5.27; range 15.5-46.4). A minority (n=85; 34.7%) had a certificate of higher 
education. ESS > 10 was present 113 patients (46.1%), and PSQI > 5 in 189 (77.1%). 
 
A comparison of the objective sleep parameters in female UCF patients versus matched age 
subgroups from the general population is presented in Table 2.  
Linear regression showed that TST, SE and NREM3 significantly decreased with age, 
whereas NREM2, WASO and AHI increased with age. No changes were observed regarding 
other sleep parameters.  
TST and SE were significantly lower in female UCF patients of the 39-49, and 50-59 age 
subgroups compared with reference subgroups. REM was significantly decreased in the 39-49 
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age subgroup. A significant increase was observed with respect to SL, NREM1, WASO and 
arousal index in female UCF patients in the 39-49, and 50-59 age subgroups. In the oldest age 
subgroup (60-69) these differences were no longer present, with the exception of WASO. 
NREM2 and NREM3 were not significantly different between the patient and reference 
subgroups. Because of missing reference data, no comparative analysis could made in the 18-
38 age subgroup.  
The mean sleep latency on MSLT was 15.9 minutes and was not statistically different from 
the results in the reference sample. In only 10 out of 169 patients (5.9%) the mean sleep 
latency was less than the pre-set cut-off value of 8 minutes.   
 
The mean values of all subjective and objective variables as well as the Spearman correlation 
coefficients are shown in Table 3. Only few significant correlations were found between 
objective sleep variables and subjective outcome data. The SF36 global mental health was 
correlated with TST and SE, and inversely correlated with SL. The ESS was correlated with 
TST and SE, and inversely correlated with WASO and MSLT mean sleep latency. All these 
correlations were weak. In addition, a low but statistically significant inverse correlation was 
found between PSQI and TST. No correlation was observed between SF36 global physical 
health or FQ with any of the PSG or MSLT parameters. 
On the other hand, stronger correlations were found between the different subjective measures 
with respect to each other (Table 3). 
 
 
Further regression analyses demonstrated that MSLT mean sleep latency and WASO 
significantly predicted ESS values. An inverse relation was also found between TST and 
PSQI. However, for all these items, the explained variance was low, as evidenced by the R
2
 
values (Table 4). No significant relation was found between any of the PSG or MSLT 
parameters and FQ values.  
 
 
Discussion 
This study is the first to statistically describe both objective and subjective sleep data in a 
large sample of clinical patients with UCF. The demographic characteristics of the present 
sample of 245 patients are in keeping with previously published data on CFS, showing 
predominance of female patients in the middle-age group, and remarkably low values on 
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global physical and mental health related quality of life as measured by SF36 [5, 13]. 
Therefore, the results from this sample can be inferred to the broader population of patients 
with presumed or confirmed CFS who seek medical attention in specialized care centers. 
 
A salient objective of the present study was to match the objective sleep data in UCF patients 
with those from a reference population. Since reference data have not been established in our 
center, data from the literature were accessed. Published data on objective sleep parameters in 
healthy subjects are rare. Many studies are biased by small sample size or too specific 
selection criteria. The demographic dataset published by Unruh et al. (2008) was selected for 
the intended comparison as it covers a sample of 5407 community-dwelling adults from the 
general population. In analogy with the design of this reference study, patients with UCF were 
partitioned in age groups. Furthermore, the comparative analysis was limited to the female 
subgroup, given the predominance of this gender category in the patient sample.  
Common age related phenomena, including effects on TST, SE, SL and distribution of time 
spent in different sleep stages were clearly present in both the patient and the reference 
groups.  However, significant differences between patient and reference groups were observed 
regarding several PSG parameters. TST and SE were decreased, whereas SL, NREM1, 
WASO and arousal index were increased in patients with UCF. These differences were 
prominent in the 39-49 and the 50-59 age subgroups. Interestingly, REM was decreased in the 
39-49 age subgroup only. Unfortunately, no reference data were available for the 18-38 age 
group, precluding any inference about sleep quality in this category. 
 
These results would indicate that middle-aged women with UCF have less and more disrupted 
nocturnal sleep than controls, which would point to the co-existence of an insomnia-
phenotype. This finding is at variance with previous studies showing that key characteristics 
of sleep architecture were not different between control subjects and CFS patients, despite 
subjective reports of poor sleep quality by the latter [14-17]. The reason for this discrepancy 
is not entirely clear. However, previous studies in clinical patients that failed to show an 
altered sleep structure in subjects with CFS may have been hampered by small sample size. 
An alternative explanation may be offered by the fact that subjects in the present study had to 
abstain from sleep medication, whereas in other studies the use of hypnotics was not 
controlled. Since PSG is not recommended for routine assessment of primary insomnia in 
clinical practice, there is a paucity of published data, which precludes comparison of objective 
sleep parameters in this diagnostic entity. Despite this limitation, the sleep profiles in different 
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age subgroups of female patients with UCF seamlessly match the diagnostic criteria of 
chronic insomnia, defined as an average SL and WASO exceeding 30 minutes, SE of less than 
85% or TST of less than 6.5 hours [18, 19]. A relevant insomnia trait in middle-aged women 
with UCF is certainly a novel finding that requires further investigation and confirmation. 
Prospective studies on UCF should include diagnostic tools geared to assess insomnia. 
Moreover, validated treatment approaches to insomnia, e.g. cognitive behavioural therapy, 
may have a role in the management of UCF.  
 
It is known from the literature that CFS patients experience EDS, at least subjectively [3]. The 
mean ESS in the present study was 10.0, which is just below the cut-off value for clinical 
relevance. Moreover, 113 patients (43.1%) had an ESS value > 10. Although a weak 
correlation between ESS and MSLT was found, the results of MSLT were not indicative of 
objective hypersomnolence. The mean MSLT sleep latency was 15.9 minutes, a value that 
substantially surpasses the present cut-off point of 8.0 minutes, and was not significantly 
different from the results in the reference cohort. A value below this threshold was present in 
only 5.9% of patients. Altogether, these results underpin the earlier reported discrepancy 
between objective and subjective accounts of sleepiness in patients with CFS [5]. 
 
In the present study, only few significant correlations were found between objective sleep 
variables and subjective outcome data. The SF36 global mental health was correlated with 
TST and SE, and inversely correlated with SL, but these correlations were weak. PSQI was 
inversely correlated with TST. No correlation was observed between SF36 global physical 
health or FQ with any of the PSG parameters. The lack of correlation between objective and 
subjective sleep parameters has been reported before in patients with CFS [16]. These authors 
concluded that sleep quality misperception might exist in CFS, or that potential 
neurophysiological sleep disturbances are not expressed by sleep PSG variables. Obviously, 
the lack of correlation between objective and subjective reports of sleep quality is a source of 
ambiguity in CFS. Our findings would corroborate the contention that PSG parameters are 
insufficiently capable of explaining symptom scores in CFS patients across the domains of 
mental or physical health, sleep quality, daytime sleepiness or fatigue. Whether this paradox 
may be explained by an as yet undisclosed deficit in the neurobiology of sleep or be inherent 
to the technical limitations of PSG, remains to be determined [5].  
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Although correlations between subjective scores and objective indices of sleep were few and 
weak, coefficients of correlation between results from the different questionnaires were more 
robust. These questionnaires have been validated for the clinical evaluation of sleep, daytime 
sleepiness and/or fatigue. Given the good reproducibility of results across different studies [3] 
these scales are still the mainstay for the assessment of patients with UCF. Whilst clinically 
valid, these instruments do not disclose the causes of disturbed sleep nor the mechanisms of 
fatigue in these patients. 
 
Some limitations of the present study must be acknowledged. First, no conclusions could be 
drawn regarding male subjects with UCF, as they represented only 13.9 % of the sample. 
Given the scarcity of the male gender in this patient group, a multicenter study would 
probably be required to collect sufficient numbers. Second, the study lacks an original case-
control design. Our department has not constructed a PSG database on healthy controls over 
the years. Therefore, a historical source had to be accessed. The dataset from the Sleep Heart 
Health Study seemed suitable, as it comprises a large sample from a general population [12]. 
The reported information was sufficiently detailed to allow age group comparisons of patients 
versus controls in the female gender category. Third, there was a difference in applied PSG 
methodology between the present patient sample and the reference cohort. Laboratory sleep 
recording was carried out in the patient group versus portable monitoring in the reference 
group. This methodological difference may induce a measurement bias, as sleep is influenced 
by the environment. However, a study comparing effects of home-based versus laboratory 
conditions on PSG variables in insomniacs showed that there were no significant main or 
interaction effects attributable to the settings in which sleep recording was carried out [20]. 
Certainly, the laboratory environment may have had a limited influence on sleep in the 
present study. Conversely, some of these effects may have been counterbalanced by a known 
paradoxical effect, namely the fact that patients with insomnia often sleep better than usual on 
their first night in the laboratory [21, 22]. Fourth, sleep may vary in consistency and duration 
across nights. This is especially true in patients with insomnia [21]. As such, a single night 
study may not be representative and may fail to properly characterize the full extent of the 
sleep problem. However, this effect may be averaged out when the number of included 
subjects is sufficiently high, as is the case in the present study. Nevertheless, night-to-night 
variability may compromise representative sampling, and a potential sampling error could 
have played a role in the lack of correlation between subjective scores and objective PSG data 
observed in the present study. 
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To conclude, it was observed that objective sleep parameters are significantly worse in 
middle-aged women with UCF as compared to a reference population, suggesting an insomnia 
phenotype. While subjectively sleepy, most of these patients have normal MSLT values. The 
overall lack of correlation between subjective scores and objective indices of sleep and 
daytime sleepiness would imply that the latter do not contribute to explaining the symptoms 
of fatigue and EDS. As a consequence, conventional single PSG and MSLT investigations do 
not seem appropriate to authenticate sleep complaints in relation with symptoms of daytime 
dysfunction in these patients. However, this observation does not invalidate the role of PSG 
and MSLT in the diagnosis of primary sleep disorders that may be comorbid factors in the 
clinical picture of UCF.  
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Table 1. Overview of psychodiagnostic questionnaires 
Screening tool Item measured Scale 
Medical Outcomes Study 36-item  
Short Form Health Survey (SF36) [8]  
Global mental and physical 
health 
0-100 on 8 health domains: higher 
score = better health status, no cut-
off 
Epworth Sleepiness Scale (ESS) [9]  Excessive daytime sleepiness 0-24: higher score = more severe 
sleepiness, cut-off > 10 
Pittsburgh Sleep Quality Index 
(PSQI) [10]  
Global sleep quality 0-3 on 7 components, 0-21 global 
score: higher score = worse sleep 
quality, cut-off global score > 5 
Fatigue Questionnaire (FQ) [11]  Fatigue severity 0-33: higher score = more severe 
fatigue, no cut-off  
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Table 2. Comparison of objective sleep parameters (means, standard deviation) in female patients with chronic fatigue/CFS and reference female 
controls according to age 
 
 Patients with chronic fatigue/CFS  Reference adults (Unruh et al., 2008) 
 18-38 years 39-49 years 50-59 years 60-69 years p trend  39-49 years 50-59 years 60-69 years p trend 
Polysomnography n = 106 n = 65 n = 34 n = 6   n = 314 n = 793 n = 759  
TST (min) 372.30 (65.12) 358.05*** (63.76) 325.15*** (75.52) 352.83 (27.33) <.001  385.5 (62.9) 374.6 (58.1) 362.2 (60.9) <.001 
SE (%) 76.90 (12.18) 74.59*** (13.25) 68.32*** (15.46) 73.48 (12.28) <.001  85.6 (9.8) 84.6 (8.4) 81.7 (10.3) <.001 
SL (min) 36.79 (31.88) 33.82** (25.53) 41.07*** (40.99) 30.67 (11.80) .70  24.2 (26.5) 21.9 (21.9) 25.0 (25.4) .38 
REM SL (min) 172.52 (84.09) 170.62 (89.61) 173.77 (103.03) 193.50 (96.76) .71  ND ND ND  
NREM1 (% TST) 5.89 (4.59) 6.05*** (2.85) 5.76** (2.84) 3.83 (1.95) .71  4.2 (2.8) 4.3 (3.1) 4.7 (3.3) .03 
NREM2 (% TST) 51.41 (10.95) 53.75 (13.58) 55.31 (8.97) 57.32 (24.91) .02  54.4 (10.3) 53.0 (10.9) 52.0 (11.7) .75 
NREM3 (% TST) 25.54 (10.00) 21.61 (13.76) 19.72 (8.42) 18.85 (19.77) <.001  19.7 (9.8) 21.7 (10.9) 23.0 (11.5) .004 
REM (% TST) 17.13 (6.16) 18.58*** (7.19) 19.12 (7.50) 19.89 (10.79) .12  21.7 (6.2) 21.0 (5.8) 20.3 (5.9) <.001 
WASO (min) 73.72 (46.15) 87.74*** (55.56) 110.82*** (56.81) 104.33** (72.25) <.001  39.0 (30.2) 48.5 (33.5) 57.7 (40.1) <.001 
Arousal index 23.48 (11.44) 26.91*** (12.82) 26.39*** (14.27) 15.83 (8.12) .06  13.9 (7.1) 16.0 (8.6) 17.2 (8.3) <.001 
AHI 2.98 (3.85) 5.12 (5.02) 8.64 (12.08) 8.30 (9.36) <.001  ND ND ND  
Multiple sleep latency n = 74 n = 50 n = 18 n = 6       
MSLT mean sleep latency 15.79 (4.89) 15.31 (4.95) 18.58 (5.25) 17.89 (6.58) .23  ND ND ND  
p trend: tests for statistical significance of a linear age effect within sample 
Comparison with corresponding age group of reference subjects (Unruh et al., 2008) is given by p-values: p < .05* p < .01** p < .005*** (Welch test) 
AHI, apnea hypopnea index; MSLT, multiple sleep latency test; REM SL, REM sleep latency; SE, sleep efficiency; SL, sleep latency; TST, total sleep time; WASO, wake 
after sleep onset 
ND, no data 
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Table 3.  Means, standard deviation (SD) and Spearman correlations of the variables used in this study 
 
 Mean (SD) 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
1. SF36 global physical health 34.30 (16.75) .42** -.20** -.46** -.46** .02 .03 .02 -.04 -.07 -.01 -.01 .05 -.05 -.07 .13 -.06 
2. SF36 global mental health 49.53 (18.44)  -.11 -.32** -.46** .14* .17** -.14* -.12 -.10 -.01 -.00 .07 -.13 -.07 .04 -.08 
3. ESS 10.00 (5.68)   -.06 .31** .17** .19** -.11 -.08 -.02 .06 -.05 -.00 -.21** -.02 .03 -.22** 
4. PSQI  9.48 (4.37)    .26** -.14* -.10 .08 .07 .03 .04 -.06 .05 .10 .06 -.04 .06 
5. FQ  22.76 (5.98)     .07 .07 -.07 .07 -.03 -.09 .09 .02 -.08 .03 -.06 -.01 
6. TST (min) 359.68 (67.72)      .92** -.53** -.27** -.40** .01 -.08 .26** -.79** -.21** -.07 -.14 
7. SE (%) 74.96 (13.51)       -.57** -.36** -.44** .00 -.06 .28** -.89** -.21** -.03 -.17* 
8. SL (min) 35.25 (29.89)        .47** .12 -.05 .10 -.14* .23** -.00 -.06 .18* 
9. REM SL (min) 167.96 (87.12)         .19** .03 .08 -.34** .23** .04 -.05 .02 
10. NREM1 (% TST) 5.77 (3.64)          .17** -.17** -.40** .48** .65** .35** -.10 
11. NREM2 (%TST) 53.41 (12.17)           -.84** -.32** .03 .13* .08 -.05 
12. NREM3 (%TST) 22.67 (11.58)            -.11 -.00 -.15* -.13* .02 
13. REM (%TST) 18.14 (6.71)             -.24** -.23** -.05 .06 
14. WASO (min) 84.40 (54.51)              .25** .07 .13 
15. Arousal index 24.96 (12.51)               .46** -.22** 
16. AHI 5.44 (7.46)                .06 
17. MSLT mean sleep latency 15.90 (5.24)                 
p < 0.05* p < 0.01** 
AHI, apnea hypopnea index; ESS, Epworth Sleepiness Scale; FQ, Fatigue Questionnaire; MSLT, multiple sleep latency test; PSQI, Pittsburgh Sleep Quality Index; REM SL, 
REM sleep latency; SF36, Medical Outcomes Study 36-Item Short Form Health Survey; SE, sleep efficiency; SL, sleep latency; TST, total sleep time; WASO, wake after 
sleep onset                                                               
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Table 4. Multiple regressions with ESS sleepiness, PSQI global quality of sleep and FQ 
fatigue respectively as dependent variables. 
 
Criterion 
variable 
Entry Predictor β ΔR2 Adj.R2 
      
ESS: sleepiness 
1 MSLT sleep latency  -.19* .04** .04 
2 WASO: wakefulness after sleep onset  -.15* .02* .06 
      
PSQI: global 
quality of sleep. 
1 TST: total sleep time  -.21** .05** .04 
     
      
FQ fatigue      
      
p < 0.05* p < 0.01** p < 0.005*** 
In each regression, the following PSG and MSLT variables were entered stepwise: total sleep time, sleep latency, 
REM sleep latency, time spent in NREM1, NREM2, NREM3, REM, wakefulness after sleep onset, arousal 
index, apnea-hypapnea index and MSLT sleep latency. The stepwise entry method was used with Prob.-of-F-to-
enter <= 0.05, Prob.-of-F-to-remove >0.10. The Variance Inflating Factors did not indicate collinearity 
problems. All beta values are, for each criterion variable, from the last step. 
AHI, apnea hypopnea index; ESS, Epworth Sleepiness Scale; FQ, Fatigue Questionnaire; MSLT, multiple sleep 
latency test; PSQI, Pittsburgh Sleep Quality Index; TST, total sleep time; WASO, wake after sleep onset 
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Abstract 
Objective 
To explore the interrelationship of different dimensions (fatigue, neuroticism, sleep quality, 
global mental and physical health) as assessed through self-report questionnaires in the 
construct of chronic fatigue and chronic fatigue syndrome (CFS). 
Methods 
Patients with chronic unexplained fatigue in a tertiary referral centre filled out the Fatigue 
Questionnaire (FQ) and Checklist Individual Strength (CIS), respectively, NEO-Five Factor 
Inventory (NEO-FFI), Pittsburgh Sleep Quality Index (PSQI) and Medical Outcomes Study 
36-item Short Form Health Survey (SF36).  Path and regression analyses were performed. 
Results 
Out of 296 patients fulfilling the enrolment criteria, a full dataset allowing statistical analysis 
was available in 203 patients (mean age 39.0 years, SD 10.37, 89% female). In a first path 
analysis, using FQ for assessment of fatigue and involving the questionnaires alone, night-
time PSQI sleep quality had a direct effect on SF36 physical health quality of life (PHQL) and 
no effect on FQ fatigue. This was confirmed by a similar path analysis with CIS fatigue for 
assessment of fatigue and by regression analyses. These unexpected results raised the question 
whether FQ and CIS fatigue sufficiently operationalises fatigue, as the major complaint in 
CFS. For both fatigue scales, the introduction of a latent variable, coined as ‗intrinsic fatigue‘, 
into the model resulted in an indirect effect of PSQI sleep quality on SF36 PHQL via intrinsic 
fatigue. Furthermore, this latent variable had a direct effect on FQ and CIS fatigue, 
respectively and on the two SF36 quality of life variables. NEO neuroticism had a direct 
effect on FQ and CIS fatigue, respectively, but not on intrinsic fatigue, and its positive direct 
effect on SF36 PHQL, as was seen in the first path analysis, disappeared.  
Conclusions 
Path analysis on a large sample of patients with presumed CFS led to the introduction of a 
latent variable, intuitively called ‗intrinsic fatigue‘, as missing link in the relationship between 
the subjective complaints neuroticism, fatigue, poor sleep quality and outcome measures of 
mental and physical quality of life. This new variable seems to correspond better with the 
subjective feelings of fatigue, mentioned by CFS patients, than the FQ and CIS fatigue 
variables. These findings emphasize the complex and heterogeneous concept of fatigue as 
well as the need for more appropriate and innovative tools for measuring fatigue in CFS.  
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Introduction 
Fatigue is a subjective experience associated with impaired functioning, and refers to a lack of 
energy, weakness, attention deficits, memory problems and emotional instability. It is a 
common complaint among the general population that often may be attributed to a diagnosis 
of a well defined medical condition, psychiatric illness or primary sleep disorder. However, a 
definite cause of fatigue cannot be determined in many patients, even after comprehensive 
clinical investigations. If unexplained fatigue persists for more than six months, the term 
‗chronic fatigue‘ is used. If, in addition, at least four out of eight minor diagnostic criteria are 
present, a diagnosis of ‗chronic fatigue syndrome‘ (CFS) may be established [1].  
The 1994 CFS case definition stipulates that patients have 1) clinically evaluated, 
unexplained, persistent or relapsing chronic fatigue of at least six months duration, 2) that is 
of new or definite onset, 3) that is not the result of ongoing exertion, and 4) that results in 
substantial reduction in previous levels of occupational, educational, social or personal 
activities [1]. This description of fatigue is, however, difficult to apply in practice [2]. 
Furthermore, ‗effort tolerance‘ is considered to be a minor parameter as mirrored by ‗post-
exertional malaise‘, which often has been criticized in literature [3-5]. Since fatigue is highly 
subjective, multidimensional and variable during the course of disease, the specific meaning 
remains unclear within the 1994 CFS case definition. 
A substantial number of patients with a presumed diagnosis of CFS in tertiary care have 
psychiatric problems [6-8]. Personality, e.g., is regarded as a contributing factor in CFS [9, 
10], and one of the most consistent findings is the high level of neuroticism in CFS patients 
compared to healthy control groups [11, 12]. Sleep disorders as well are frequently observed 
in patients with chronic fatigue and CFS [13]. Nevertheless, the relation between fatigue, 
psychiatric and sleep problems remains unclear in this clinical sample.  
The aim of the present study is to explore the interrelationship of self-report questionnaires on 
fatigue, neuroticism, and sleep quality and their effect on the global quality of life of patients 
with chronic unexplained fatigue, in order to improve insights in the concept of ‗fatigue‘ 
within the CFS definition.   
 
Methods 
Enrolment criteria in the present study were unexplained fatigue for at least six months and a 
minimum age of 18 years. These patients were recruited from an integrated multidisciplinary 
diagnostic pathway for chronic unexplained fatigue offered to patients referred with a 
presumed diagnosis of CFS. Participants gave written informed consent. Patient recruitment 
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took place between June 2010 and February 2011. The study was approved by the 
institutional Ethical Review Board of the University Hospital Ghent, Belgium. 
All patients filled out a set of validated questionnaires in order to evaluate personality, 
fatigue, sleep quality and mental and physical quality of life (Table 1). The seventh 
component score of the Pittsburgh Sleep Quality Index (PSQI) probes daytime dysfunction, 
which consists in part of daytime sleepiness. This component overlaps with part of the fatigue 
questionnaire (FQ), containing the question ‗do you feel sleepy or drowsy?‘. Consequently, 
we used the global PSQI without the seventh component score, labelled as ―night-time PSQI‖, 
to assess the relation between sleep quality and the other variables of this study [14, 15].  
 
Statistical analysis  
Data were analysed with SPSS (PASW 17.0) and the AMOS module (5.0). 
  
Path and regression analyses were performed in order to assess the relationship between 
subjectively measured variables NEO neuroticism, FQ and Checklist Individual Strength 
(CIS) fatigue, respectively, night-time PSQI sleep quality, Medical Outcomes Study 36-item 
Short Form Health Survey (SF36) mental (MHQL) and physical health quality of life 
(PHQL). The study protocol allowed the further exploration of the interrelationship between 
these variables through the introduction of latent variables, in the presence of insufficient 
explanatory modeling.  
The CIS variable was transformed with a classical transformation (New value = - logarithm 
[maximum value + 1 - value], because it was not normally distributed, and had high kurtosis 
and negative skewness [16]. 
 
The path analyses were estimated and tested with the maximum likelihood algorithm, which 
is known to be asymptotically efficient and to give correct chi-square estimators if there is not 
too much multivariate kurtosis [17, 18]. The indices used in the path analyses for goodness-
of-fit modelling were chi square (χ2) and its related degrees of freedom (df), probability (P), 
goodness-of-fit index (GFI), adjusted goodness-of-fit index (AGFI), comparative fit index 
(CFI), and the Consistent Akaike Information Criterion (CAIC). Chi square assesses whether 
a significant amount of observed covariance between items remains unexplained by the 
model. A significant chi square (e.g., P < .05) indicates a bad model fit.  
The GFI and AGFI assess the extent to which the model provides a better fit compared to no 
model at all. [19]. These indices have a range between 0 and 1, with higher values indicating a 
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better fit. A GFI larger than 0.90 and an AGFI larger than 0.85 indicate a good fit of the 
model. The CFI is an incremental fit index [20] and represents the proportionate improvement 
in a model fit by comparing the target model with a baseline model (usually a null model in 
which all the observed variables are uncorrelated). The CFI ranges between 0 and 1, with 
values larger than 0.90 indicating an adequate fit. 
The CAIC is a goodness-of-fit measure that adjusts the model‘s chi square to penalize for 
model complexity and sample size [21]. This measure can be used to compare non-
hierarchical as hierarchical (nested) models. Lower values on the CAIC measure indicate 
better fit [21]. 
  
Results 
Three hundred seventy-seven patients were referred for evaluation of chronic unexplained 
fatigue. Seven patients (1.9%) were excluded because of age requirement. Fifty-eight patients 
(15.4%) did not give informed consent. In sixteen patients (4.2%), complaints of fatigue had 
been present for less than six months. Out of 296 patients (78,5%) fulfilling the enrolment 
criteria, a full dataset was available in 203 patients, which were suitable for further analysis.  
The majority of the patients was female (n = 181; 89%). The mean age was 39.0 years (SD 
10.37); mean body mass index (BMI) was 24.7 kg/m² (SD 5.18). A minority (n = 73, 36%) 
had a certificate of higher education. 
In a first path analysis, using FQ for assessment of subjective fatigue (Figure 1A) and 
involving the questionnaires alone, night-time PSQI sleep quality has no direct effect on FQ 
fatigue, but does have a direct effect on SF36 PHQL. A similar path analysis with CIS fatigue 
for assessment of fatigue (Figure 1B) demonstrated a moderate effect of night-time PSQI on 
CIS fatigue and a direct effect on SF36 PHQL as well. These results were confirmed with 
regression analyses (Table 2 and 3).  
The findings raise the question whether fatigue, as operationalised by the FQ and CIS fatigue, 
respectively, is a rather poor representative of the dimension of fatigue as represented in the 
‗F‘ of ‗CFS‘. To test this hypothesis, a second path analysis was performed for FQ and CIS 
fatigue, respectively, with an additional latent variable for which the denominator ‗intrinsic 
fatigue‘ (Figure 2A and B) was coined. 
In this modeling, night-time PSQI sleep quality has a direct effect on intrinsic fatigue. This 
latent variable has a direct effect on the measured fatigue variables FQ and CIS fatigue, 
respectively, and on the two SF36 quality of life variables. NEO neuroticism has a direct 
effect on the result of the FQ and CIS fatigue, respectively, but not on intrinsic fatigue. 
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Furthermore, neuroticism no longer had a positive direct effect on SF36 PHQL, as was the 
case in the first path analyses. 
In each path analysis, the critical ratio given for the multivariate kurtosis by AMOS (-0.47 in 
the case of the two analyses with FQ, -1.92 in the case of the two analyses with CIS fatigue) 
was not significant at the 5% level, showing that the maximum likelihood algorithm was 
appropriate to carry out the estimation and testing for the path analyses.  
 
Discussion 
In this study, the relationship between the variables neuroticism, fatigue, night-time sleep 
quality and mental and physical quality of life as measured by the self-report questionnaires 
NEO- Five Factor Inventory (NEO-FFI), FQ and CIS, respectively, PSQI and SF36 was 
assessed in a large sample of patients with chronic unexplained fatigue by means of path and 
regression analyses.  
 
Path analysis of these variables demonstrated a direct effect of PSQI sleep quality on SF36 
PHQL and no or moderate effect on FQ and CIS fatigue, respectively. However, it should be 
expected that PSQI sleep quality only has an indirect effect on SF36 PHQL via FQ and CIS 
fatigue, respectively. These findings suggest that these fatigue scales do not sufficiently 
operationalise fatigue, as the major complaint in CFS. 
 
The introduction of a latent variable into the model, intuitively called ‗intrinsic fatigue‘, 
resulted in effects that better correspond with complaints of CFS patients in clinical practice: 
the sleep quality (night-time PSQI) considerably effects intrinsic fatigue, which in turn 
influences patients‘ physical quality of life (SF36 PHQL). As such, the new fatigue variable 
mediates between PSQI sleep quality and SF36 PHQL. Additionally, a substantial effect of 
intrinsic fatigue on FQ and CIS fatigue results strengthens the hypothesis that these fatigue 
scales do not fully measure fatigue, as experienced by patients with chronic unexplained 
fatigue and CFS. Possibly, the FQ and CIS fatigue insufficiently measure the lack of tolerance 
to mental and/or physical effort, and a new variable may be needed to take into account this 
dimension. FQ and CIS fatigue may essentially measure the major criterion within the Fukuda 
definition, but maybe the Fukuda criteria themselves do not correspond well with the 
subjective feeling of CFS patients. It can be hypothesised that post-exertional physical and 
mental malaise may play a role, as partially implicated in the Canadian guidelines by 
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Carruthers et al. [3]. Nevertheless, the nature of this missing link needs to be further explored 
and may lead to a revision of the Fukuda case definition.  
 
Furthermore, the findings of both path analyses suggest a more complex and heterogeneous 
concept and hence warrant the search for other measurement tools of fatigue in CFS. Self-
report questionnaires, objective measures, as well as a combination of both subjective and 
objective tools may be considered in order to better estimate the lack of tolerance to effort in 
this patient sample. 
 
Path analysis showed a direct effect of NEO neuroticism on FQ and CIS fatigue, respectively 
and SF36 MHQL, whereas its positive direct effect on SF36 PHQL, as was seen in the first 
path analysis, disappeared. Nater et al. [10] also found that personality dimensions, as 
measured by the NEO-FFI, were associated with fatigue and functional impairment in CFS. 
Among the five personality dimensions, the strongest correlations were found between 
neuroticism and fatigue and both SF36 health quality of life [10].  
 
In conclusion, path analysis on a large sample of patients with presumed CFS led to the 
introduction of a latent variable, intuitively called ‗intrinsic fatigue‘, as missing link in the 
relationship between the subjective complaints neuroticism, fatigue, poor sleep quality and 
outcome measures of mental and physical quality of life. This new variable seems to 
correspond better with the subjective feelings of fatigue, mentioned by CFS patients, than the 
FQ and CIS fatigue variables. These findings emphasize the complex and heterogeneous 
concept of fatigue as well as the need for more appropriate and innovative tools for measuring 
fatigue in CFS.  
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Table 1. Overview of psychodiagnostic questionnaires 
Screening tool Item measured Scale 
NEO-Five Factor Inventory [22] 
 
 
 
Fatigue Questionnaire (FQ) [23] 
 
Checklist Individual Strength (CIS) [24] 
 
 
Pittsburgh Sleep Quality Index (PSQI) 
[25] 
 
Medical Outcomes Study 36-item  
Short Form Health Survey (SF36) [26] 
Personality assessment 
(neuroticism, extraversion, 
openness, agreeableness, 
conscientiousness) 
Fatigue severity 
 
Fatigue phenomenology (fatigue, 
concentration, motivation, physical 
activity) and severity  
Global sleep quality 
 
 
Global mental and physical health 
 
0-4 on 12 items for each personality 
dimension: ranging from ‗totally not 
agree‘ (score 0) to ‗totally agree‘ 
(score 4) 
0-33: higher score = more severe 
fatigue, no cut-off  
0-7 on 20 items, 0-140 global score, 
cut-off global score > 76 
 
0-3 on 7 components, 0-21 global 
score: higher score = worse sleep 
quality, cut-off global score > 5 
0-100 on 8 health domains: higher 
score = better health status, no cut-off 
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Table 2. Multiple regressions with SF36 Physical Health Quality of Life and SF36 Mental 
Health Quality of Life respectively as dependent variables. Fatigue was evaluated by the 
Fatigue Questionnaire (FQ). 
 
Criterion 
variable 
Entry Predictor β ∆R2 Adj.R2 
      
SF36 Physical 
Quality of Life  
1 FQ Subjective Fatigue  -.33*** .24*** .24 
2 SF36 Mental Quality of Life   .46*** .09*** .32 
 3 Night time PSQI Sleep Quality  -.24*** .04*** .36 
 4 NEO Neuroticism   .29*** .05*** .40 
      
SF36 Mental 
Quality of Life. 
1 NEO Neuroticism  -.59*** .46*** .46 
2 FQ Subjective Fatigue  -.26*** .06*** .51 
      
      
            
p < 0.05* p < 0.01** p < 0.005***    
 
 
In each regression, the independent variables were entered stepwise. In the first regression, all independent 
variables had a significant contribution, and were thus entered by the stepwise entry method. In the second 
regression, Night time PSQI Sleep Quality did not have a significant contribution. The stepwise entry method 
was used with Prob.-of-F-to-enter <= 0.05, Prob.-of-F-to-remove >0.10. The Variance Inflating Factors (VIF) 
did not indicate collinearity problems. All beta values are, for each criterion variable, from the last step
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Table 3. Multiple regressions with SF36 Physical Health Quality of Life and SF36 Mental 
Health Quality of Life respectively as dependent variables. Fatigue was evaluated by the 
Checklist Individual Strength (CIS) fatigue. 
 
Criterion 
variable 
Entry Predictor β ∆R2 Adj.R2 
      
SF36 Physical 
Quality of Life  
1 CIS Subjective Fatigue  -.35*** .31*** .30 
2 SF36 Mental Quality of Life   .39*** .05*** .35 
 3 Night time PSQI Sleep Quality  -.19*** .02** .37 
 4 NEO Neuroticism   .21** .02** .40 
      
SF36 Mental 
Quality of Life. 
1 NEO Neuroticism  -.57*** .46*** .46 
2 CIS Subjective Fatigue  -.37*** .13*** .58 
      
      
            
p < 0.05* p < 0.01** p < 0.005***    
 
 
In each regression, the independent variables were entered stepwise. In the first regression, all independent 
variables had a significant contribution, and were thus entered by the stepwise entry method. In the second 
regression, Night time PSQI Sleep Quality did not have a significant contribution. The stepwise entry method 
was used with Prob.-of-F-to-enter <= 0.05, Prob.-of-F-to-remove >0.10. The Variance Inflating Factors (VIF) 
did not indicate collinearity problems. All beta values are, for each criterion variable, from the last step
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Figure 1A. Path analysis with the measured variables FQ, NEO-FFI neuroticism, night-time 
PSQI sleep quality and SF36 mental and physical health quality of life 
 
Goodness-of-fit values:  
2 
= 3.98 (df = 2) (A), n.s. : p = .14, GFI = .99, AGFI = .94, CFI = . 99, CAIC = 86.05 (A). 
All fit values are acceptable. Standardized -coefficients (all regression coefficients are significant) and R² 
values are shown, with R² values shown above each variable. 
 
 
A 
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Figure 1B. Path analysis with the CIS fatigue, NEO-FFI neuroticism, night-time PSQI sleep 
quality and SF36 mental and physical health quality of life 
 
Goodness-of-fit values:  
2 
= 0.02 (df = 1), n.s. : p = .90, GFI = 1., AGFI = 1., CFI = 1., CAIC = 88.40 (B).  
All fit values are acceptable. Standardized -coefficients (all regression coefficients are significant) and R² 
values are shown, with R² values shown above each variable.  
 
 
B 
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Figure 2A. Path analysis with the measured variables FQ, NEO-FFI neuroticism, night-time 
PSQI sleep quality and SF36 mental and physical health quality of life and the latent variable 
intrinsic fatigue 
 
Goodness-of-fit values:  
2 
= 8.51 (df = 3), n.s. : p = .04, GFI = .98, AGFI = .92, CFI = . 98, CAIC = 84.27. The 
2 
is significant at the 5% 
value, but not at the 1% value, and all other fit values are acceptable (A).  
Standardized -coefficients (all regression coefficients are significant) and R² values are shown, with R² values 
shown above each variable.  
 
NEO-FFI, NEO-Five Factor Inventory; CIS, Checklist Individual Strength; SF36, Medical Outcomes Study 36-
item Short Form Health Survey; PSQI, Pittsburgh Sleep Quality Index; GFI, Goodness-of-fit index; AGFI, 
Adjusted Goodness-of-fit Index; CFI, Comparative Fit Index; CAIC, Consistent Information Criterion 
A 
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Figure 2B. Path analysis with the CIS fatigue, respectively, NEO-FFI neuroticism, night-time 
PSQI sleep quality and SF36 mental and physical health quality of life and the latent variable 
intrinsic fatigue 
 
Goodness-of-fit values:  
2 
= 6.35 (df = 3), n.s. : p = .10, GFI = .99, AGFI = .94, CFI = . 99, CAIC = 82.11. All fit values are acceptable 
(B). 
Standardized -coefficients (all regression coefficients are significant) and R² values are shown, with R² values 
shown above each variable.  
 
NEO-FFI, NEO-Five Factor Inventory; CIS, Checklist Individual Strength; SF36, Medical Outcomes Study 36-
item Short Form Health Survey; PSQI, Pittsburgh Sleep Quality Index; GFI, Goodness-of-fit index; AGFI, 
Adjusted Goodness-of-fit Index; CFI, Comparative Fit Index; CAIC, Consistent Information Criterion 
B 
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CHAPTER 7: SUMMARY, FUTURE PERSPECTIVES AND 
CONTRIBUTION TO PATIENT CARE 
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1. Major findings of the doctoral thesis 
The presented research focuses on the role of sleep in patients with hitherto insufficiently 
explained chronic fatigue or presumed chronic fatigue syndrome (CFS). It aims at exploring: 
- the diagnostic categories of patients with unexplained chronic fatigue through 
systematic clinical analysis 
- the existing literature on sleep in CFS 
- subjective sleep parameters and sleep quality in CFS patients 
- the objective sleep measures and subjective sleep parameters in a large sample of 
patients with unexplained chronic fatigue and their mutual correlation 
- the interrelationship of self-report questionnaires on different dimensions in the 
construct of chronic fatigue and CFS 
  
Mariman A, Delesie L, Tobback E, Hanoulle I, Sermijn E, Vermeir P, Pevernagie D, 
Vogelaers D. Undiagnosed and comorbid disorders in patients with presumed chronic 
fatigue syndrome. Submitted to Journal of Psychosomatic Research, under revisio. 
A systematic approach through a diagnostic pathway of a large sample of patients with 
presumed CFS results into significant diagnostic categorization relevant to appropriate care. 
This study points to a high prevalence of hitherto under- or unrecognised  psychiatric 
disorders or sleep disorders as either a primary diagnosis or significant comorbidity to CFS. 
Mood disorder, anxiety disorder, cluster C and cluster B personality disorder were most 
frequently observed. The prevalence of obstructive sleep apnea (OSA) is similar to that in 
recognised indications for polysomnographic (PSG) screening such as morbid obesity, atrial 
fibrillation and heart failure.  
 
This study distinguishes itself from previous reports through a low prevalence of psychiatric 
comorbidity in CFS. This probably reflects lower validation of psychiatric diagnoses as mere 
comorbidity and a clearer separation into diagnostic categories. Hence, there was a lower 
propensity to use the label of a syndromal definition such as CFS, which lacks a 
pathophysiologic substrate, through a diagnostic pathway and a multidisciplinary assessment. 
 
The recognition of these primary sleep or psychiatric disorders seems essential for an 
adequate approach of incapacitating fatigue in individual patients. Hence systematic 
psychodiagnostic testing or, upon indication, psychiatric screening on the one hand, and 
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objective assessment of sleep through PSG and multiple sleep latency test (MSLT) on the 
other hand needs to be recommended in this patient sample. This recommendation needs to be 
at least considered in future evidence-based clinical approaches or algorithms of chronic 
fatigue and CFS.  
 
Pevernagie D, Mariman A, Vandenbussche N, Tobback E, Overeem S, Delesie L, Janssen 
H, Vogelaers D. Behavioral hyperventilation as a novel clinical condition associated with 
central sleep apnea: a report of three cases. Sleep Med 2012;13(10):1317-1320. 
The systematic approach through a diagnostic pathway of patients with chronic fatigue 
allowed the description of a novel entity within the primary sleep disorders, namely central 
sleep apnea through behavioral hyperventilation. 
 
Mariman A, Vogelaers D, Tobback E, Delesie L, Hanoulle I, Pevernagie D. Sleep in the 
chronic fatigue syndrome. Sleep Med Rev 2013;17(3):193-199. 
This review article is the first analysis in depth of sleep in CFS. It points towards 
inconsistencies and incomplete descriptions of elements of sleep in the syndromal definition 
of CFS.  
 
The concept of nonrestorative sleep (NRS), a main minor criterion within the Fukuda-
definition, implies that fatigue is the consequence of dysfunctional sleep, whilst evidence for 
such cause-effect relationship has not yet been provided. The complaint is often described as 
‗waking up unrefreshed‘. However, no uniform working definition is currently available and 
should be validated, based on an empirical approach involving experts, clinicians and 
patients. Furthermore, the concept lacks any pathophysiological substrate or quantification 
tool in order to be reliably used in the clinic. 
 
A significant prevalence of primary sleep disorders is found in different series of patients 
labelled as CFS, which is in line with our findings. These disorders could contribute to the 
presence and severity of daytime dysfunctioning. However, a diagnosis of CFS can only be 
excluded by satisfactory symptomatic relief obtained by causal treatment.  
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Mariman A, Vogelaers D, Hanoulle I, Delesie L, Pevernagie D. Subjective sleep quality and 
daytime sleepiness in a large sample of patients with chronic fatigue syndrome (CFS). Acta 
Clin Belg 2012;67(1):19-24. 
A high level of poor sleep quality (high mean Pittsburgh Sleep Quality Index, PSQI) and 
excessive daytime sleepiness (high mean Epworth Sleepiness Scale, ESS) were observed in a 
large patient sample of CFS presenting at a tertiary care referral centre. The further analysis of 
this patient sample allowed the identification of a subgroup with insomnia phenotype. This 
seems to substantiate a need for differentiation into different subgroups or diagnostic 
categorisation within a patient sample with a seemingly homogenous presentation based on a 
mere constellation of aspecific symptoms.  
 
Mariman A, Vogelaers D, Hanoulle I, Delesie L, Tobback E, Pevernagie D. Validation of 
the three-factor model of the PSQI in a large sample of chronic fatigue syndrome (CFS) 
patients. J Psychosom Res 2012;72:111-113. 
On a large sample of CFS patients, we evaluated whether a three-factor model of the PSQI 
scale would fit the constellation of sleep disturbances. We found the PSQI to effectively 
operate as a three-factor scoring model, as initially observed in healthy and depressed older 
adults. The separation into three discrete factors suggests the limited usefulness of the global 
PSQI as a single factor for the assessment of subjective sleep quality in this patient sample.  
 
Mariman A*, Tobback E*, Hanoulle I, Delesie L, Vogelaers D, Pevernagie D. 
Polysomnographic and MSLT data in a large sample of patients with unexplained chronic 
fatigue: comparison with a reference sample and relation with subjective scores. In 
preparation. (*: shared first author) Submitted to Sleep Medicine 
Data from PSG and MSLT were obtained in a large sample of patients with unexplained 
chronic fatigue (UCF) and compared with these from a reference group. Decreased total sleep 
time, sleep efficiency on the one hand and increased SL, wake after sleep onset and arousal 
index on the other hand were observed in the patient sample, suggesting an insomnia 
phenotype in patients with UCF. In the assessment of the relation between these objective 
results and subjective scores derived from validated questionnaires, neither PSG nor MSLT 
data were correlated with fatigue, and were only weakly correlated with mental health and 
subjective sleepiness. The latter was not substantiated by objective data from the MSLT.  
The overall lack of correlation between subjective scores and objective indices derived from 
PSG and MSLT may suggest that these tests are inappropriate to explain symptoms of 
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daytime sleepiness and fatigue in patients with UCF. However, their application remains 
justified for the demonstration of comorbid primary sleep disorders in this patient group.  
 
Tobback E*, Hanoulle I*, Mariman A, Delesie L, Pevernagie D, Vogelaers D. What does 
fatigue mean in the chronic fatigue syndrome? A path analysis on a large sample of 
patients with chronic fatigue. In preparation. (*: shared first author) 
Path analysis on a large sample of patients with presumed CFS led to the introduction of the 
latent variable, intuitively called ‗intrinsic fatigue‘, as missing link in the relationship between 
the subjective complaints neuroticism, fatigue, poor sleep quality and outcome measures 
mental and physical quality of life. This new variable seems to correspond better with the 
subjective feelings of fatigue, mentioned by CFS patients, than the Fatigue Questionnaire 
(FQ) and Checklist Individual Strength (CIS) fatigue variables. These findings emphasize the 
complex and heterogeneous concept of fatigue as well as the need for more appropriate and 
innovative tools for measuring fatigue in this patient sample.  
 
2. Future perspectives 
The role of sleep disturbances in the pathogenesis of chronic fatigue and CFS remains 
speculative. Whilst the Fukuda definition include NRS as one of the minor criteria that define 
CFS, they do not address the relevance of disturbed sleep in the pathogenesis of CFS.  
Generally, a causal relationship between sleep and daytime dysfunction may be inferred from 
the observation that treatment of the underlying sleep disorder may result in the improvement 
of daytime symptoms such as fatigue, excessive sleepiness and pain. This implies the need for 
clinical trials to get more insight in the responsiveness to adequate treatment of comorbid 
sleep disorders in patients whose presenting complaint is severe chronic fatigue. 
 
a. The effect of nasal CPAP in patients with chronic fatigue and sleep-disordered 
breathing 
A recent randomized placebo-controlled trial in patients with moderate to severe OSA showed 
evidence that fatigue may be responsive to continuous positive airway pressure (CPAP) 
treatment. The beneficial effect of CPAP treatment was most pronounced in subjects with 
high levels of fatigue at onset [1]. In clinical practice, however, it is often observed that 
complaints of chronic fatigue do not or only transiently respond to CPAP treatment.  
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To evaluate the effect of improved sleep quality on fatigue, a double-blind, randomized, 
placebo controlled cross-over trial with nasal CPAP will be carried out in patients who 
present with a primary complaint of chronic disabling fatigue and who are found to have an 
apnea-hypopnea index (AHI) ≥ 15 on PSG. As secondary outcomes, the CPAP 
responsiveness regarding sleepiness, sleep quality and general health will be evaluated in the 
same target sample.  
 
b. The effect of sodium oxybate in patients with chronic fatigue syndrome 
Sodium oxybate is a commercial sodium salt of gamma-hydroxybutyrate and is known to 
increase slow-wave sleep [2]. In patients with narcolepsy, it has been approved to treat 
cataplexy and a beneficial effect on daytime sleepiness has been shown as well [3]. A number 
of studies have also been reported on the efficacy of sodium oxybate in the treatment of 
fibromyalgia (FM) [3-8]. In a small randomized placebo controlled cross-over trial in FMS 
patients, treatment with sodium oxybate showed significantly improved subjective sleep 
quality, pain and fatigue. PSG records demonstrated an increase in slow wave sleep and a 
decrease in the severity of alpha anomaly [4]. Similar improvements in sleep physiology and 
FM-related symptoms were recently seen in a large cohort of patients with FM [5-7].  
Sodium oxybate treatment has hitherto not been studied in CFS patients, although a positive 
effect may be considered since this disorder shares considerable overlap in symptoms with 
FMS including sleep-related complaints, pain and fatigue. A preliminary retrospective study 
recently showed promising results for a role of sodium oxybate treatment in CFS since 
improvements of fatigue and/or pain after sodium oxybate treatment were observed in the 
majority of patients with long-standing fatigue in a pattern consistent with CFS [9]. However, 
some methodological shortcomings such as the inability to distinguish CFS and FMS and the 
inconsistent use of subjective questionnaires make it difficult to interpret the results.  
To evaluate the effect of sodium oxybate on fatigue and to explore the interdependence of 
sleep quality and fatigue in CFS, a double-blind, randomized, placebo controlled cross-over 
trial with sodium oxybate will be carried out in CFS patients. 
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3. Contribution to patient care 
 
a. Development of an integrated path of care 
The care for patients with CFS in Belgium has been organized as a pilot project in tertiary 
care referral centres from 2002 onwards. Patients with a syndromal definition of CFS 
according to the 1994 Centers for Disease Control and Prevention (CDC) criteria [10] were 
included in a revalidation program, consisting of a combination of cognitive behavioural 
therapy (CBT) most often organised as a program of group educational sessions, and 
progressive aerobic reconditioning or graded exposure/exercise therapy (GET) in different 
modalities. In 2008, the Belgian Health Care Knowledge Centre performed an assessment of 
the initial years of this program within the background of updated evidence based knowledge 
of definitions, epidemiology, therapeutic interventions and their cost-effectiveness, prognosis 
and organisational models in the care for CFS patients in different countries [11]. The 
evaluation of the results of the pilot projects mainly focused on the end point of socio-
professional reintegration, which proved to be disappointing. Hence, the federal health 
authorities asked the Committee for Chronic Diseases within the National Institute for 
Disease and Disability Insurance (RIZIV/INAMI) to elaborate a new and innovative model of 
stepped care, aiming at improved integration of diagnosis and treatment into primary care and 
between levels of health care for patients with CFS.  
A similar approach is warranted both for the more limited group of patients who fit the 
syndromal definition of CFS and a larger sample of patients who develop somatic complaints 
without a classical psychiatric or internal medicine diagnosis. They share common or similar 
pathogenic mechanisms, including vulnerability, triggering and maintaining factors for 
somatisation within a biopsychosocial model [12]. The approach should focus on a restriction 
of a continuous search for a somatic explanation through a simple biologic model, CBT and 
GET in order to avoid syndromal entrenchment with a poorer prognosis. 
To achieve a new model of care for CFS that integrates this broader perspective in a 
multidisciplinary approach, the reference centre of the University Hospital Ghent developed 
the initiative recruiting partners through the provinces of East and West Flanders from 
different professional categories involved in the diagnosis and treatment of patients with 
medically unexplained symptoms (MUS), in particular unexplained chronic fatigue.  
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Uniform perceptions of deficits and focus points at different levels of care 
The partners within the network agree that different deficits should be addressed to improve 
appropriate care for patients with unexplained chronic fatigue including CFS. Although the 
etiology and pathophysiology of chronic fatigue and CFS remain essentially unknown, a clear 
vision that underlies the current concepts in pathogenesis, focusing on the biopsychosocial 
model [12], should be offered within the network and towards the patients. Expertise 
concerning prevention, detection and referral should be shared and reported in guidelines. In 
Belgium, the current graduate and postgraduate training of medical doctors but also of other 
health professionals pay insufficient attention to the management of CFS or other forms of 
aspecific complaints and somatisation. Hence, improvement of these training programs 
represents a priority in order to better organise care. A prolonged duration of the syndrome 
should be avoided since this is likely to be associated with a pattern of disease benefits and 
inflexibility/unresponsiveness to therapeutic improvement. Therefore, early recognition of the 
patient at risk is essential in order to avoid disease or rather illness progression and should be 
integrated at primary care. Treatment needs to be initiated at an early stage, preferably within 
the first two years after disease onset, in order to safeguard significant health improvement 
opportunities. In the pilot study of the Belgian reference centres, the mean duration of 
symptoms at the time of initiation of the revalidation program (CBT and GET) averaged eight 
years, which may explain the disappointing results of socio-professional reintegration. It is 
within this time frame of the first two years after initiation of symptoms that revalidation 
(rehabilitation) including assessment of professional reintegration through e.g VDAB/GTB 
(integrated career coaching), needs to addressed and stimulated, in contestation with 
controlling instances. 
 
b. Towards a new health care model 
Approach in the early stage (< 6 months) 
Within this new perspective, primary care physicians will play a central role in the majority of 
patients with unexplained chronic fatigue and MUS. They need to focus on increased 
recognition and pre-emptive management of patients at risk, in order to avoid chronic 
somatisation. Such an attitude is often lacking, resulting in a continued search for a biological 
explanation and patterns of ‗medical shopping‘. The development of such patterns, fed by 
culturing a sense of diagnostic uncertainty and (often sequentially) focusing on different 
individual symptoms through biological models rather than on the whole syndrome through a 
biopsychosocial model, needs to be avoided.  
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Early communication should be of an assertive and reassuring nature, following careful 
clinical history taking and physical examination for excluding underlying somatic or 
psychiatric causes. If sufficient factors, such as prolonged or recurrent complaints, argue for 
the development of unexplained chronic fatigue, the patient may be referred to a program of 
physical reconditioning and eventually to psychological therapy in the early stage. The 
physical therapists and clinical psychologists involved need to dispose of a standardized 
therapy program that still needs to be elaborated. 
Timely referral for more extensive specialist assessment (often including synchronous internal 
medicine and psychodiagnostic screening) is only necessary if the above approach fails within 
a reasonable time period and/or with suspicion of comorbidity.  
 
Approach in the later stage (≥6 months) 
Specialised centres need to evolve into centres of diagnostic expertise, focussing on patients 
that are referred because of evolution towards chronicity with a tentative cut-off length of 
symptoms in the range of six months. These patients are generally in need of a more intensive 
revalidation program, often including individual psychologic coaching and GET. This can be 
outsourced within a validated network that needs to be visualised into a regularly updated 
social map. Both social map and standardized therapy program need to be readily accessible, 
e.g. in a dedicated website of a government agency. From this perspective, it seems logical to 
continue to build on the expertise of the current CFS reference centres and shifting focus from 
a revalidation convention agreement towards diagnosis and subsequent referral in a network 
of identified and validated health care providers.  
The evaluation of seemingly unexplained chronic fatigue for more than six months requires 
an integrated holistic approach based on the biopsychosocial model [12], before allowing an 
exclusion diagnosis of CFS. Undoubtedly, a large proportion of  patients referred to the 
tertiary CFS reference centres prove to have received prior to referral an unjustified label of 
CFS. Pathologic fatigue can often be explained through psychiatric comorbidity and/or  
sleeping disorders and, less frequently, by internal pathology, that had gone under- or 
unrecognized. This underscores the need for a full diagnostic (re-)assessment. Hence, these 
referrals have been re-categorized in the department of general internal medicine of the 
University Hospital Ghent as ‗chronic fatigue of yet undetermined origin‘. The same under-
recognition of psychiatric comorbidity also applies to other entities such as fibromyalgia 
(FM).  
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At the CFS referral centre of the University Hospital Ghent, patients in whom fatigue persists 
for more than six months are eligible to enter an integrated multidisciplinary path of care. 
This includes administration of standard questionnaires, internal medicine assessment, 
psychodiagnostic screening, physiotherapeutic assessment and PSG in combination with a 
MSLT. The internal medicine assessment consists of a thorough history taking and physical 
examination and integrates the results of previous investigations. The psychodiagnostic 
screening includes an evaluation by a psychologist and psychological testing using validated 
questionnaires. Indication for psychiatric disorders from the psychodiagnostic screening are 
subsequently confirmed (or refuted) by psychiatric evaluation using the DSM-IV-TR criteria. 
Physiotherapeutic evaluation screens for musculoskeletal comorbidity that is potentially 
suitable for physical rehabilitation. The multidisciplinary discussion yields either a final 
diagnosis or a tentative diagnosis in selected patients, in whom response to treatment is 
considered an additional diagnostic criterion.  
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Extension of the concept to somatic unexplained complaints 
Different case definitions of somatic unexplained syndromes not only share a number of 
symptom components, but also non-symptom features including sex, outlook and response to 
treatment [13], as evidenced in CFS, FM and irritable bowel syndrome (IBS) (Figure 2). 
Although there is disagreement whether these diagnostic labels represent a single disorder or 
multiple disorder, from the ‗lumping‘ point of view, these syndromes are believed to be an 
artefact of medical specialization [13]. Indeed in Belgium, patients are not infrequently 
initiated into either the care path of a Multidisciplinary Pain Centre or that of a CFS 
Reference Centre, according to whether pain or fatigue represented the dominating symptom 
within the syndrome at the time of intake. It can not be denied, however, that pain and fatigue 
undoubtedly interact. Even, if in due course, both syndromes would ultimately be proven to 
represent separate disease entities, common diagnostic and therapeutic approaches could be 
bundled into a single holistic model of care.  From this point of view, we believe that a well-
organised care path, in which different partners collaborate, is necessary in order to require 
better understanding and improved management of patients with MUS, despite validation and 
financing is no longer provided by the Belgian authorities.  
 
 
Figure 2. Overlapping conditions sharing chronic fatigue as clinical illness feature. MUS medically 
unexplained symptoms 
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Patients with MUS are not always taken seriously by the medical community and the society 
at large. Dissatisfied patients have described encountering attitudes as dismissive, sceptical or 
openly disbelieving in a wide variety of social interactions, including families, friends, 
employers and doctors [14]. Problems in such relationships, loss of unemployment benefit 
and so on are often stressful and anxious experiences and may contribute to persistent 
disability and the maintenance of chronic illness. As a result, MUS sufferers continue medical 
shopping, between medical subspecialties, to seek administrative validation in order to regain 
social benefits, since objective proof is the generally accepted criterion of professional 
disability.  
The proposed innovative stepped care model for MUS may cope with these problems in 
emphasizing early detection and correct diagnosing (by better communication and education 
of doctors) on the one hand and improved socio-professional reintegration on the other hand. 
We believe that not only patients, but medical practitioners as well may benefit from this 
improved new care model. Indeed, physicians in primary and specialists care are frequently 
confronted with MUS patients. Health care providers not seldom feel helpless or frustrated 
when dealing with patients for whom no objective abnormalities are found in order to explain 
their subjective complaints. When they frequently have to deal with such patients without a 
supportive network, they might be at higher risk for physical and mental exhaustion and burn-
out. Therefore, it is believed that working in a multidisciplinary care network with integrated 
team discussions might give support to individual health care providers.   
The development of a centre for MUS within a university setting additionally gives the 
opportunity to educate students, trainees and the medical staff in general how to deal with and 
treat somatic unexplained symptoms. It is important to make them aware of a biopsychosocial 
approach in order to diminish the tendency of Cartesian thinking, splitting the body and the 
mind within medical science. 
 
With the present studies on one of the most important presentations of MUS, namely CFS, we 
hope to have contributed to the development of these innovative insights.  
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SAMENVATTING 
 
Het huidig onderzoek richt zich in hoofdzaak op de rol van slaap bij patiënten met 
onvoldoende verklaarde vermoeidheid of vermoeden van chronisch vermoeidheidssyndroom 
(CVS). De doelstellingen van het onderzoek bestaan  uit het exploreren van: 
 
de bestaande literatuur omtrent slaap bij CVS 
de diagnostische categorieën van patiënten met onverklaarde chronische vermoeidheid op 
basis van een systematische benadering bestaande uit een klinische evaluatie, 
psychodiagnostiek en polysomnografie 
subjectieve slaapparameters en slaapkwaliteit bij CVS patiënten 
de objectieve meting en subjectieve appreciatie van de slaap en hun onderlinge relatie in een 
grote groep patiënten met onverklaarde chronische vermoeidheid 
de onderlinge samenhang van vermoeidheid, slaapkwaliteit en persoonlijkheidskenmerken en 
hun beïnvloeding van mentale en fysieke levenskwaliteit, geëvalueerd door op zelfrapportage 
gebaseerde vragenlijsten, bij patiënten met onverklaarde chronische vermoeidheid 
 
Mariman A, Vogelaers D, Tobback E, Delesie L, Hanoulle I, Pevernagie D. Sleep in the 
chronic fatigue syndrome. Sleep Med Rev 2013;17(3):193-199. 
Dit overzichtsartikel is de eerste grondige evaluatie van de bestaande literatuur over slaap bij 
CVS. In elke syndromale CVS-definitie wordt gestoorde slaap als mineur criterium vermeld. 
Deze beschrijvingen zijn evenwel sterk uiteenlopend en inconsistent.  
 
Het concept niet-recuperatieve slaap (NRS) is een prevalent mineur criterium van de in de 
literatuur meest gehanteerde Fukuda-definitie en suggereert dat vermoeidheid mede een 
gevolg kan zijn van disfunctionele slaap. Nochtans is een dergelijke oorzaak-gevolg relatie 
nog niet aangetoond. Hoewel de klacht vaak beschreven wordt als ‗het niet uitgerust wakker 
worden‘, is een uniform gehanteerde definitie niet beschikbaar. Op heden mist dit concept een 
pathofysiologisch substraat en is er geen bruikbaar meetinstrument in de klinische praktijk.  
 
 
Zowel bij bevolkingsonderzoek als onderzoek bij CVS-discordante eeneiige tweelingen 
konden geen duidelijke afwijkingen van de slaaparchitectuur geobjectiveerd worden.  
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Uit de literatuur blijkt dat bij een aanzienlijk aantal patiënten met een CVS label een primaire 
slaapstoornis wordt aangetoond. Deze stoornissen kunnen wel degelijk bijdragen tot het 
disfunctioneren overdag. Het is plausibel dat een diagnose van CVS overeind blijft wanneer 
symptomen blijven bestaan na adequate behandeling van de primaire slaapstoornis. 
 
Mariman A, Delesie L, Tobback E, Hanoulle I, Sermijn E, Vermeir P, Pevernagie D, 
Vogelaers D. Undiagnosed and comorbid disorders in patients with presumed chronic 
fatigue syndrome. Under revision. Journal of Psychosomatic Research.   
Een systematische diagnostische evaluatie van patiënten met vermoeden van CVS resulteert 
in een waaier van diagnostische categorieën. Deze studie toont een hoge prevalentie van 
psychiatrische aandoeningen en slaapstoornissen aan, die voorheen veelal onder- of niet-
gediagnosticeerd gebleven waren. De meest geobserveerde psychiatrische stoornissen zijn 
stemmingsstoornissen, angststoornissen, cluster C en cluster B persoonlijkheidsstoornissen. 
Obstructief slaapapneu (OSA) komt in deze groep met een gelijkaardige prevalentie voor als 
bij aandoeningen zoals obesitas, atriumfibrillatie en hartfalen. Voor deze laatste indicaties 
wordt polysomnografie (PSG) als standaardonderzoek aanbevolen.  
 
In tegenstelling tot eerdere studies rapporteert het huidig onderzoek een lage prevalentie van 
psychiatrische comorbiditeit bij CVS. Dit reflecteert waarschijnlijk een affirmatievere 
indeling in diagnostische categorieën met een specifieke therapeutische benadering. Aldus 
bestond er minder de neiging om het label van een syndromale definitie zoals CVS te 
gebruiken, welke niet berust op een duidelijk pathofysiologish substraat. 
 
De herkenning van specifiek behandelbare primaire slaap- en psychiatrische stoornissen is 
van belang voor een op maat gemaakte therapie bij patiënten met onverklaarbare chronische 
vermoeidheid. Daarom moet systematische psychodiagnostische testing en psychiatrische 
screening enerzijds en objectief slaaponderzoek anderzijds sterk aanbevolen worden bij deze 
patiëntengroep.  
 
Mariman A, Vogelaers D, Hanoulle I, Delesie L, Pevernagie D. Subjective sleep quality and 
daytime sleepiness in a large sample of patients with chronic fatigue syndrome (CFS). Acta 
Clin Belg 2012;67(1):19-24. 
Slechte slaapkwaliteit (hoge gemiddelde waarde op de Pittsburgh Sleep Quality Index, PSQI) 
en toegenomen slaperigheid overdag (hoge gemiddelde waarde op de Epworth Sleepiness 
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Scale, ESS) werden geobserveerd bij een grote groep CVS-patiënten die verwezen werden 
naar ons tertiair centrum. Verdere analyse van deze patiëntengroep leidde tot de identificatie 
van een subgroep met een insomnie fenotype. Dit pleit ervoor om een schijnbaar homogene 
groep patiënten met onverklaarde chronische vermoeidheid nader te onderzoeken met 
aandacht voor verschillende subgroepen of diagnostische categorieën met betrekking tot de 
slaapkenmerken.  
 
Mariman A, Vogelaers D, Hanoulle I, Delesie L, Tobback E, Pevernagie D. Validation of 
the three-factor model of the PSQI in a large sample of chronic fatigue syndrome (CFS) 
patients. J Psychosom Res 2012;72:111-113. 
Bij een grote groep CVS-patiënten werd de scoringsmethodiek van de PSQI geëvalueerd. 
Traditioneel worden in dit model 7 componenten onderscheiden waarvan het resultaat in 1 
globaal cijfer wordt geïntegreerd. Bij CVS bleek de PSQI echter effectief te opereren als een 
driefactor scoringsmodel, wat in overeenstemming is met vroegere observaties bij gezonde 
mensen en depressieve ouderen. Deze opdeling in drie factoren suggereert een beperkte 
bruikbaarheid van de globale PSQI als één globale score of éénfactor scoringsmodel ter 
evaluatie van subjectieve slaapkwaliteit bij deze patiëntengroep.  
 
Mariman A*, Tobback E*, Hanoulle I, Delesie L, Vogelaers D, Pevernagie D. 
Polysomnographic and MSLT data in a large sample of patients with unexplained chronic 
fatigue: comparison with a reference sample and relation with subjective scores. Submitted: 
Sleep Medicine. (*: shared first author) 
Bij een grote groep patiënten met onverklaarde chronische vermoeidheid werden objectieve 
slaapparameters verzameld door PSG en MSLT. Deze data werden vergeleken met deze van 
een referentiegroep. In de patiëntengroep werd een afname van de totale slaaptijd en de 
slaapefficiëntie waargenomen en een toename van de slaaplatentie, wake after sleep onset en 
de ontwaakindex. Dit komt overeen met een insomnia fenotype. Bij onderzoek naar de relatie 
tussen deze objectieve data en subjectieve scores, uit gevalideerde vragenlijsten, werd geen 
correlatie gevonden tussen PSG of MSLT data met vermoeidheid en slechts zwakke 
correlaties met mentale gezondheid en subjectieve slaperigheid. Subjectieve slaperigheid 
werd niet geobjectiveerd door MSLT.  
Het gebrek aan correlaties tussen subjectieve scores enerzijds en objectieve slaapparameters 
anderzijds suggereert dat deze objectieve testen niet geschikt zijn voor het verklaren van 
symptomen zoals slaperigheid overdag en vermoeidheid bij patiënten met onverklaarde 
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chronische vermoeidheid. Desondanks blijven PSG en MSLT aangewezen voor het aantonen 
van primaire slaapstoornissen bij deze patiëntengroep.  
 
Tobback E*, Hanoulle I*, Mariman A, Delesie L, Pevernagie D, Vogelaers D. What does 
fatigue mean in the chronic fatigue syndrome? A path analysis on a large sample of 
patients with chronic fatigue. In preparation. (*: shared first author) 
Padanalyse op een grote groep patiënten met vermoeden van CVS toonde geen duidelijk 
rechtstreekse beïnvloeding van vermoeidheid op fysieke levenskwaliteit in tegenstelling tot 
slaapkwaliteit. Er werd ook geen duidelijke beïnvloeding van vermoeidheid door 
slaapkwaliteit gevonden. De introductie van een latente variabele, tentatief benoemd als 
‗intrinsieke vermoeidheid‘, liet toe om de onderlinge relatie tussen deze verschillende 
dimensies verklaarbaar te maken. Dit leidt tot de werkhypothese dat de klassiek gebruikte 
vermoeidheidsvragenlijsten, Fatigue Questionnaire (FQ) en de Checklist Individuele 
Spankracht (Checklist Individual Strength, CIS)  de reële dimensie van vermoeidheid bij deze 
patiëntengroep onvoldoende of slechts partieel peilen. 
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Behavioural hyperventilation as a novel clinical condition associated with central sleep 
apnoea: a report of three cases  
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Summary 
Central sleep apnoea (CSA) is a disorder characterised by repetitive episodes of decreased 
ventilation due to complete or partial reduction in the central neural outflow to the respiratory 
muscles. Hyperventilation plays a prime role in the pathogenesis of CSA. Chronic heart  
failure and dwelling at high altitude are classical conditions in which CSA is induced by 
hyperventilation. 
Hyperventilation syndrome (HVS) is a prevalent behavioural condition in which minute 
ventilation exceeds metabolic demands, resulting in haemodynamic and chemical changes 
that produce characteristic dysphoric symptoms. HVS is frequently caused by anxiety 
disorders and panic attacks. 
Until now, medical literature has focussed primarily on daytime symptoms of behavioural 
hyperventilation. It is currently unknown how this condition may affect sleep. Three cases are 
reported in which behavioural hyperventilation was associated with occurrence of significant 
central sleep apnoea, which was not present during normal tidal breathing in steady sleep. 
Therefore, behavioural hyperventilation should be added to the list of known clinical 
conditions associated with CSA. 
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1. Introduction 
Central sleep apnoea (CSA) is characterised by a temporary lack of neural drive to breathe 
during sleep, resulting in a decrease or cessation of airflow. In clinical practice, CSA is 
diagnosed when the apnoea/hypopnoea index (AHI) exceeds 15 apnoeas and/or hypopnoeas 
per h of sleep and when more than half of these respiratory events are of central origin [1]. 
During non-rapid eye movement (NREM) sleep, breathing is metabolically controlled through 
the arterial partial pressure of carbon dioxide (PaCO2). A fall of PaCO2 below the CO2 apnoea 
threshold results in cessation of respiratory effort. This is a robust physiological mechanism 
that is present in many species [2]. In humans, CSA is often observed by conditions that are 
associated with hyperventilation, for example, in chronic heart failure and dwelling at high 
altitude [3]. Transient hyperventilation is the mechanism that drives PaCO2 below the apnoea 
threshold during NREM sleep. 
The term ‗hyperventilation syndrome‘ was first introduced for anxiety-related prolonged 
excessive breathing without a distinct organic aetiology [4]. Whilst the cause–effect 
relationship between hyperventilation and anxiety/panic attacks is still a matter of debate, it is 
presumed that increased ventilation and hypocapnia by themselves contribute to an emotional 
state of anxiety/panic. In other words, the underlying psychiatric disorder and the 
inappropriate breathing response may be constituents of a vicious cycle [5]. 
Evidently, lowering PaCO2 by transiently raising minute ventilation increases proneness to 
CSA, irrespective of the mechanism that drives the ventilation. This report describes three 
cases in which polysomnography (PSG) revealed CSA caused by behavioural 
hyperventilation. 
 
2. Methods 
The cases described in this report were individuals admitted for regular medical care. The 
procedure of the present case reporting complies with the guidelines of the institutional 
review boards of both institutions (Kempenhaeghe and Ghent University Hospital). None of 
the three patients were obese (Case 1: L = 1.02 m, W=14 kg, BMI = 13.6 kg m
2
; Case 2: L = 
1.89 m, W= 90 kg, BMI =25.2 kg m
2
; Case 3: L = 1.63 m, W= 59 kg, BMI = 22.2 kg m
2
). 
None had symptoms or signs of cardiac or pulmonary disease. 
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3. Case Records 
3.1. Case 1 
A 9 year old girl with Cornelia de Lange syndrome, characterised by multiple congenital 
abnormalities and mental retardation [6], suffered from severe insomnia with difficulties 
initiating sleep. These symptoms had developed after she had been admitted to the hospital 
for a minor intervention. During her stay, she had witnessed the sudden death of a roommate. 
Ever since, she became frightened around bedtime, and when brought to bed, she became 
very agitated and was unable to fall asleep. 
PSG revealed a significantly prolonged sleep onset. In the initial phase of sustained 
wakefulness, her respiratory rate was ±40/minutes and baseline SpO2 was ±100%. Transitions 
to stage 1 and 2 NREM sleep were associated with the appearance of protracted CSA events 
(max 59s) and severe oxygen desaturation (<70%). CSA completely disappeared in the 
subsequent period of consolidated sleep, during which respiratory rate fell to ±18/minutes and 
baseline SpO2 was ±96%. Relevant PSG data are presented in Fig. 1(a). 
 
3.2. Case 2 
A 32 year old man presented with complaints of non-restorative sleep, fatigue and daytime 
sleepiness. The history was remarkable for insulin-dependent diabetes mellitus and incidental 
nocturnal migraine attacks. He mentioned that he would voluntarily start hyperventilating 
during these attacks, as he had experienced that this behaviour was effective in preventing 
migraine-associated nausea and vomiting. 
During the PSG recording, the patient unexpectedly suffered from a migraine attack. Before 
this event, sleep and breathing had been unremarkable. Respiratory rate was ±16/minutes and 
SpO2 was ±96% at baseline. The attack triggered a prolonged awakening and a significant 
increase in respiratory rate up to a maximum of 68/minutes with an associated increase of 
SpO2 to 98%. Several CSA events were observed in subsequent episodes where stage 1 
NREM sleep was reinitiated (Fig. 1(b)). 
 
3.3. Case 3 
A 43 year old woman consulted with recurrent symptoms of daytime hyperventilation, 
including diffuse paraesthesias, which were diagnosed as HVS. Recently, the patient had 
developed sudden nighttime awakenings with dyspnoea, chest oppression and paraesthesias. 
In the past 2 years, she had experienced several stressful life events, and developed a state of 
anxiety. A neurologic, pulmonary and cardiologic check-up, including echocardiography and 
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pulmonary function tests, had been unremarkable. Arterial blood gas analysis assessed at the 
department of pulmonary medicine had confirmed hyperventilation: pH 7.54 (↑↑), PaCO2 
25.5 mmHg (↓↓), PaO2 103 mmHg (↑) and bicarbonate 21.7 mmol
-1
 (↓). 
PSG demonstrated cyclic sleep architecture with intermittent prolonged awakenings. The 
respiratory rate during steady sleep was ±16/minutes. During the wakefulness episodes, the 
respiratory rate fell to ±8/minutes, but respiratory amplitude increased substantially, resulting 
in an increase of SpO2 to ±98%. Subsequent transitions to stage 1 and 2 NREM sleep were 
associated with multiple CSA events. This pattern was observed throughout the entire 
sleep period (Fig. 1(c)). 
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Fig. 1. Hypnogram, all night SpO2 trend and epoch with examples of CSA in case 1 (panel a), 2 (panel b) and 3 
(panel c). Increase in baseline oxygen saturation during episodes of hyperventilation and central sleep apnea is 
seen in the saturation graphs. Epochs are taken from episodes of sleep following a period of wakefulness during 
which hyperventilation was present. The location of the example epochs is indicated with a (h) on the 
hypnogram. CA, central apnea; ECG, electro-cardiogram; Wake and A, wakefulness, N1 and 1, non-rapid eye 
movement stage 1; N2 and 2, non-rapid eye movement stage 2; N3 and 3, non-rapid eye movement stage 3; 
REM and R, rapid eye movement; SaO2 and SAO2, oxygen saturation. 
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Fig. 1. (continued) 
 
4. Discussion 
In the current report, we describe a new clinical condition associated with hyperventilation-
mediated CSA, namely behaviourally induced overbreathing in the context of panic attacks or 
anxiety. None of the patients had evidence of cardiac or pulmonary disease, and 
hyperventilation appeared to be a behavioural manifestation of incident anxiety or panic 
attacks. 
In all three cases, an increase in baseline oxygen saturation was observed as a hallmark of 
increased ventilation associated with major episodes of CSA (Fig. 1(a)–(c)). Two patterns of 
behavioural hyperventilation and associated CSA became evident: an incidental ‗panic‘ 
phenotype incited by acute triggers (fear and pain) versus a more chronic ‗anxiety‘ pattern 
maintained by latent stressors. In the former phenotype, CSA emerged during a limited stretch 
of time, whereas in the latter, CSA appeared in clusters throughout the entire sleep period. In 
the first two cases, significant CSA emerged in the context of sudden tachypneic  
hyperventilation due to distinct and transient emotional triggers. The first case was consistent 
with a panic response conditioned by a previous psychotrauma and elicited by fear for going 
to bed. Remarkable CSA occurred in the wake-to-sleep transitions, but once the stage of 
steady sleep was reached, respiratory rate decreased and CSA disappeared. In the second case, 
behavioural hyperventilation was induced by a migraine attack. Repetitive central apnoeas 
were present in the subsequent period, while breathing had been normal before this event. In 
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both cases, hyperventilation had started during an initial phase of wakefulness and continued 
through the subsequent transitions to superficial NREM sleep, thereby causing sequences of 
long central apnoeas. The third case is a classical example of HVS in the context of a  
generalised anxiety disorder including paroxysmal nighttime symptoms. PSG demonstrated 
clusters of central apnoeas after periods of prolonged awakening during which hyperpneic 
hyperventilation was present. 
Periodic breathing, and sometimes limited clusters of respiratory interruptions, may be 
observed in healthy subjects in the unstable phase between wakefulness and stage 1 NREM 
sleep [7]. This is considered a normal physiological phenomenon. Rarely, these physiological 
apnoeas may prolong the time needed to progress from light to consolidated deeper sleep. The 
respiratory events that are observed in the present cases are clearly different because of their 
severity: the central apnoeas persisted during an extended time period, were long in duration 
(up to 59 s in case 1) and were associated with substantial oxygen desaturations. Because of 
the obvious clinical relevance, behaviourally induced hyperventilation with CSA qualifies as 
a breathing disorder. 
Whilst chronic hyperventilation and associated hypocapnia are in fact protective against 
central apnoea, increased chemosensitivity to CO2 may counterbalance this advantage [2,8]. 
Indeed, brisk transient surges in minute ventilation may drive the PaCO2 below the apnoeic 
threshold, even in the presence of steady state hyperventilation. This mechanism has been 
shown to be a prime pathogenic factor for CSA in altitude-related hypoxia and chronic heart 
failure. Whether increased chemosensitivity may play a role in behavioural hyperventilation is 
uncertain. However, the present case records illustrate that behavioural hyperventilation may 
be sufficiently robust to cause major episodes of CSA. 
Patients with nocturnal panic attacks are known to have a greater incidence of insomnia. 
Phobic avoidance behaviour may impair initiation and/or maintenance of sleep in these 
patients [9]. Bodily symptoms observed in nocturnal panic include dyspnoea, chest pain and 
feelings of choking [10]. Mild breathing pattern abnormalities, but not frank sleep apnoea, 
have been described in patients with panic disorder [11]. Overall, their sleep structure does 
not seem remarkably abnormal [12]. Based on the current findings, PSG may reveal CSA in 
some of these patients. 
To the best of our knowledge, this is the first report to draw attention to CSA as a significant 
disturbance of sleep in patients with panic or anxiety disorders and co-morbid behavioural 
hyperventilation. We believe that the findings in the present paper are pertinent and warrant 
prospective surveys exploring the incidence and impact of CSA on sleep quality in patients 
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with anxiety and panic disorders. From a therapeutic point of view, treating the underlying 
psychiatric disorder would be the preferred approach, rather than starting treatment with 
positive airway pressure. 
In conclusion, these case records illustrate that behavioural hyperventilation is causally 
associated with sleep-disordered breathing of central origin. From these observations, it is 
proposed to add behavioural hyperventilation as a distinct aetiological factor to the list of 
known causes of CSA. 
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